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ABSTRACT 
In this study, a characterization of iron supplements used as parenteral and oral 
preparations for the treatment of severe anaemia based on spheroidal Fe-carbohydrate 
nanoparticles and bioavailability studies of such in biological samples have been developed.  
On the one hand, a complete characterization of a commercial preparation for the 
parenteral treatment of anaemia (Venofer®), has been carried out using High Resolution 
Transmission Electron Microscopy (HR-TEM), Dynamic Light Scattering (DLS), Energy Dispersive 
X-Ray analysis (EDX), and Size Exclusion Chromatography (SEC) coupled to UV-Vis and ICP-MS 
detection. With the aim of evaluating iron bioavailability from these sucrose coated-iron oxide 
nanoparticles, solubilisation studies of the drug have been conducted in serum and blood. 
Moreover, speciation experiments of serum proteins were conducted using UV-vis and ICP-MS 
detection, providing more in-depth information about the drug and its behaviour in the body. 
On the other hand, tartrate-modified coated-iron oxide nanoparticles (FeNPs) have been 
synthesized according to a precipitation method of a Fe(III) salt in basic medium followed by an 
additional step of surface coating with sodium tartrate and adipic acid in order to obtain non-
aggregated particles. This protocol has been also applied to the synthesis of isotopically enriched 
57FeNPs. Nanoparticles were further characterized using HR-TEM, EDX, DLS, Small Angle X-Ray 
Scattering (SAXS), Wide Angle X-Ray Scattering (WAXS) and UV-vis. As these nanoparticles are 
potentially suitable for the oral supplementation in anaemia’s treatment, the lability of these 
FeNPs in acidic medium (similar to stomach acidic conditions) was evaluated, and total Fe was 
quantified in nanoparticulate and soluble fraction. With the aim of determining nanostructure 
behaviour in cellular media, a speciation strategy for nanoparticles and ionic species of iron 
based on a reversed-phase high-performance liquid chromatography (HPLC) coupled to ICP-MS 
was carried out and applied for the first time to Caco-2 cell samples. Moreover, a quantification 
approach was also tackled by applying an online post-column isotope dilution analysis with 57Fe 
as isotopically enriched standard. With the aim of evaluating cytotoxicity from these tartrate-
modified iron oxide nanoparticles, colorimetric assays have been conducted in different cell 
lines (THP-1, macrophages, Caco-2, and HT-29) and oxidative damage was assessed by 
measuring ROS production. Finally, in vivo models were used to determine iron absorption 
degree in the small intestine after perfusion experiments in rats. The fate of the FeNPs was also 
studied by analysing other tissues as liver, kidney, spleen, or blood after the intestinal uptake. 
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ABSTRAKT  
In dieser Studie wurde eine Charakterisierung von Eisenpräparaten entwickelt, die als 
parenterale und orale Präparate zur Behandlung schwerer Anämie auf Basis von sphäroidalen 
Fe-Kohlenhydrat-Nanopartikeln verwendet werden, sowie von Bioverfügbarkeitsstudien solcher 
in biologischen Proben. 
Einerseits wurde eine vollständige Charakterisierung eines kommerziellen Präparats für die 
parenterale Behandlung von Anämie (Venofer®) unter Verwendung von hochauflösender 
Transmissionselektronenmikroskopie (HR-TEM), dynamischer Lichtstreuung (DLS), 
energiedispersiver X- Ray-Analyse (EDX) und Größenausschlusschromatographie (SEC) 
gekoppelt mit UV-Vis- und ICP-MS-Detektion. Mit dem Ziel, die Bioverfügbarkeit von Eisen aus 
diesen Saccharose-beschichteten Eisenoxid-Nanopartikeln zu untersuchen, wurden 
Solubilisierungsstudien des Arzneimittels in Serum und Blut durchgeführt. Darüber hinaus 
wurden Speziationsexperimente von Serumproteinen unter Verwendung von UV-vis- und ICP-
MS-Detektion durchgeführt, die detailliertere Informationen über das Arzneimittel und sein 
Verhalten im Körper liefern. 
Auf der anderen Seite wurden Tartrat-modifizierte Eisenoxid-Nanopartikel (FeNPs) nach 
einem Fällungsverfahren eines Fe(III) -Salzes in basischem Medium synthetisiert, gefolgt von 
einem zusätzlichen Schritt der Oberflächenbeschichtung mit Natriumtartrat und Adipinsäure um 
nicht-aggregierte Partikel zu erhalten. Dieses Protokoll wurde auch auf die Synthese von 
isotopenangereicherten 57FeNPs angewendet. Nanopartikel wurden mit HR-TEM, EDX, DLS, 
Kleinwinkel-Röntgenstreuung (SAXS), Weitwinkel-Röntgenstreuung (WAXS) und UV-vis weiter 
charakterisiert. Da diese Nanopartikel möglicherweise für die orale Supplementierung bei der 
Behandlung von Anämie geeignet sind, wurde die Labilität dieser FeNPs in saurem Medium 
(ähnlich den sauren Bedingungen im Magen) bewertet, und das gesamte Fe wurde in 
nanopartikulärer und löslicher Fraktion quantifiziert. Mit dem Ziel, das Verhalten von 
Nanostrukturen in zellulären Medien zu bestimmen, wurde eine Speziationsstrategie für 
Nanopartikel und ionische Eisenspezies basierend auf einer Umkehrphasen-
Hochleistungsflüssigkeitschromatographie (HPLC) gekoppelt mit ICP-MS durchgeführt und 
erstmals angewendet Caco-2-Zellproben. Darüber hinaus wurde ein Quantifizierungsansatz 
durch Anwendung einer Isotopenverdünnungsanalyse mit 57Fe als Isotopen-angereichertem 
Standard durchgeführt. Mit dem Ziel, die Zytotoxizität von diesen Tartrat-modifizierten 
Eisenoxid-Nanopartikeln zu untersuchen, wurden kolorimetrische Assays in verschiedenen 
Zelllinien (THP-1, Makrophagen, Caco-2 und HT-29) durchgeführt und die oxidative Schädigung 
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wurde durch Messen der ROS-Produktion bewertet. Schließlich wurden In-vivo-Modelle 
verwendet, um den Eisenabsorptionsgrad im Dünndarm nach Perfusionsexperimenten an 
Ratten zu bestimmen. Das Schicksal der FeNPs wurde auch untersucht, indem andere Gewebe 
wie Leber, Niere, Milz oder Blut nach der intestinalen Aufnahme analysiert wurden. 
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1 INTRODUCTION 
1.1. The role of iron in living organisms 
Iron (Fe) is a metal and an essential micronutrient for animals, plants, microorganisms, and 
human beings as it is required in the transport of oxygen and electrons, and catalysis of reactions 
necessary for the development, differentiation and cellular proliferation. It is found naturally in 
earth’s crust at about 5 % concentration form as hematite (Fe2O3) and magnetite (Fe3O4) ore. In 
aquatic environments under anoxic conditions, iron is present in elemental form or as iron oxide 
when oxygen is available.  
Regarding its composition, this metal has four natural isotopes, which masses and relative 
abundances are collected in Table 1 [1]. Additionally, it has 24 unstable isotopes, with lifetimes 
between 20 milliseconds (46Fe) and 1.5x106 years (60Fe). 
Table 1. Iron Isotopes. 
Isotope Lifetime Relative abundance (%) Atomic mass (u) 
54Fe Stable 5.845 53.9396 
56Fe Stable 91.754 55.9349 
57Fe Stable 2.119 56.9354 
58Fe Stable 0.282 57.9333 
 
Despite being one of the most abundant metals in the Earth’s crust, its physico-chemical 
properties make it difficult to be available for living organisms as it is almost insoluble at pH 7. 
Most of the iron is present in oxidized/ferric insoluble forms and thus, microbes cannot assimilate 
it. In consequence, evolution has developed mechanisms to solubilize, capture from the 
environment, store, and use it in case of necessity [2].  
Like most transition metals, iron has a variety of chemical reaction possibilities. The reversible 
change of Fe(II) into Fe(III) through redox-reactions and its naturally high abundance might explain 
why iron plays an extremely important role virtually in all living organisms [3, 4]. In plants this 
trace metal is involved in the photosynthesis, the generation of chemical energy by reaction of 
photons with photosynthetic membranes [5]. In vertebrates, iron is present in its most important 
oxidation states +2 and +3 and in cofactors like haem. This prosthetic group, more precisely       
haem b, is present in the haemoglobin (Hb), the oxygen transport protein in blood. It can also be 
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found in myoglobin, the haemoglobin analogue in the muscle tissue. Haem b contains Fe(II) in the 
centre of the planar porphyrin ring (bound to the four pyrrolic groups) which is responsible for the 
coordination and transport of oxygen [6]. 
Most of the iron present in living organisms is tightly complexed in proteins, although it can 
be also present in a soluble “pool” of low molecular weight complexes such as ferric citrate and 
Fe(III)-ATP [7]. 
Although the participation of iron in many biochemical processes explains its significant role 
in most living systems, its careful management is critical for them: an excess of iron can cause 
tissue damage, but a depletion of this trace metal is also harmful, as it is required for many 
physiological functions. Considering this ambivalent role, nature has developed a sophisticated 
system to maintain iron homeostasis by balancing its uptake, storage, and mobilization of 
reserves.  
 
1.2. Iron metabolism 
1.2.1. Iron in the body 
Healthy humans contain between 2000 and 5000 mg of iron depending on various factors 
such as gender, age, or nutrition [8].  Around two third of it is within erythrocytes and 15-25 % is 
stored in splenic and hepatic macrophages. The rest is distributed in various proteins such as 
myoglobin, cytochromes, or other ferroproteins. Only about 3 mg are bound to plasma transferrin 
and constitute the mobile iron compartment that supplies the intracellular iron stores, but the 
daily exchange of iron through plasma transferrin is ten times this amount. About 1-2 mg of iron 
is lost every day, through skin and enteric desquamation and minor blood losses. This loss is tightly 
balanced by intestinal absorption. Therefore, iron recycling represents most of the iron 
homeostasis in human body. It is graphically represented in Figure 1.  
The situation is different in menstruation women where there are controversial discussions 
about iron stores, ferritin, and haemoglobin levels. Apparently, lower haemoglobin and ferritin 
levels in menstruating women have been accepted as normal rather than possibly representing 
widespread iron deficiency [9].  
Under pathological conditions (e.g. iron overload or serum transferrin deficiency) the amount 
of iron not bound to transferrin becomes important. This is distributed to organs in an 
inappropriate manner leading to iron overload in parenchymal organs such as liver and pancreas. 
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This absorption depends on the form of iron that is present in the diet. The haem form is found 
in haemoglobin, myoglobin, cytochromes and other haemoproteins which are present mainly in 
food of animal origin. Ionic iron composed by inorganic salts of this metal is mainly found in food 
of plant origin and most of the pharmaceutical preparations used for the treatment of iron 
deficiency.  Dietary non-haem iron primarily exists in an oxidized form (Fe3+) that is not 
bioavailable and must first be reduced to Fe2+ form by ferrireductase enzyme, expressed in the 
apical surface of the enterocyte, using vitamin C as coenzyme and hydrochloric acid present in the 
stomach [13]. This absorption can be facilitated by ingestion of meat and organic acids, particularly 
ascorbic acid. Conversely, polyphenols, phytates or a phosphate enriched diet decreases this 
absorption [14]. The DMT1 (Divalent Metal Transporter 1) is a membrane protein that transports 
ferrous ions through epithelial cells of the intestine. It can also transport other divalent metals 
such as zinc, manganese, copper, cadmium or lead [15]. 
Haem iron crosses cellular membranes of the enterocyte in the form of intact 
metalloporphyrin, after being separated from the globin by endoluminal proteases action. This is 
made by a transporter protein for the haem group called Haem Carrier Protein-1 (HCP1) [16]. Once 
inside the cytosol of the enterocyte, hemoxygenase releases iron from the tetrapyrrolic structure 
and incorporates it to bloodstream as a free metal. Although it represents only a 10 % of total iron 
from the diet, haem iron absorption is higher and is less affected by diet variations. 
Once the iron is absorbed, 3-4 mg of the iron circulates in the bloodstream, mainly bounded 
to transferrin. This small amount plays an important role in the iron metabolism, since all the iron 
transported in the organism has to pass through the plasma. In this sense, the transferrin (Tf) is 
the main iron protein transporter both in serum and extracellular fluid. It is known that Tf can bind 
different metals, but it shows a special affinity for ferric ions, whereas it is not bound to ferrous 
species [15]. Tf is responsible of the transport of iron to bone marrow for the haemoglobin 
synthesis. It is also known that iron can also be bound to other proteins as ceruloplasmin, 
lactoferrin, α1 and α2-globulins, aminoacids as histidine or lysine, organic acids. ferritin and other 
plasma proteins not identified [17]. 
Most of iron in the organism (2.5 g) is found in the erythrocytes of haemoglobin, but the bone 
marrow is the place of most usage of iron (where red blood cells are formed). When erythrocytes 
reach the end of their average life (120 days approximately), they are destroyed by macrophages 
from the reticuloendothelial system, mainly in spleen, liver and bone marrow. Most of iron 
released from macrophages is incorporated into plasma where Tf binds and transports it to new 
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erythrocytes formation or to store in the liver. The reticuloendothelial system also receives a small 
amount of iron (around 2 mg) coming from the inefficient erythropoiesis [11]. 
 
1.2.3. Iron storage  
Most of the stored iron is found in the liver (one third approximately), spleen and bone 
marrow, as ferritin and hemosiderin associated forms. The rest of iron is captured by different 
tissues for the synthesis of myoglobin, cytochromes, peroxidases and other enzymes and proteins 
which use iron as cofactor.  
Iron contained in haemoglobin, tissues, and bloodstream remains practically constant 
whereas stored iron varies depending on the amount present in the organism and availability from 
the diet. For this reason, iron deposits act as a damper when there is a decrease in the 
haemoglobin, myoglobin or intracellular ferroenzymes levels [15, 18].  
Ferritin concentration together with hemosiderin reflects the body iron stores, but most of 
iron is bound to ferritin and thus, serum ferritin concentrations correlate well with total body iron 
stores under steady state conditions [11]. The ferritin molecule is a hollow protein shell (outer 
dimeter 12-13 nm, inner diameter 7-8 nm; Mr ≈ 450 kDa) composed of 24 polypeptide subunits 
[7]. It has several functions such as acquiring Fe(II), catalysing its oxidation, and inducing 
mineralization inside the cavity, which can store up to 4500 atoms of iron. The high storage 
capacity is achieved by sequestering the iron as a compact mineral, resembling the structure of 
the mineral ferrihydrite FeO(OH). This is possible due to the two structurally similar, but 
mechanistically different protein subunits contained in the protein shell: the heavy (H) and the 
light (L) chains. The H-type subunit catalyses the oxidation of Fe(II) to Fe(III), while the L-type 
subunit promotes mineralization inside the protein cage [19]. 
On the other hand, hemosiderin is an iron storage complex that less readily releases iron for 
body needs. Despite the name "hemosiderin", the iron is in the nonheme form. Hemosiderin can 
be isolated as insoluble granules which may contain small amounts of ferritin, but most of the iron 
is not water-soluble. Most estimations of the iron content in hemosiderin granules lie in the range 
24-45 % as compared with 16-23 % in ferritin. The morphology and properties of ferritin and 
hemosiderin iron, together with the results of experiments with radioactive iron, suggest that 
ferritin may be a metabolic precursor of hemosiderin and that the latter consists of aggregates of 
ferritin molecules from which much of the protein has been removed by proteolytic digestion. 
However, other results suggest that hemosiderin may be formed independently when the rate of 
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uptake of iron exceeds the tissue's capacity to make ferritin protein, and that hemosiderin iron 
may subsequently move into ferritin. These results are not necessarily contradictory but may 
reflect different responses to different conditions [20]. 
1.2.4. Function of iron in the body 
In the human body, iron generally appears bound to proteins and not as free metal ions. As 
can be seen in Table 3, between 60-70 % of the total body iron is bound to haemoproteins 
(haemoglobin, myoglobin) and only a small fraction (≈ 2 %) of iron is incorporated in the porphyrin
ring of other proteins such as cytochromes, peroxidases, catalases, and NO-synthases.  
Table 3. Iron distribution in human body 
Protein Function 
Concentration 
Male Female 
µg·g-1 % µg·g-1 % 
Haemoglobin O2 transport 31 62 28 74 Myoglobin 5 10 4 11 
Enzymes Metabolism 1 2 1 2 
Transferrin Fe transport 0.1 0.2 0.08 0.2 
Ferritin Fe storage 13 26 5 13 Hemosiderin 
1.2.5. Iron excretion 
Apart from iron losses due to menstruation, other bleeding or pregnancy, iron is highly 
conserved and not readily lost from the body. There is some obligatory loss of iron from the body 
that results from the physiologic exfoliation of cells from epithelial surfaces, including the skin, 
genitourinary and gastrointestinal tract. However, these losses are estimated to be very limited (1 
mg/day). Iron losses through bleeding can be substantial and excessive menstrual blood loss is the 
most common cause of iron deficiency in women [11]. 
1.2.6. Regulation of iron homeostasis 
The absorption of iron is dependent on body iron stores, hypoxia, inflammation and rate of 
erythropoiesis [21]. A constant balance is required between the absorption, transport, storage, 
and use of iron to keep iron homeostasis. Since there is no appropriate regulatory pathway for 
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active excretion of iron, iron homeostasis is only regulated by the release of the trace metal into 
the blood serum [11].  
Mechanisms that regulate systemic iron homeostasis are mainly found in the liver and involve 
two molecules, hepcidin and ferroportin. These two proteins together regulate the flow of iron 
from cells into the systemic circulation. Ferroportin is the only known cellular iron exporter protein 
and is expressed especially in macrophages, duodenal enterocytes, and hepatocytes. Its 
expression can be controlled at the transcriptional, translational and post-translational levels. The 
transcription of macrophage ferroportin gene can be promoted by haem and inhibited by 
inflammatory stimuli. At a systemic level the most important mechanism regulating ferroportin 
involves the iron regulatory hormone hepcidin [22, 23]. This peptide was discovered in recent 
years after being isolated from human urine samples [24]. Then, it was found that hepcidin-25 can 
inhibit the iron efflux from cells by binding ferroportin [25]. Hepcidin binding to ferroportin 
induces the rapid ubiquitination and internalization of the hepcidin-ferroportin complex, thereby 
reducing cell surface expression and iron export. Since it was discovered, its interaction with 
ferroportin not only has been established as a critical factor for systemic iron regulation but also 
the perturbations in the complex are proven to be the basis of many iron-associated disorders 
[22]. 
 
1.3. Iron metabolic disorders and pharmacological treatments 
Under physiological conditions, there is an equilibrium between iron absorption, iron 
transport, and iron storage in the human body. However, slightly modifications on the uptake 
from the diet or the regulatory system can affect directly the iron stores. Depending on there is 
an increment or a decreasing of iron concentration in the body, different metabolic disorders can 
be associated and will be discussed in the following section. 
1.3.1. Iron overload and iron deficiency 
Iron overload 
Iron overload responds to an excess of iron accumulation in the human body and is the result 
of many disorders and could lead to the development of organ damaged and increased mortality 
[26]. Even in mild cases, iron excess can cause cellular damage by catalysing the formation of ROS 
and accumulating hemosiderin in the affected organs, especially liver, heart, pancreas, kidney, 
and cerebellum [17].  
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The main reason for iron overload is an inadequate iron absorption by means of altered 
hepcidin-25 secretion. Low plasma hepcidin leads to high ferroportin levels, which allow increased 
iron uptake, hepatic iron overload, and low levels of iron stored in macrophages. In addition, as 
transferrin becomes saturated in iron-overload states, non-transferrin bound iron appears. Part 
of this labile plasma iron is highly reactive, inducing free radical formation. Free radicals are 
responsible for the parenchymatous cell injury associated with iron-overload syndromes [27]. 
 Alterations include hereditary defects either of compounds involved in the expression of 
hepcidin-25 which lead to low hepcidin-25 concentrations or the ferroportin, resulting in 
increased hepcidin-25 response known as primary hemochromatosis (it must be remarked that a 
decrease in hepcidin-25 produces a higher iron mobilization from cells into the bloodstream). 
Despite the alterations and degrees of iron induced damage are multiple, modifications in serum 
iron levels are comparable and targets of iron deposition and damage are identical. As a 
consequence of the progressive iron uptake, the binding capacity of transferrin in serum is 
exceeded, leading to non-specific iron binding and accumulation of iron in hepatic cells [28]. This 
is associated to liver pathologies such as cirrhosis and hepatic carcinoma, endocrine disorders 
(diabetes mellitus or impotence), heart damage (cardiac dysrhythmia, heart failure) and joint 
disease (destructive arthritis) [29, 30]. 
Another kind of iron overload is the transfusion iron overload or secondary hemochromatosis 
and it is not caused by primary genetic defects in the regulation of iron homeostasis. Actually, it 
may occur due to a variety of causes including the ingestion of large amounts of dietary iron, 
repeated blood transfusions and various haematological conditions that result in the increased 
absorption and storage of excess iron [22]. In this case, plasma hepcidin levels are elevated 
resulting in degradation of ferroportin. The reduced levels of ferroportin limit the uptake of iron 
from the intestine, reduce the export from macrophages and increase iron storage [30]. 
One more type of syndrome is called iron loading anaemia and is caused by an ineffective 
erythropoiesis which leads to low levels of hepcidin. Despite increased iron stores, increased 
erythropoiesis releases a number of growth differentiation factors, which in turn suppress liver 
hepcidin production by inhibiting inflammatory and iron-sensing pathways, causing an insatiably 
iron demand [28, 31]. A complete classification of the iron-overload syndromes is collected in 
Figure 2 [27]. 
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3. IDA: iron stores are exhausted; haematocrit and levels of haemoglobin decline; and the 
resulting microcytic, hypochromic anaemia is characterized by small red blood cells with 
low haemoglobin concentrations [34]. 
The term anaemia (from the ancient Greek άναιμία, anaimia, meaning ‘lack of blood’) is used 
for a clinical diagnosis caused by an inability of erythropoietin tissues to keep normal haemoglobin 
levels as a consequence of inadequate supply of one or more nutrients leading to a reduction in 
the total circulating haemoglobin. It might be triggered due to menstruation, childbirth, deficient 
vegetarian diet, malabsorption of iron, hookworm infections, or excessive blood loss. Among its 
common adverse effects maternal mortality, low weight at birth, reduced immune-competence, 
poor cognitive development, behavioural complications, and reduced work capacity are included. 
Initial diagnostic test is usually based on serum ferritin assessment as it seems to be the most 
sensitive assay. Dietary diversification, supplementation, and fortification of staple foods and 
nutrition education are the first approaches to combat iron deficiency anaemia [35]. 
Apart from these pathologies related to iron deficiency, patients can also suffer anaemia of 
chronic disease (ACD) or anaemia of inflammation which is an accompanying phenomenon of 
many chronic infections, neoplastic and autoimmune diseases. Anaemia of chronic disease and 
inflammation involve the same biological pathway: antimicrobial peptides like hepcidin are 
components of the host defense, synthesized by the liver where the immune response starts in 
human beings. Due to infection or inflammation, the hepatocytic expression of peptides is 
accelerated by lipopolysaccharides. As a direct response, an elevated hepcidin expression is 
detected correlated with the beginning of a hypoferremia after 6 hours [36]. This can be explained 
by the biochemical reaction of the increased hepcidin concentration. Iron absorption in the 
intestine decreases and recycling iron from erythrocytes by the macrophages is limited [37]. 
Moreover, this defense mechanism implies the abnormal behaviour of homeostasis detected in 
inflammation, accompanied by low serum iron and elevated hepcidin levels which can provoke 
anaemia. In patients with chronic diseases such as cancer, infections or autoimmune diseases, the 
same defense strategy is observed.  
It can be diagnosed when the following conditions are found: 
1. An evidence of chronic inflammation by detecting a high C reactive protein level (C-
reactive protein (CRP), which is an annular, pentameric protein found in blood plasma, 
whose levels rise in response to inflammation). 
2. Haemoglobin concentrations below 13 g dL-1 for men and below 12 g dL-1 for women. 

1 INTRODUCTION 
19 
 
lived with disability worldwide, 68.4 million human years were negatively impacted by anaemia in 
2010 [48, 49]. 
 
1.3.2. Treatments to overcome iron deficiency 
Oral iron therapy has a long and rich history as it has been used to treat the anaemia for more 
than 300 years. According to Stockman’s review in 1893, Sydenham recognized the importance of 
iron replacement in chlorosis already in 1681 [50]. However, it was not until the 19th century when 
Pierre Blaud, the French physician who introduced pills containing ferrous sulphate, reported 
cures [49].  
Oral iron supplements are an inexpensive and effective way of treating the majority of iron 
deficient states. However, it is important to remember that duodenal absorption of iron is limited 
and only a 10 % of the ingested non-haem iron is absorbed by the duodenum under normal steady-
state conditions (approximately 1 mg/day). It was observed that duodenal absorption of iron is 
increased in iron-deficient states [51], however it is generally assumed that 25 mg of elemental 
iron is sufficient to essentially saturate the duodenal absorptive capabilities. Oral iron therapy is 
usually best carried out in 3-4 divided doses per day, with a total of 150-200 mg of elemental iron 
for adults or 6 mg iron/kg body weight in children [52]. 
Different preparations are available for oral iron supplements. These preparations are based 
on either the iron ferric or the iron ferrous salt forms, coated by shells of diverse nature (amino-
acid chelates, carbonyl iron, polysaccharide-iron complex, combination products, extended-
release products, etc.). Iron needs to be in the ferrous form to be absorbed by the intestinal 
mucosa. Thus, ferric forms need to be reduced to ferrous first, for optimal absorption. Since food 
can decrease absorption of iron up to 50 %, iron supplements should ideally be taken with an 
empty stomach. Haem-iron preparations are also available. While commercial forms of haem iron 
polypeptide are more expensive than the common iron salts, they represent an attractive 
alternative for those patients who cannot tolerate iron salts and who have reacted to or refuse 
parenteral iron replacement. Although this form of iron is better absorbed that iron salts, it is 
derived from animal sources and due to this in many countries, it is considered a “medical food” 
rather than a dietary supplement [53]. 
Among the most common causes why oral treatment can fail or induce undesirable responses 
are the following: 
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• Lack of adherence to therapy or insufficient length of therapy for the degree of iron 
deficiency. 
• Concomitant/causal underlying blood loss pathology not resolved. 
o Poor duodenal absorption (gastrointestinal pathology associated) 
o Insufficient gastric acidity 
o Chemical inhibition of absorption (lead-aluminium) 
• Side effects (nausea, constipation, upper gastrointestinal irritation). 
Gastrointestinal side effects are the most frequent side effects reported for oral iron therapy 
affecting up to 70 % of patients [54]. In addition to diarrhea or constipation, upper gastrointestinal 
symptoms include nausea, abdominal discomfort/pain, and more rarely vomiting. The symptoms 
appear mostly in the first hour after the ingestion of iron supplements and may be alleviated by a 
reduction in the dose. In pregnant women, who already suffer from constipation due to elevated 
progesterone levels which slow bowel transit and pressure from the enlarging uterus on the 
rectum, oral iron may worsen symptoms. 
Recently, several iron preparations that claim superior tolerance are marketed. These 
preparations often show a slow release property and some of them deliver the iron further down 
the intestinal tract. Although they seem to be better tolerated, these preparations may not be 
absorbed so efficiently as the cells with the greatest ability to absorb iron are found in the 
duodenum and proximal jejunum. In this sense, new studies are being developed trying to 
improve iron bioavailability with minimum side effects [55] and providing a better understanding 
about iron supplements effects, their dose dependence and the corresponding impact on iron 
absorption levels [56]. 
On the other hand, oral iron therapy should not be considered for patients on haemodialysis 
therapy and cancer patients receiving erythropoiesis-stimulating agents (ESA). In those cases, it 
has been proven that the addition of intravenous iron increased efficacy of ESA in cancer patients 
[52, 57].  
For those contraindicated cases, intolerant of or unresponsive to oral iron, intravenous iron 
is an attractive and effective alternative. However, it is generally supposed by most physicians that 
parenteral iron is dangerous and associated with anaphylactic shock and death. The evidence 
actually indicates that this perception is incorrect but persists because of misinformation and 
misinterpretation of the incidence and clinical nature of infusion reactions associated with the 
administration of parenteral iron, especially in former times [49, 58].  
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Parenteral iron was first introduced in the early 20th century. Ferric hydroxide solutions were 
injected subcutaneously and intramuscularly into patients with hypochromic anaemia, and the 
observed increments in haemoglobin were proportional to the amount of iron administered. The 
lack of a carbohydrate shell resulted in immediate iron release and severe toxic reactions that led 
to use this therapy only in extraordinary circumstances [59]. Fortunately, in successive decades 
improvements in the intravenous preparations were accomplished and different biocompatible 
shells and iron nanoparticles cores are being commercialized with more effective and safer results 
for the patients. In fact, they present several advantages over oral supplementation: intravenous 
iron enables a fivefold erythropoietic response to significant blood-loss anaemia in normal 
individuals [60], Hb starts to rise after a few days, the percentage of responding patients is higher 
and iron stores are replete [27, 61]. Modern formulations in the market will be discussed in detail 
in following sections. 
In general, intravenous iron administration is indicated in the following situations: 
• In acquired or hereditary decreased intestinal iron absorption and/or liberation of iron 
from macrophages. Patients with high hepcidin levels secondary to any kind of 
inflammation [62] or cases where, because of surgery, intestinal iron absorption is 
abolished, e.g. post gastrectomy, are included.  
• In cases with true severe iron deficiency due to constant severe iron bleeding (Rendu-
Osler-Weber disease) [63] or because of increased iron needs (pregnancy) or a mixture of 
both previous situations (post-partum anaemia). 
• As it was previously mentioned, in situations of functional iron deficiency particularly 
when an erythropoietin stimulating agent (ESA) is used such as in renal anaemia, anaemia 
of cancer patients and autologous blood donation before elective surgery. 
• In cases where there is a short time to surgery [64]. 
• For intolerant patients to oral treatment or when there is a failure with such strategy. 
Although parenteral iron efficacy for treating anaemia has been consistently proven in a 
variety of clinical settings [65], intravenous preparations have been reported to cause 
anaphylactoid reactions characterised by nausea, hypotension, tachycardia, chest pain, dyspnoea 
(lung oedema) and bilateral oedema of the hands and feet. Moreover, current information on the 
relationship between intravenous iron and infection, and between intravenous iron and oxidative 
stress, deserves special consideration. Elemental iron is an essential growth factor for bacteria 
with many species expressing iron transport proteins that compete with transferrin, and it has 
been suggested that patients with iron overload are at increased risk of infection [66]. The 
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evidence argues for caution in prescribing intravenous iron [67] and new insights are necessary to 
obtain the ideal formulation. 
 
1.3.2.1. Iron salts 
As it was commented before, oral treatment is mainly based on the use of iron salts. Most 
frequently used preparations are ferrous sulphate and ferric preparations with an iron 
polymaltose complex. They vary in their bioavailability, efficacy, side effects, and cost depending 
on chemical state of iron, salt biocompatibility or galenic forms. Table 4 shows most extended oral 
formulations, galenic form of administration and the percentage of elemental iron in each one. 
Table 4. Oral iron preparations in the market. 
Formulation % Elemental iron (w/w)[53] Galenic form 
Carbonyl iron (Fe (0)) 100 Tablets, suspension, chewable tablets 
Ferric citrate (Fe3+) 18 Capsules 
Ferrous bisglycinate (Fe2+) 20 Capsules, tablets 
Ferrous fumarate (Fe2+) 33 Tablets, chewable tablets 
Ferrous gluconate (Fe2+) 12 Tablets 
Ferrous sulphate (Fe2+) 20 Oral solution, tablets, enteric-coated tablets, film- coated tablets 
Ferrous sulphate anhydrous (Fe2+) 30 Capsules, tablets, extended- release tablets, capsules 
Polysaccharide-iron complex (Fe3+) 100 Capsules, solution, film- coated tablets 
 
Ferrous sulphate preparations usually present good bioavailability, while bioavailability of 
some other iron ferric preparations is 2 to 3 times less than conventional ferrous salts [68]. This is 
due to the extremely poor solubility of ferric iron in alkaline media and the fact that ferric iron 
needs to be transformed into ferrous iron before being absorbed [69].  
Despite the wide use of the ferrous salts in cases of iron deficiency, they have lately come 
under the spotlight in high-profile intervention trials as they may enhance systemic infection rates, 
induce undesirable changes to commensal bacteria of the colon and increase proinflammatory 
signalling of the gut epithelium. Moreover, concerns over ‘available’ iron in the colon as a risk 
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factor for colorectal carcinogenesis are being reported, showing a possible failure in these 
treatments and questioning their effectiveness [70, 71]. 
On the other hand, some forms of ferric iron (e.g. ferric pyrophosphate) are considered safer 
and better tolerated in the gut lumen than Fe2+ but are still poorly absorbed. Chelation may 
overcome the issue of oral Fe3+ bioavailability but then pronounced risk enhancement of colon 
cancer was detected in rodent models using EDTA [72] or citrate [73] as chelating agents.  
Additionally, it should be remarked that non-absorbed iron salts may produce a variety of 
highly reactive oxygen species including hypochlorous acid, superoxide and peroxides leading to 
a possible digestive intolerance, causing nausea, flatulence, abdominal pain, diarrhea or 
constipation, and black or tarry stools, and perhaps an activation of inflammatory bowel disease. 
Therefore, lower doses of iron salts (50-100 mg of elemental iron) would be always preferable 
[27]. 
 
1.3.2.2. Iron nanoparticles 
Nanoparticulate pharmaceutical drug delivery systems are widely used in pharmaceutical 
research and in clinical settings to enhance the effectiveness of diagnostic agents and drugs, 
including anticancer, antimicrobial and antiviral drugs [74]. The types of nanocarriers that exist 
are diverse and include the following: liposomes, polymeric nanoparticles, polymeric micelles, 
silica, gold, silver and other metal nanoparticles, carbon nanotubes, solid lipid nanoparticles and 
dendrimers. Thus, they can be separated into two broad categories: inorganic (metallic, oxides, 
etc.) and organic nanoparticles (polymeric, micelles, liposomes, etc.).  
The main reasons behind the interest in nanoparticle technologies are the advantages they 
present in comparison to many ordinary pharmaceuticals: they can be designed and formulated 
to offer enhanced drug protection, controlled release, extended circulation and improved 
targeting to diseased tissues. Moreover, some specific nanoparticles benefit from stimuli-
responsive functions that come from their surface plasmon resonance or magnetic responsiveness 
(e.g. magnetic resonance imaging) and analogous drugs cannot offer [75]. The use of nanoparticles 
can overcome several problems that are associated with traditional drugs, such as poor aqueous 
solubility, low bioavailability and nonspecific distribution in the body [76]. There are several 
studies demonstrating the increase of bioavailability when materials are prepared in the 
nanometer size range [77, 78]. In fact, there are evidences to believe that when nanocarriers are 
used for oral intake of iron, iron absorption increases 1.35 times compare to the reference ferrous 
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sulphate [79]. Moreover, in vitro assays showed that iron absorption from nanoparticles 
containing iron was 13.42 % more than ferrous sulphate [80]. Therefore, it is expected that 
nanoparticulate iron improves significantly bioavailability, minimizing doses required in the 
treatment, and consequently leading to reduced side effects in the gastrointestinal system [81, 
82]. 
 
1.3.2.2.1. Parenteral treatment 
Iron-replacement therapies for treatment of anemia are one of the clinical areas where 
nanoparticles have made a significant impact [83–85]. These nanoparticle approaches come from 
the need to address toxicity issues associated with the injection of free iron [86]. 
 Structurally, all intravenous iron agents are colloids that consist of spheroidal iron-
oxyhydroxide nanoparticles of less than 10 nm surrounded by a shell of carbohydrate as stabilizer 
that slows down the release of bioactive iron, maintains the resulting particles in colloidal 
suspension and protects the mineral core against further polynuclearization [87]. Different 
carbohydrates have been used as coating of the particles and examples of commercial 
formulations are included in Table 5 [83, 88]. 
The kinetic and thermodynamic stability of these formulations (mainly driven by the 
interaction of the organic shell with the metallic core) condition their mode of action in biological 
media. The mechanism of iron release depends on the lability of the bond in the complexes so the 
weaker the bond, the higher the bioavailability of iron in bloodstream [89].  
In addition to their use as drug carriers and contrast agents in preclinical and clinical setting, 
iron oxide nanoparticles have recently revealed a hidden intrinsic therapeutic effect on early 
tumours. Zanganeh et al. reported that tumour cells co-injected with ferumoxytol exhibited a 
markedly delayed growth rate compared with tumour cells injected without addition of 
ferumoxytol [90]. 
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Table 5. Classification of intravenous iron NP preparations according to the nature of the binding. 
 Type 1 Type 2 Type 3 Type 4 
Compound -Ferric 
carboxymaltose 
-Iron dextran 
-Ferumoxytol 
-Iron sucrose -Sodium ferric 
gluconate 
-Iron(III)-citrate 
-Iron(III)-sorbitol 
-Iron(III)-citrate + 
Iron(III)-sorbitol + 
iron dextrin  
-Sodium ferric 
gluconate + iron 
sucrose 
Commercial 
name 
Ferinject® 
InFeD® 
Cosmofer® 
Imferon® 
Dexferrum® 
Feraheme® 
Venofer® 
Fesin® 
AuryxiaTM Jectofer® 
Ferrlecit® 
Nulecit® 
Characteristics Robust, strong Semi-robust, 
moderately 
strong 
Labile, weak Mixtures 
containing at 
least two 
different iron 
complexes 
Molecular 
weight (Da) 
> 100000 30000-100000 < 50000 < 50000 
 
1.3.2.2.2. Oral supplementation 
The physiology of the gastrointestinal tract can lead to poor absorption and availability of the 
drugs or actives because of the low mucosa permeability and drug degradation prior to 
absorption. In fact, drugs should go through the stomach, intestinal lumen, the mucus membrane 
coating the intestinal epithelium, and finally the epithelium itself after oral administration. 
Nanomedicine offers improvement of oral delivery by bioavailability enhancement, adverse-effect 
minimization, and food-effect mitigation. By using nanocarriers, dissolution rate of poorly soluble 
molecules in the gastrointestinal tract can increase significantly. The nanocarrier systems provide 
intimate contact with the gastrointestinal epithelium, prolonging residence time and improving 
permeation for drug delivery [91]. 
In the particular case of the oral treatment for iron deficiency anaemia, iron nanoparticles are 
mainly found related to encapsulation strategies. This process consists on a micro-packaging 
where a great variety of iron compounds are protected with different matrix materials leading to 
a wide range of size particles (from millimetres to nanometres) by using diverse methodologies 
[92]. Main reasons to encapsulate iron for the treatment of anaemia are:  
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▪ The enhancement of non-haem iron bioavailability by protecting iron compounds through 
the gastrointestinal path;  
▪ The decrease of gastrointestinal side effects commonly associated to iron salts (e.g. 
abdominal pain, sickness, diarrhoea, constipation);  
▪ The reduction of iron precipitation in the stomach by selecting certain encapsulant 
materials so that the release of the mineral can be reduced to a minimum and totally 
degraded in duodenum, where iron is absorbed (controlled release); 
▪ The possibility to mix different iron sources in the same nanocapsule so it can be combined 
with compounds which promote iron absorption (e.g. haem/non-haem, ascorbic acid). 
It is observed that encapsulated iron increases efficiency by improving the bioavailability and 
reducing its negative organoleptic characteristics. It has shown a significant impact on 
haematological indexes and thus, this strategy provides a competitive alternative in the food 
fortifications and oral supplements for the treatment of anaemia [93]. 
In pursuit of strategies for optimal oral iron supplementation designed studies have shown 
that Fe3+ is well absorbed from ferritin. Ferritin is found in both meat and plant-based foods of the 
human diet: it is composed of a protein shell with a ferrihydrite-like mineral core. Ferrihydrite is a 
poly oxohydroxide Fe(III) nanoparticle (about 2- to 5-nm diameter) and it is surrounded by a 
soluble protein coat which not only prevents the uncontrolled growth and coalescence of the 
small mineral particles into larger insoluble aggregates, but also limits the accessibility of cell 
constituents to the iron mineral [94]. However, it is still unknown whether the protein shell and 
ferrihydrite-like core of ferritin controls the slow release of Fe3+ ions from the gastric environment, 
or, if entire ferritin or the protein-detached mineral nanoparticle is rapidly emptied from the 
stomach, endocytosed by the enterocytes and broken down via intra-lysosomal pathway [95, 96]. 
Although ferritin is an effective, bioavailable form of dietary iron, supplementation with pure 
ferritin would be immensely challenging due to the required scale of purification or the complexity 
of in vitro synthesis, leading to expensive overall costs. As an alternative, synthetic routes to get 
the ferritin core model were assayed using different low-molecular-weight organic acids as ligands 
with promising results [71, 97].  
 
1.3.3. Pharmacokinetics of nanoparticles 
A nanodrug system can offer several pharmacokinetic advantages such as specific drug 
delivery, high metabolic stability, high membrane permeability, improved bioavailability and long 
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duration of action. By altering these pharmacokinetic properties of nanodrugs, they can become 
drugs of promising efficacy [98]. These characteristics are determined by particle size, chemical 
structure, and surface chemical characteristics and absorption, distribution and clearance 
pathways will depend on them.  
Generally, nanomedicines can be classified according to their pharmacokinetic properties 
[99]. A classification example is collected in Table 6. 
Table 6. Classification of nanodrugs considering pharmacokinetic properties. 
Formulations  Pharmacokinetic properties 
Advantages Disadvantages 
Dendrimers Polysine 
Poly(amidoamine) 
PEGylated polylysine 
Lactoferrin-
conjugated 
- High permeability 
- Release control 
- Drug-selective   
delivery 
- Improved solubility 
Limit of 
administration routes 
Engineered materials Nanocrystal 
Nanosized 
Amorphous 
 
- Improved systemic 
exposure 
- Increased retention 
time in mucus 
- Various routes of 
administration 
Insufficient persistent 
emission 
Lipid nanosystems Emulsion  
Liposome 
Solid lipid 
Nanoparticle 
- Degradation or 
metabolism of 
formulated materials 
- Improved systemic 
exposure 
- Drug-selective 
delivery 
- Accumulation in 
tumour cells 
- Quick removal by 
RES uptake 
- Limit of 
administration routes 
Micelles  - High permeability 
- Improved solubility 
- Improved systemic 
exposure 
Insufficient persistent 
emission 
Polymeric 
nanoparticles 
Ethyl cellulose/casein 
PLGA alginate 
PLGA-PEG 
Hydrogel 
Albumin 
Chitosan analog 
- Stable drug release 
in vivo 
- Increased retention 
time of drug 
- Required initial 
burst protection 
- Limit of 
administration routes 
 
1.3.3.1. Administration route 
The administration route determines whether the action will be systemic or local. Also, the 
physicochemical characteristics of nanoparticles and the ligands employed affect the uptake. The 
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choice of local administration route depends on the target region. If the target is the liver or 
spleen, intravenous route is the best alternative. In the case of muscle or skin targeting, the route 
used can be topical, intramuscular, intradermal or subcutaneous. Whereas oral or intranasal 
administration are used in the case of targeting the mucosa. The advantage of these routes is the 
reduction of systemic toxicity associated. In this case, mucoadhesive nanoparticles are more 
useful because they increase the residence time at the absorption site. Considering this 
characteristic, different nanosystems, such as liposomes and polymeric nanoparticles, have been 
designed for treatment of pulmonary infections through inhalation [100, 101]. 
 
1.3.3.2. Distribution 
Nanoparticle size and physicochemical characteristics of the nanoparticle surface play a 
decisive role in uptake and other important processes like biodistribution or clearance. Uptake 
can occur through different mechanisms such as phagocytosis, macropinocytosis or endocytosis. 
This mainly depends on size, being the endocytosis pathway the most common one, owing to the 
typical small size of nanoparticles. Moreover, the smaller the nanoparticles, the slower the uptake 
rate by phagocytic cells, and faster biodistribution due to rapid dissolution [102]. Small size is 
better for reaching the lymphatic system, preventing uptake by RES and guiding distribution inside 
the cell [103]. In addition, small size is sometimes necessary for nanoparticles to circulate through 
capillaries, sinusoids, tissue structures and membrane or mucosa pores in order to reach extra- 
and intracellular compartments [104]. So, it is proved that smaller sizes increase the drug loading 
efficiency and the antimicrobial effect, lowering minimum inhibitory concentration (MIC) [101]. 
Another factor affecting biodistribution and uptake is the zeta(ζ)-potential because 
interactions with proteins of the blood, tissues or mucosa, and with the cellular membrane are 
charge dependent. In fact, these interactions will be responsible for the amount and type of 
proteins adsorbed; the adhesion or not to the mucosa and for how long; the endocytosis 
mechanisms; and biodistribution. The increment of hydrophobicity also affects the distribution as 
it decreases the diffusion kinetic in mucus, favours cellular uptake (due to interactions with the 
lipids of the cell membrane), and influences output from endosome and drug release [101, 105]. 
Distribution and uptake can also be driven by the addition of specific compounds or ligands to 
the nanoparticle surface which favour interactions with the cell membrane, enhancing the 
recognition of nanoparticles by cells. As an example, saccharide ligands have shown to be useful 
for targeting to macrophages and phagocytic cells [106]. So, the ligand is chosen depending on its 
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stability and selectivity considering the target cells, too. The availability and interactions with 
immunologic cells or with membranes must be also taken into account. Ligands also play an 
important role in intracellular biodistribution of the particle, because the carrier could remain 
within the endosome or escape from it to reach other organelles in the cytoplasm, depending on 
the ligand nature. 
Once nanoparticles reach the target site, the drug must be released. Some polymers can 
control and self-regulate drug delivery by modifying their structure, which may occur immediately 
or be sustained over a certain time. Modifications are induced by physiological conditions such as 
pH, hydrophilic/hydrophobic equilibrium, ionic strength or presence of specific molecules. The pH 
can modify the kinetics of release, thus protecting the drug from degradation in undesirable 
conditions or, conversely, promoting nanoparticles destruction and total release of the drug [107]. 
Similarly, ionisable polymers can modify their size, solubility and fluorescence due to changes in 
ionic strength [108]. Changes can also be provoked by external stimuli, such as electricity, 
magnetic fields, ultrasound or light which strengthen the drug release [109]. Therefore, the 
stimulus can be used in different ways to favour the treatment [101]. 
 
1.3.3.3. Elimination 
Elimination pathway has a crucial role in determining chronic toxicity of nanoparticles. When 
drug release is completed, nanoparticles must exit the cell if they have not been degraded. The 
exocytosis rate depends mainly on particle composition, ligands and surface properties. In this 
sense, cationic nanoparticles have a slow rate of exocytosis from macrophages because they 
agglomerate intracellularly [110], whereas PEG nanoparticles have the highest exocytosis rate 
because they hardly have interactions with intracellular proteins [111]. 
Eventually, nanoparticles are excreted from the body. In case they are smaller than 5 nm, it 
can occur by urine. Bigger ones are reabsorbed and trapped in the collagen network of the 
glomerular basal membrane, where they are taken up by macrophages [112]. If they are smaller 
than 200 nm, they are mainly excreted in the bile, but the process is slow and saturable, and 
accumulation is possible. However, this effect is of concern in the case of naked nanoparticles. 
According to some clinical trial results, this effect is reduced or even disappears when 
nanoparticles are protected with ligands or drugs [101, 112, 113]. 
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1.3.4. Impact evaluation in biological media: nanotoxicity 
Nowadays, our exposure to nanomaterials is significantly increasing but, there is still little 
understanding about toxicological properties of nanoparticles and their long-term impact on 
human health. There is a considerable gap between the available data on nanomaterials 
production and their corresponding toxicity evaluations.  
The most challenging aspect with the use of nanotherapeutic products is accumulation, 
analysis, classification, and characterization of the safety data about their clinical applications. 
Due to their small size, nanoparticles represent a huge health hazard since they can penetrate the 
barriers present within the human body and entering the organism by inhalation, ingestion, skin 
penetration or injections. Consequently, nanoparticles have the potential to interact with 
intracellular structures and macromolecules for long periods of time. There are evidence of these 
particles causing serious harm to cellular membranes, organelles and DNA owing to generation of 
free radicals [114]. Nanotoxicity assessment must be taken in consideration, especially in the case 
of new nanomaterials in the early stages of production [115]. 
Physicochemical properties such as chemical composition, small size, large surface- to-volume 
ratio, and surface property influence the biological interaction of nanoparticles and thus, they 
must be evaluated for determination of potential toxicity of nanomaterials [116].  
Particle size and surface area are crucial material characteristics, as interactions between 
nanomaterials and biological organisms typically take place at the surface of the nanosystem. As 
the size decreases, the surface area increases, and a greater proportion of atoms or molecules will 
be displayed on the surface of the particle rather than within the bulk of the material. Thus, the 
nanomaterial surface becomes more reactive with surrounding biological components with 
decreasing size, and the potential catalytic surface for chemical reactions increases [117].  
Shapes and aspect ratios are key factors to determine the toxicity of the nanoparticles. 
Nanomaterials can present different shapes including fibres, spheres, tubes, rings and planes and 
this can influence the membrane warping process during particle internalization via endocytosis 
or phagocytosis [118]. 
Importance of chemical composition has been also demonstrated, especially concerning cell 
molecular chemistry and oxidative stress [119]. 
The potential adverse effects of nanoparticles maybe eliminated or minimized by 
incorporation of surface coatings. Proper surface coatings can stabilize particles, avoid 
agglomeration and prevent from dissolution and release of toxic ions [120]. 
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Surface charge also plays an important role in toxicity, as it influences the adsorption of ions 
and biomolecules that may change organism or cellular responses toward particles. Moreover, 
surface charge is a major determinant of colloidal behaviour, which influences the organism 
response by changing the shape and size of nanoparticles through aggregate or agglomerate 
formation. In general, cationic nanoparticles are considered more toxic than neutral or anionic 
ones, possibly due to their high affinity towards the negatively charged plasma membrane. 
Therefore, nanotoxicity must be evaluated by changing nanoparticle properties systematically, 
one at a time [117]. 
Additionally, the medium that contains nanoparticles can affect negatively the toxicity of 
nanomaterials. Proper and stable dispersion of nanoparticles are necessary for their biological 
distribution and activity. However, the tendency to agglomerate makes the use of dispersion or 
wetting agents essential. These media would improve the physicochemical and solution 
properties of nanomaterials formulations but could have adverse effects on the safety of these 
materials [121, 122]. 
In the case of iron oxide nanoparticles, the information reported in the literature may be 
conflicting. Depending on the chemical nature of their coating, iron nanoparticles do not have the 
same behaviours in biological systems, e.g. they can be internalized into cells or attached onto the 
cell membranes, leading to cell death or cell proliferation. Uncoated iron-based nanoparticles 
induce a dramatic decrease in the metabolic activity and proliferation of human cells. Generally, 
the coating of these nanoparticles seems to be of great importance with regard to cell adhesion, 
internalization efficiency, and cytotoxic effects [123–125]. 
 
1.3.4.1. Cell toxicity 
Due to the effect of the aspects previously commented, it is expected that nanoparticles exert 
several mechanisms by which they affect cell homeostasis, apart from some nanoparticle-type 
specific considerations. 
As nanoparticles have defined physical dimensions, the intracellular volume they occupy can 
lead to alterations in cellular morphology or affect the structure of the cellular cytoskeleton 
network. For different types of nanosystems, the effects described have been dependent on 
intracellular nanoparticle concentration and transient, where after recurrent cell divisions, the 
intracellular nanoparticle concentrations decrease exponentially, and the effects are no longer 
observed. 
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Inorganic nanoparticles can also interfere with the delicate balance of cellular homeostasis 
and hereby alter complex intracellular signalling pathways, resulting in a cascade of possible 
effects. These interactions can occur by several mechanisms, such as:  
(1) Genotoxic effects caused by high levels of ROS (explained more in detail in the following 
section). 
(2) Modified protein or gene expression due to the perinuclear localization of the particles 
which may hinder the functioning of the transcription and translation steps. 
(3) Altered protein or gene expression levels due to leaching of free metal ions. 
(4) Different activation status of proteins by interfering with stimulating factors such as cell-
surface receptors. 
(5) Altered gene expression levels in response to the cellular stress induced by the 
nanoparticle. 
As it was already mentioned, the high surface area and high local charge densities of 
nanostructures generate a large area ready to interact with surrounding biological molecules. 
When the nanoparticles are subjected to physiologically relevant conditions, the surface charges 
favour the binding of available serum proteins, leading to a so-called protein corona [126]. The 
presence of serum proteins in the surrounding media of nanoparticles automatically lead to a tight 
association of both entities, unless a specific nanoparticle coating which inhibits protein 
attachment is employed. In terms of possible biological/toxicological effects, it was further 
observed that the proteins interacting with nanoparticles undergo conformational changes. These 
conformational changes could have profound effects on cellular stability since our immune system 
may then not recognize these proteins as native but rather as foreign objects and may try to 
eliminate them, inducing then autoimmunity. Binding of serum proteins to nanoparticles may also 
directly affect their endocytic route and degree of cytotoxicity [127, 128]. 
Currently, most nanoparticle-related cytotoxicity data are generated by individual studies, 
with a few specific parameters monitored for a certain type of nanostructure and a certain cell 
line. To enhance the comparison of generated data and improve our understanding in this matter, 
there is an urgent need for standardization of the protocols used. For a specific sort of 
nanoparticle, the range of concentrations and incubation times employed should always be 
precisely defined and should be the same for all studies. The type of cells used is also of great 
importance as different cell types can react quite differently even for the same type of 
nanomaterial. In general, those cell lines which are most involved in the biomedical applications 
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of the nanoparticles should be preferably tested (epithelial, endothelial cells), or multiple cells 
derived from the different germ layers. 
Standardization is also necessary concerning the kind of assays used. The in vitro methods are 
ideal in nanotoxicology research because they can produce reproducible results rapidly and 
inexpensively without the use of animals [121]. Basically, to assess the toxicity profile of 
nanoparticles, two main approaches have been established:  
1) Functional assays evaluate the effects of nanoparticles on cellular processes;  
2) Viability assays probe whether the nanoparticles cause death in a cell or a system of cells 
[117]. 
Cell viability is quite a general term and can be investigated by numerous assays which 
determine one or more cellular parameters:  
a. WST or MTT assays measure mitochondrial activity  
b. Lactate dehydrogenase (LDH), trypan blue or propidium iodine assay check cell 
membrane permeability 
c. Calcein AM for the assessment of intracellular esterase activity 
d. Fluorescent Annexin V or caspase substrates focus on apoptosis indicators. 
Although the cytotoxic effects of iron oxide nanoparticles are known, the mechanism(s) of 
their induced cytotoxicity is not clearly understood. Moreover, there is a lack of consensus among 
the different studies found in the literature, but it is clear that the surface coatings and particle 
size are crucial for iron nanoparticle-induced effects, as they are critical determinants of cellular 
responses, intensity of effects and potential mechanisms of toxicity. In order to make results 
comparable across these investigations on iron nanoparticles with different coatings and 
characteristics, the use of standardized methods would be highly desirable [129]. 
1.3.4.2. Oxidative stress 
The generation of reactive oxygen species (ROS) by cultured cells incubated with nanoparticles 
is quite a common phenomenon. When cells are exposed to environmental stress such as 
pathogens or heat, they can generate chemically active oxygen-containing molecules [128]. ROS 
can be classified into two different types: radical ROS (superoxide anion and hydroxyl radical) and 
non-radical ROS (hydrogen peroxide and hypochlorous acid). Cells have defense mechanisms to 
clear radicals, such as glutathione redox system (GSH). Under normal conditions, a balance exists 
between the generation and clearance of radicals that does not negatively affect the body. 
However, when the increase in ROS is too high that it cannot be handled by normal removal 
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mechanisms, ROS accumulate and can damage the structure of cells, affecting their functions. ROS 
can oxidize membranes, and the end-product of lipid oxidation is malondialdehyde (MDA). 
Therefore, ROS, GSH, and MDA are usually used as biomarkers of oxidative damage to measure 
the toxicity of a material [116]. 
There are different pathways by which nanoparticles can induce oxidative stress: 
a) A nanomaterial present in the acidic environment of lysosomes can induce ROS by direct 
reactivity of their surface coating, degradation of the coating and direct interaction of the 
acidic media on the metal surface or degradation of the whole nanoparticle and 
production of ions (Fe2+, Cd2+) which can induce ROS species by various chemical reactions. 
b)  They can also directly interact with oxidative organelles such as the mitochondria by 
destabilizing the outer membrane, deregulating the mitochondrial membrane potential 
and disrupting the electron transport chain of the oxidative phosphorylation. 
c) Nanoparticles can directly interact with redox active proteins such as NADPH oxidase and 
hereby stimulate large ROS production in cells of the immune system. 
d) Interaction of nanoparticles with surface located receptors can lead to receptor activation 
and triggering of intracellular signalling cascades (activation of second messenger or 
calcium waves), finally resulting in expression of stress response genes which can 
upregulate ROS (Figure 5 [128] (d)). 
As ROS has been claimed to be of major importance in the toxicological profile of 
nanoparticles, the evaluation of elevated ROS levels is of crucial importance. Commonly, 
Figure 5. Graphic overview of different pathways to induce oxidative stress from nanoparticles [128]. 
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fluorescent probes such as dichlorodihydrofluorescein and its derivatives are used to assess ROS 
levels. It is important to use multiple time points to accurately define the maximal ROS levels, as 
the kinetics of ROS induction can largely differ between various nanoparticles and it is also 
important to know whether the effects are transient or more long-lasting. As the link between 
elevated ROS levels and cytotoxicity is unclear, it is also important to further investigate any 
possible secondary effects in case significant ROS induction is observed. Useful parameters to 
study would be mitochondrial metabolism (using fluorescent probes), lipid or protein 
peroxidation, cytoplasmic calcium levels, cytoplasmic redox state (by measuring glutathione 
levels) or DNA defects [128]. 
Iron, which plays an active redox-catalytic role in many energy-transfer or electron-transfer 
processes due to its partially filled d orbitals and variable oxidation states, is intimately linked to 
ROS chemistry.  Successive one-electron or two-electron reduction of molecular oxygen to water 
in the aqueous solution yields a series of ROS such as superoxide radicals (O2-/HO2·), hydrogen 
peroxide (H2O2), and hydroxyl radicals (OH·). Metal iron and iron oxide nanoparticles can be 
involved in these redox reactions as a reactant or a catalyst via homogeneous or heterogeneous 
methods, based on dissolved iron species or solid surfaces, respectively. 
Many in vitro experiments confirmed the production of these radical species which can be 
explained in terms of the following reactions:  
• The classic homogeneous Fenton reaction, which involves one-electron reduction of 
hydrogen peroxide by soluble ferrous iron species, generates hydroxyl radicals that are 
powerful enough to oxidize most organic molecules: 
Fe (II) + H2O2 → Fe (III) + OH- + OH·                     (1) 
• The non-radical mechanism for the homogeneous Fenton reaction involves the 
generation of ferryl-oxo complexes, less powerful oxidants compared to hydroxyl radicals, 
via two-electron reduction of hydrogen peroxide with soluble ferrous iron species: 
Fe (II) + H2O2 → Fe (IV)O2+ + H2O                         (2) 
• The homogeneous Fenton-like reactions, which involve the generation of superoxide 
radicals, hydroxyl radicals, or ferryl-oxo complexes from hydrogen peroxide and soluble 
ferric iron species, consist of two steps; a slow one-electron reduction of ferric iron by 
hydrogen peroxide and a rapid generation of powerful oxidants via reaction (1) or (2): 
Fe (III) + H2O2 → Fe (II) + HO2·/O2-· + H2O         (3) 
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• The Haber-Weiss reaction, which involves generation of hydroxyl radicals from hydrogen 
peroxide and superoxide, can be catalyzed by soluble ferric iron species through reaction 
(4) and (1) [130]: 
Fe (III) + HO2·/O2-· → Fe (II) + H2O/OH- + O2    (4)  
Iron-induced oxidative stress has the following implications: (i) failure in redox regulation 
leading to DNA damage, lipid peroxidation and oxidative protein damage and free radical-induced 
activation of signal transduction pathways [131]. 
In spite of the large number of studies on iron nanostructures, there is still too much unknown 
about how their intrinsic physicochemical properties affect the redox reactivity of iron 
nanoparticles. Additional work is needed to characterize the redox activities of these 
nanostructures under various bio-microenvironmental conditions, which is one of the aims in this 
study. 
 
1.4.  Analytical strategies for the characterization and 
determination of metallic nanoparticles  
The analysis of metallic and metal oxide nanoparticles in biological and environmental 
samples is a complex analytical challenge due to different factors: 
• Low concentration level (mg L-1 to ng L-1) that makes the use of highly sensitive and 
selective detection techniques essential to obtain low detection limits. 
• In complex matrixes, dilution or pre-treatment is a must, with the consequence of 
decreasing of the metal concentration. 
• Nanoparticles characterization may be a difficult task in biological or environment 
samples due to agglomeration/aggregation or protein corona formation that usually occur 
in presence of proteins or saline solutions.  
• Sample handling during all analytical steps must be careful in order to keep the nature of 
metallic species in the nanostructure and avoid wrong information about degradation or 
particle size. 
• The target metal, which is in low concentration in the nanostructure, can be found in 
different species (different size particles, ions, biomolecules, protein complex, etc.) so 
limits of detection required for the target would be significantly lower than for total 
concentration, or impossible to differentiate. 
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• Possible analyte losses or sample transformation during the analytical process are 
important variables to monitor in order to get reliable results in ultra-trace analysis. 
In addition to all these general factors, it is remarkable that nanoparticles in biological 
matrixes usually present polydispersity and can experience degradation, functionalization, 
agglomeration and other in vivo processes leading to different species formation in the medium. 
This can affect the separation or speciation strategy chosen, as it should be able to distinguish 
between nanoparticles, conjugates, agglomerates and free ions. The ideal technique would be 
able to differentiate among different species without their modification, allowing quantitative 
recoveries in less time possible with the highest reproducibility.  
Analytical chemistry for the determination and characterization of nanoparticles is mainly 
focused on searching strategies which provide information about chemical composition (core and 
surface), size/size distribution and shape, agglomeration state and crystalline structure. 
As it has already been explained, most of properties and applications of nanoparticles depend 
on their size. Likewise, their separation is based on particle size or size distribution. In Table 7, a 
summary of principal techniques used for the characterization of particle size is presented with 
their major advantages and limitations according to a review from Shang et al. [117]. Most of them 
will be discussed in more detail in following sections. 
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Table 7. Most common techniques to characterize nanoparticle size. 
Technique Advantages Limitations 
ICP-MS  
Single 
Particle 
mode 
- Determines the particle 
number concentration 
(particles/mL) and the 
mass of metal in individual 
particles and size 
distribution 
 
- Does not provide direct 
information on particle 
shape or diameter 
- Minimum particle size is 
limited by ICP-MS 
sensitivity, background and 
dissolved (ionic) element 
content 
 
Hyphenated 
Techniques 
- Minimum particle size is 
not limited by ICP-MS 
sensitivity 
- Determine total metal  
concentration as a 
function of particle size 
fraction 
 
- Do not provide direct 
information on number of 
particles or characteristics 
of individual particles 
 
TEM (Transmission Electron 
Microscopy) 
- Direct visualization 
- High resolution 
- NP aggregation during 
sample preparation 
- Electron beam damage 
- Preference for electron-
dense atomic species 
DLS (Dynamic Light 
Scattering) 
- Size distribution 
information available 
- Fast, simple 
- Signal dominated by larger 
NPs 
- Interference from 
luminescent species 
Absorption spectra - Simple, fast 
- Applicable to plasmonic 
(Au, Ag) and 
semiconductor (CdSe, 
CdTe) NPs 
Analytical centrifugation 
- Size distribution 
information available 
- High size resolution 
- Density of NPs needs to be 
known 
- Long measurement time 
 
1.4.1. Non-hyphenated techniques 
1.4.1.1. Inductively coupled plasma mass spectrometry (ICP-MS) 
Since its development in the early 80s, ICP-MS has become one of the most important 
techniques in the field of atomic spectroscopy. The technique has been continuously refined over 
the years and adapted to new requirements, but the basic principle remains nearly unchanged. 
ICP-MS allows the analysis of gaseous, liquid and solid samples which are introduced as an aerosol 
into an atmospheric plasma. The plasma torch is the centrepiece of this ionization source and is 
represented in Figure 6. A plasma torch is composed of three concentric quartz tubes which 
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different Ar gas flows are injected: a cooling gas flow of ≈ 12-17 L·min-1 injected tangentially, 
preventing the outer quartz tube from melting by physical contact to the extremely hot plasma; 
an auxiliary gas flow (≈ 0.5-1.5 L min-1) applied to change the position of the plasma base relative 
to the injector tube and prevent it from melting; and the nebulizer gas flow (0.5-1.5 L min-1 
depending on the applied nebulizer) that allows the introduction of the sample as an aerosol [132, 
133]. 
The end of outer quartz tube is surrounded by a load coil, typically made from copper. Before 
plasma ignition, a tangential argon gas flow is injected between the outer and middle tube quartz 
torch (auxiliary gas). Then, an oscillating electric current (750-1500 W) is applied to the load coil. 
For power supply, radio frequency (RF) generators using frequencies of 27 MHz are used. As a 
result, a strong oscillating electromagnetic field is generated at the end of the torch. By 
introduction of a start ignition spark, free electrons are generated that are accelerated by the 
influence of the electromagnetic field. The electrons collide with neutral Ar atoms resulting in the 
formation of further ions by either direct ionization (electron impact) or secondary ionization 
(charge transfer from ionized Ar species). This process results in the formation of a plasma 
discharge which is sustained as long as RF power is supplied to the load coil. Since the plasma is 
consisted of ions, excited ions, electrons, and neutrals it is electrically conductive but neutral to 
its surrounding (electroneutrality of the plasma) [132]. 
Figure 6. Schematic setup of the plasma torch in the ICP-MS (source: www.thermoscientific.com). 
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If a sample aerosol, containing the analyte in solution, is injected into the plasma, the droplets 
are first desolvated by the influence of the plasma temperature (≈ 6000-10000 K). The remaining 
solid or liquid particles are then vaporized or sublimated. Then, the high energy density in the 
plasma causes that molecules break down into their atomic components (atomization). 
Consequently, all structural information is lost and only the total element amount is accessible. 
Finally, the atoms are excited due to the high plasma temperature. Also, sufficient energy is 
transmitted to remove an electron from the outer electron shell of the atom, leading to the 
formation of positively charged ions as well. This process depends on the first ionization energy 
of the corresponding element. Therefore, all elements having a first ionization potential below 
15.75 eV (first ionization potential of Ar) are ionized in the Ar-based plasma. The ionic species 
generated can be analysed by the mass spectrometer (MS). In this case, the ions must be 
transferred from the atmospheric pressure of the plasma (≈ 1 bar) to the high vacuum of the mass 
spectrometric device (≈ 10-9 bar) thanks to the interface of the ICP-MS. More precisely, ions from 
the plasma are extracted through two adjacent metal cones: the sampler and the skimmer cone 
(orifice diameter 0.8-1.2 mm and 0.4-0.8 mm, respectively). Between both cones, a pressure of 
approximately 2·10-3 bar is maintained by a rotary vane pump. Behind the skimmer cone, the high 
vacuum part of the MS devices keeps the ion optics, the mass analyser and the detector [132, 
134]. 
The ICP-MS enables a very sensitive and robust determination of a certain hetero atom 
present in a sample. Moreover, due to the fact that ICP-MS is well suited for gaseous and liquid 
samples, it can be hyphenated online with powerful separation techniques such as gas 
chromatography, high performance liquid chromatography or electrophoretic techniques.  
In terms of nanoparticle analysis, ICP-MS has demonstrated to be a rapid, accurate, sensitive 
technique for characterizing and quantifying nanoparticles in a wide range of sample types. The 
main benefits of ICP-MS for the detection, characterization, and quantification of nanoparticles 
are related to its high sensitivity and specificity, which can provide additional information 
compared to other techniques such as dynamic light scattering. ICP-MS is also fast and requires 
little sample preparation compared to techniques such as scanning or transmission electron 
microscopy (SEM, TEM), atomic force microscopy (AFM), or separation techniques such as 
differential centrifugation. Characterization of nanoparticles using ICP-MS detection can be 
achieved via one of two different strategies: single particle or hyphenated mode [135]. Both will 
be described in more detail in following sections. 
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However, ICP-MS analysis implies some limitations related to interferences that can affect 
sample measurements. There are three major groups of interferences: spectral, matrix, and 
physical. Each of them is potentially problematic, but modern instrumentation and good software, 
combined with optimized analytical methodologies, has minimized their negative impact on trace 
element determinations by ICP-MS [136]. 
Among the spectral interferences, the most common type is known as a polyatomic or 
molecular spectral interference, which is produced by the combination of two or more atomic 
ions. They are caused by a variety of factors but are usually associated with either the plasma and 
nebulizer gas used, matrix components in the solvent and sample, other analyte elements, or 
entrained oxygen or nitrogen from the surrounding air. There are several alternatives to avoid 
these interferences: blank subtraction, matrix modifications, mathematical corrections or 
chemical separations. But there are other solutions based on instrumental corrections such as the 
use of collision/reaction cells or a high-resolution mass analyser. In the case of collision/reaction 
cells, the basis is the use of ion–molecule collisions and reactions to cleanse the ion beam of 
harmful polyatomic and molecular interferences before they enter the mass analyser. For that 
purpose, inert gases (mainly He) are used to collide with interferent ions, or reaction gases (H2, O2 
or NH3) are applied to convert the ion into a new mass that is not interfered. Thus, 
collision/reaction cells are showing enormous potential to eliminate spectral interferences and 
make available isotopes that were previously unavailable for quantitation. However, the best and 
probably most efficient way to remove spectral overlaps is by the use of a high-resolution mass 
spectrometer. During the past 10 years this approach, particularly with double-focusing magnetic 
sector mass analysers, has proved to be invaluable for separating many of the problematic 
polyatomic and molecular interferences seen in ICP-MS, without the need to use cool plasma 
conditions or collision/reaction cells [136]. Lately, a more “affordable” alternative that allows 
removal of isobaric and polyatomic interferences has been developed based on a mass shift mode 
by using a triple quadrupole system. Basically, it consists on the online configuration of two 
quadrupoles and one reaction cell between them. The first quadrupole acts as a filter and rejects 
all masses except analyte mass (analyte and on-mass interferences). Then, analyte reacts 
selectively with a reaction gas in the reaction cell, turning into a new product ion mass and being 
differentiated from the interferences that are not reactive. Finally, last quadrupole rejects all cell 
formed ions apart from analyte product ion, leaving analyte free from overlap. It can only be seen 
as a reaction cell ICP-MS evolution [137]. 
Another type of spectral interferences is called “isobaric overlaps” and are produced mainly 
by different isotopes of other elements in the sample that create spectral interferences at the 
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same mass as the analyte. For example, both Fe and Ni have isotopes at mass 58. Therefore, any 
signal measured at m/z 58 will have contributions from both Fe and Ni. To avoid this kind of 
interferences it is necessary to choose different isotopes of the analyte or apply mathematical 
corrections [138].  
In the case of the Fe, the determination of the four isotopes (54Fe 5.845 %, 56Fe 91.754 %, 57Fe 
2.119 %, 58Fe 0.282 %) by ICP-MS using single quadrupole mass analysers, is limited by the isobaric 
and molecular interferences collected in Table 8. 
Table 8. Spectral interferences of the four isotopes of Fe. 
 54Fe 56Fe 57Fe 58Fe 
Isobaric 
interferences 
54Cr   58Ni 
Polyatomic 
interferences 
40Ar14N+ 
38Ar16N+ 
36Ar18N+ 
40Ar16O+ 
40Ca16O+ 
40Ar16OH+ 
38Ar18OH+ 
40Ca16OH+ 
40Ar18O+ 
40Ca18O+ 
42Ca16O+ 
 
The most common way to overcome Fe interferences such as the one produced by 40Ar16O+ 
(m/z 55.957) over the most abundant isotope of iron 56Fe (m/z 55.935) is by using H2 as reaction 
cell gas [139, 140] and so it was done in this work. Other gases like NH3, N2, CO, CH4, He, Kr, etc. 
have also been used for the same aim [141]. Similarly, polyatomic interferences of Ar over other 
isotopes like 54Fe or 57Fe can also be reduced by using collision/reaction cells [142, 143]. 
 
Single Particle detection (spICP-MS) 
Single particle detection or spICP-MS is a relatively simple and direct technique for the 
determination of particle size and concentration in terms of number of particles present in a 
sample. The main principle behind spICP-MS is detection of a discrete pulse, originated from 
ionization of a single particle, using short detection or dwell time. If the particle composition is 
known, the signal from a single particle event can be correlated to particle mass, and the number 
of signals detected in the sample to particle number concentration.  
It requires an ICP-MS system properly configured and an appropriate dilution of the sample. 
ICP-MS configuration will be discussed in following sections. This technique enables not only the 
determination of particle size, but also size distribution with corresponding percentage of each 
population present in the sample. Number of events or signals per nanoparticle gives information 
about concentration of particles, while signal intensity is related with the element mass and can 
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be turned into size particle if particle shape is assumed as perfectly spherical. On the other hand, 
released ions from nanoparticles (at a sufficiently high concentration to be detected) produce 
signals in constant intensity pulses [144]. The concentration of these ions is related to the 
background signal of the analysis and therefore, can be easily calculated using an external 
calibration. 
A proper adjustment of detection time (dwell time) and an accurate concentration of 
nanoparticles in the sample are critical factors for the optimization of the measurement and key 
steps to overcome the main limitation of this method in terms of calculations: partial signal 
counting (too short dwell time) or double counting of particle events (too long dwell time or too 
high concentration of the sample). Additionally, transport efficiency estimation is the major 
source of error for the calculation of particle size. In this sense, differences between transport 
efficiency for the calibration matrix and sample matrix must be taken into account for the 
calculation [145]. 
Although the spICP-MS can be a suitable tool for the direct characterization of metallic 
nanoparticles, it is highly dependent on the signal to noise ratio of the ICP-MS used for the 
analysis, especially between nanoparticles signal and background caused by the ions. This does 
not allow to distinguish between small nanoparticles signal and ions in the sample or coming from 
nanoparticle degradation. Actually, detection limits in terms of particle size for silver, gold, and 
titanium oxide nanoparticles were recently established at 13, 13 and 91 nm, respectively [146]. 
 
Laser Ablation coupled to ICP-MS (LA-ICP-MS) 
In addition to quantitative MS-based methods, which allow the quantification of nanoparticles 
and their elemental composition in solutions, methods that allow similar analysis to be performed 
on surfaces have also been developed. In Laser Ablation coupled to ICP-MS (LA-ICP-MS), also 
referred to as “chemical imaging” [147, 148], a pulsed laser beam is used to ablate (eject) small 
quantities of material from the solid surface of a sample, enclosed in a chamber filled with inert 
gas. The ablated aerosol is transported with the stream of carrier gas to an ICP-MS instrument for 
elemental and/or isotopic analysis. A schematic set-up of the coupling between the laser ablation 
and the ICP-MS from Günther et al. [149] is presented in Figure 7. 
LA-ICP-MS requires little or no sample preparation, offers good sample throughput and in 
optimal conditions sample resolution < 1 μm. This resolution can be achieved using a narrow beam 
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diameter and low laser rastering rate but decreasing the number of detectable atoms in this area 
and thus, sacrificing analyses time and sensitivity. Still, the μ-range resolution is not enough for 
the detection of nanoparticles, and for nano-range resolution, additional methodological 
advances are to be expected [150].  
Examples of studies where LA-ICP-MS has been used to evaluate cell–NP interactions include 
the work of Drescher et al., which demonstrated the applicability of the technique for the 
quantitative imaging of 50 nm-silver and 25 nm-gold nanoparticles in single eukaryotic cells. 
Quantification was achieved based on a matrix-matched calibration using nitrocellulose 
membranes doped with nanoparticle suspension [151]. Böhme et al. applied LA-ICP-MS to study 
metallic NPs in crustaceans and zebrafish embryos [152] and Managh et al. showed the 
applicability of LA-ICP-MS for the analysis of single human macrophages exposed to 50 nm Au 
particles [153]. All these results demonstrate a great potential of LA-ICP-MS for nanotoxicity 
investigations, nanobioanalytics, and quantitative elemental microscopy. 
 
1.4.1.2. Electron microscopy 
Microscopic techniques are employed for the characterization of nanoparticles in terms of 
size, morphology, and, in some cases, composition and has made research of these nanomaterials 
possible. Electronic microscopy (EM) is often used for the characterization of metallic 
nanoparticles due to sub-nanometer range resolution and the information they can provide about 
Figure 7. Schematic set-up of laser ablation system coupled to ICP-MS [149]. 
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particle size, size distribution, dispersity, morphology, and aggregation state from the direct 
visualization of metallic core of nanoparticles [154]. 
There are basically two alternatives available in electron microscopy: Transmission Electron 
Microscopy (TEM) and Scanning Electron Microscopy (SEM). All these techniques use high 
vacuum mode (at around 10-4 Pa) which minimises scattering of the electron beam before 
reaching the specimen. This is important as scattering or attenuation of the electron beam would 
increase the probe size and reduce resolution.  
Among all of them, TEM is the most used technique and it is based on the use of a beam of 
highly energetic electrons that impacts on a sample deposited on an ultrafine grid. On the way 
through the sample, some parts of the material stop or deflect electrons more than other parts. 
The electrons are collected from below the sample onto a phosphorescent screen or through a 
camera. In the regions where electrons do not pass through the sample the image is dark. Where 
electrons are unscattered, the image is brighter, and there are a range of greys in between 
depending on the way the electrons interact with and are scattered by the sample. Magnifications 
of up to 1,000,000 and resolution below 1 nm are achieved routinely. A scale is essential on a TEM 
image. From this the actual size of structures in the image can be calculated. It also enables the 
possibility of coupling to other techniques such as Electron Energy-Loss Spectroscopy or energy 
dispersive X-ray analysis, providing additional information about electronic structure and chemical 
composition of the nanomaterial, respectively [155, 156]. 
In summary, TEM is a useful tool for: 
• Imaging morphology of samples e.g. view sections of material, fine powders suspended 
on a thin film, small whole organisms such as viruses or bacteria, and frozen solutions. 
• Analysing the composition and some bonding differences (through contrast and by using 
spectroscopy techniques: microanalysis and electron energy loss). 
• Acquiring electron diffraction patterns (using the physics of Bragg Diffraction). 
• Perform electron energy loss spectroscopy of the beam passing through a sample to 
determine sample composition or the bonding states of atoms in the sample [157]. 
However, it also has some limitations: 
• TEM cannot take colour images so it could not be used for staining procedures. 
• TEM cannot image through thick samples: the usual sample thickness is around 100-200 
nm because electrons cannot readily penetrate sections thicker than 200 nm. 
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• A standard TEM cannot image surface information. 
• The TEM cannot reliably image charged molecules that are mobile in a matrix. For 
example, some species (e.g. Na+) are volatile under the electron beam because the 
negative electron beam exerts a force on charged material. 
• It is a laborious and expensive technique to be established as routine analysis [158]. 
High Resolution Transmission Electron Microscope (HR-TEM) is an image mode used to study 
nanomaterial properties and structure at atomic scale and create crystallographic structure 
images [159]. It is also used on the study of coatings and the protein corona surrounding the 
nanoparticle in commercial and biological samples [160]. 
TEM analysis in biological samples such as cell cultures or tissue samples enables the 
assessment of nanoparticle incorporation into the tissues and allows to follow the fate inside the 
cells. Conditions must be modified to work with these biological matrixes in order to avoid the 
excessive damage that the electron beam can cause on the sample (accelerating voltage must be 
reduced to 100 keV). Moreover, a pre-treatment of the samples is required based on fixation, 
dehydration and staining processes [161]. 
SEM uses a focused beam of high-energy electrons to generate a variety of signals at the 
surface of solid specimens that derive from electron-sample interactions and reveal information 
about the sample including external morphology (texture), chemical composition, and crystalline 
structure and orientation of materials making up the sample. In most applications, data are 
collected over a selected area of the surface of the sample, and a 2-dimensional image is 
generated that displays spatial variations in these properties. Accelerated electrons in a SEM carry 
significant amounts of kinetic energy, and this energy is dissipated as a variety of signals produced 
by electron-sample interactions when the incident electrons are decelerated in the solid sample. 
These signals include secondary electrons (most valuable for showing morphology and 
topography on samples), backscattered electrons (most valuable for illustrating contrasts in 
composition in multiphase samples), diffracted backscattered electrons (used to determine crystal 
structures and orientations of minerals and most valuable for illustrating contrasts in composition 
in multiphase samples), photons (characteristic X-rays that are used for elemental analysis and 
continuum X-rays), visible light (cathodoluminescence–CL), and heat [162]. 
However, it is not possible to:  
• Image through water. 
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• Reliably image charged molecules that are mobile in a matrix.  
• Quantify surface roughness at small scale. Atomic Force Microscope (Scanning Probe 
Microscopy) is more useful for this task. 
• Do directly measurements that involve height (z-axis). This requires two images that have 
been tilted relative to one another to create a 3D image, and specialised processing 
software. 
• Use for experiments involving liquids, chemical reactions, and air-gas systems although 
some specialised machines and sample chambers do allow for these experiments. 
• Achieve high enough resolution to image individual atoms (it is better to use a 
transmission electron microscope). 
• Carry out elemental analysis below micron scale (although it would be possible to get 
elemental information on the sub-micron scale working below 7keV) [163]. 
Main characteristics of the two techniques are summarized and collected in Table 9 according 
to publication of Eaton et al. [164]: 
Table 9. Main aspects of Electron microscopy techniques. 
 
In Figure 8, examples of 15 nm-gold nanoparticles (6A) and 50 nm-silica nanoparticles (6B) 
images taken from AFM, TEM, and SEM can be observed according to the previous cited paper 
[164]. 
 
 
 
 
 
 
Technique Resolution Physical basis Environment Parameters 
measured 
TEM 0.1 nm Scattering of electrons 
Vacuum Size and shape 
SEM 1 nm Emission of electrons 
Vacuum Size and shape 
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detector coupled to other separation techniques such as Field Flow Fractionation, liquid 
chromatography or capillary electrophoresis [171–173].  
One of the major advantages is that the sample can be measured in solution and thus, in 
conditions closer to original state, which means without altering the structure. DLS also provides 
information about nanoparticles stability in solution with time [174]. 
Although DLS is a highly powerful technique, it suffers some limitations such as: 
• High sensitivity to temperature and solvent viscosity. Therefore, the temperature must be 
kept constant and solvent viscosity must be known for a reliable DLS experiment. This 
implies that samples must be thermodynamically stable during measurements. 
• It is a low-resolution method that often cannot separate molecules that are closely related 
(e.g., monomer and dimer). 
• Particles must have a different refractive index from the matrix or solvent. 
• Concentration must be high enough but DLS is also restricted to transparent solution 
preparation, so a compromise must be reached in order to get reliable results. 
• Large aggregates, even a very small amount, can affect the measurements. Therefore, the 
sample-holding cuvette must be cleaned thoroughly, and sample must be filtered prior to 
DLS measurements [166]. 
Scattering intensity depends on the sixth power of the hydrodynamic diameter of the particle 
and thus, signal decreases significantly when particle size also decreases. Therefore, it is also 
difficult to determine accurate size distributions by DLS in highly polydisperse nanoparticle 
samples.  
Multiangle light scattering (MALS) is a scattering variant technique which measures the light 
scattered by a sample into a plurality of angles. It is used for determining both the absolute molar 
mass and the average size of molecules in solution. Collimated light from a laser source is most 
often used, in which case, the technique can be referred to as multiangle laser light scattering 
(MALLS). The "multiangle" term refers to the detection of scattered light at different discrete 
angles as measured, for example, by a single detector moved over a range that includes the 
particular angles selected or an array of detectors fixed at specific angular locations. It requires 
cleaner or more diluted samples than DLS to detect particle size. MALS is frequently used as a 
detector in separation techniques to monitor eluting colloidal and nanoparticle fractions [175–
178].  
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1.4.1.4. X-ray diffraction 
X-ray diffraction (XRD) is a non-destructive tool for the investigation of the matter structure. 
X-rays are photons whose energies range from 100 eV to 100 keV (wavelength from 0.01 to 10 
nm). Photons with energies above/below 5–10 keV (below/above 0.2–0.1 nm wavelength) are 
called hard/soft X-rays, respectively. X-rays are scattered by interaction with the electrons of the 
atoms in the material investigated, providing information of the atomic structure and chemical 
bonds within the nanoparticles. Basically, the X-ray beam impacts the sample forming an angle, 
Ɵ, to subsequently, generate diffraction X-rays collected at angles 2Ɵ [179].   
This technique uses X-rays to examine and quantify the crystalline nature of materials by 
measuring the diffraction of X-rays from the planes of atoms within the material and is sensitive 
to both the type and relative position of atoms in the material as well as the length scale over 
which the crystalline order persists. Thus, it can be used to:  
• Measure the crystalline content of materials. 
• Identify the crystalline phases present (including the quantification of mixtures in 
favourable cases).  
• Determine the spacing between lattice planes and the length scales over which they 
persist.  
• Study preferential ordering and epitaxial growth of crystallites.  
Essentially, it probes length scales from approximately sub-angstroms to a few nanometres 
and is sensitive to ordering over tens of nanometres [180–182]. 
 
Small-angle X-ray scattering (SAXS) belongs to X-ray techniques and allows the quantification 
of nanoscale density differences in a sample. Therefore, it can determine nanoparticle size 
distributions, resolve the size and shape of (monodisperse) macromolecules, determine pore sizes 
and characteristic distances of partially ordered materials by analysing the elastic scattering 
behaviour of X-rays when travelling through the material, and recording their scattering at small 
angles (typically 0.1 - 10°). The major problem that must be overcome in SAXS instrumentation is 
the separation of the weak scattered intensity from the strong main beam. The smaller the desired 
angle, the more difficult this becomes. However, it enables the characterization of a wide variety 
of samples including solid or liquid, crystalline or amorphous materials, colloids of all types, 
metals, cement, oil, polymers, plastics, proteins, foods and pharmaceuticals [183, 184]. 
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Small and wide-angle diffraction and scattering are often used as synonymous (SAXD and 
SAXS working at the nanoscale; WAXD and WAXS working at the atomic scale) [179]. Only the 
distance from sample to the detector is shorter in WAXS and thus, diffraction maxima at larger 
angles are observed. Depending on the measurement instrument used it is possible to do WAXS 
and SAXS in a single run (SWAXS). 
 
Energy-dispersive X-ray spectroscopy (EDS, EDX, EDXS or XEDS), sometimes called energy 
dispersive X-ray analysis (EDXA) or energy dispersive X-ray microanalysis (EDXMA) provides 
information about the elemental composition or chemical characterization of a sample. Its use is 
frequently associated to electronic microscopy instruments (TEM or SEM) for the analysis of 
metallic and metal oxides nanoparticles composition [185, 186]. Due to this coupling, 
determination of elemental composition in liquid samples, assessment of nanocrystals growing, 
or the assurance of crystals purity are possible. Application of EDX as a technique for qualitative 
and quantitative analyses has been found in the analysis of a great variety of materials (macro to 
nano scale) in organic and inorganic syntheses, in the metallurgical, environmental or 
pharmaceutical fields. However, the overlapping over spectral peaks and its inability to determine 
light elements with atomic number lower than oxygen are few of the drawbacks associated with 
the techniques. Hopefully, limitations could be overcome with further innovative and engineering 
research [187, 188]. 
 
1.4.2. Hyphenated techniques 
Hyphenated techniques combine chromatographic and spectral methods of detection to 
exploit the advantages of both. Chromatography produces pure or nearly pure fractions of 
chemical components in a mixture; spectroscopy produces selective information for identification 
using standards or library spectra [189]. Hirschfeld introduced the term “hyphenation” to refer to 
the on-line combination of a separation technique and one or more spectroscopic detection 
techniques [190]. 
In the case of nanoparticles, where there is a strong need of separation from other 
constituents (coming from synthesis or partial degradation) and among different size particles, 
hyphenated techniques are attractive and competitive strategies that must be optimized to get 
the best results. 
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1.4.2.1. Chromatographic and electrophoretic methods 
High-performance liquid chromatography (HPLC) is considered as one of the most exploited 
technique for metallic nanoparticles determination and separation. In fact, it has demonstrated 
to enable the separation among particles of different sizes and even among the metallic ions 
coming from the degradation of nanoparticles themselves. 
In this sense, ICP-MS is the most competitive detection mode and size exclusion, 
hydrodynamic, reversed phase, and ion exchange chromatography are the most widely used 
hyphenations in nanoparticles applications. 
In size exclusion chromatography (SEC), separation of NPs is based on the entrapment of the 
species in a porous stationary phase as they pass through the column carried by the mobile phase 
flow. Residence time depends on the size and shape of the particles, so the bigger the particles, 
the shorter the time they keep retained in the column. Particles with significantly smaller 
diameters than the pore size can penetrate deeply and thus, be trapped in the column during 
longer times. In the case of medium size particles, they can be trapped in the column to a lesser 
or greater extent depending on their specific size and consequently, fractionation is achieved. 
It is important to avoid or minimize possible chemical interactions between analyte and the 
stationary phase to guarantee that a combined separation mechanism does not take place and 
thus, efficacy of the column is not compromised. This theoretical lack of interaction with analytes 
and short analysis times makes this technique very attractive to evaluate nanoparticles size [191–
193], shape [194], stability or progression during synthesis process [195, 196], incubations or 
reactions in different media. 
The main limitation when analysing some specific nanoparticles (gold, silver) is the high 
surface activity they show. Therefore, they not only interact with stationary phase, but also are 
irreversibly adsorbed by the column. In order to overcome this drawback, different stabilizers, 
commonly used during the synthesis of nanoparticles (e.g. sodium citrate, tannic acid, sodium 
chloride or surfactants) have been added to the mobile phase [191, 197]. Some of them proved 
to prevent from agglomeration and surfactants as SDS has been seen as efficient additive that 
prevents nanoparticles from adsorption on the column, enabling the elution and separation of 
gold nanoparticles [197, 198]. 
There are several studies where SEC is coupled to ICP-MS satisfactorily. One recent example 
is reported by Jiménez-Lamana et al. and shows the detection of silver ions released from 
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nanoparticles oxidation in biological media. Moreover, separation of different silver species 
associated to proteins in the range of 70-25 kDa was achieved [199]. 
Hydrodynamic chromatography (HDC) is a solution-phase liquid chromatographic separation 
method in which the dissolved sample is injected into an open tube, a column packed with solid 
beads, or a column packed with porous beads of pore size substantially smaller than the size of 
the analytes in solution. In packed-column HDC, the beads should be inert so the non-HDC 
enthalpic interactions between the beads and the dissolved analytes are minimized. Separation in 
HDC arises from the parabolic or Poiseuille-like flow profile that develops, under laminar flow 
conditions, in an open tube or in the interstitial medium of a packed column, where the fastest 
streamlines of flow are in the middle of the tube (or the interstitial medium) and the slowest are 
near the walls (or the packing particles). The larger analyte remains near the centre of the tube, 
preferentially experiencing the faster streamlines, whereas the smaller analyte experiences a 
slower average velocity through the tube because of its ability to sample slower streamlines near 
the tube walls. Thus, elution order in HDC is the same as in SEC: the larger analytes elute ahead of 
the smaller ones in both cases. However, the mechanisms of retention of these two techniques 
are different: in SEC, retention is due to preferential sampling of pore volume, whereas in HDC, it 
is due to preferential sampling of the streamlines of flow (or to a preferential distribution of 
analyte between fluid mechanical phases) [200]. 
HDC has become a powerful technique for characterizing NPs due to separation relies solely 
on size and does not depend on the coating or the surface charge of the particle. Tiede et al.[201] 
published an application of HDC coupled to ICP-MS for separating a mixture of TiO2, SiO2, Al2O3, 
and Fe2O3 NPs in sewage sludge, showing this method as versatile and suitable for the separation 
from ionic/molecular background signals, simultaneous sizing, and quantification in a short time 
frame. However, HDC-ICPMS has a detection limit in the μg·L−1 range and does not provide 
information on the structure or the mass of the particles as it measures only the effective 
diameter. Thus, combinations of sp-ICPMS and HDC (HDC-sp-ICPMS) are being used more 
frequently to determine the size, number concentration, and mass fraction of metallic NPs [202] 
and give information about agglomerates of mixing particles [203]. 
Reversed phase chromatography (RP-HPLC) is also reported as an alternative for the 
separation of metallic nanoparticles. The most popular column is an octadecyl carbon chain (C18) 
with large size of particle and small pores in its packing (1000 Å). This added to the 
functionalization of the stationary phase with SDS to avoid adsorption between nanoparticles and 
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the column, makes possible the elution of the particles from the column without undesirable 
interactions. In other words, a mechanism similar to size exclusion is achieved. 
It has been applied by Helfrich et al. for the separation of gold nanoparticles coupled to ICP-
MS detection [192, 193]. A C18 column with 7 µm of particle size and 1000 Å of pore size was 
used. Irreversible adsorption of metallic nanoparticles to the stationary phase by the forming 
bonds with silanol groups of the column is solved by SDS addition to the mobile phase. At the 
same time, a modification of the stationary phase is produced by changing the chemistry nature 
of the surface and thus, enabling the elution of nanoparticles. As it has been described, 
nanoparticles fractionation depends on their size, hydrodynamic volume and shape. As it occurs 
in SEC, the smaller the particle, the more probability to keep entrapped in stationary phase pores 
and elute from the column at longer retention times. However, larger particles are retained in the 
column due to adsorption mechanisms or pore clogging [204]. 
Ion Exchange chromatography (IC) is based on the separation of ions and polar molecules 
depending on their affinity to the ion exchanger (stationary phase). The water soluble and charged 
molecules bind to oppositely charged stationary phase by forming covalent bonds. It has been 
applied for separation of silver ions and nanoparticles in the range of 1-100 nm in food 
supplements and water samples [205, 206]. 
In this sense, Hanley et al. proposed a method based on the use of a carboxylic acid 
functionalization of the column and HNO3 and ethanolamine 0.1 % (w/v) as mobile phase for the 
separation of silver nanoparticles and ions. Quantification was achieved in a concentration range 
between 40 µg kg-1 and 50 mg kg-1 and recoveries of 90 % are obtained for 10 nm AgNPs and Ag+, 
and 33 % for 100 nm AgNPs. It is proved to be rapid and valid for discrimination between 
nanoparticles and ionic species, although differentiation among different size nanoparticles is not 
possible as they all elute at the death volume of the column [205].  
Although IC is a competitive tool for preparative and analytical chromatography, one of the 
main disadvantages is its buffer requirement. Ion exchange columns must be loaded in low-salt 
buffers because binding to media is dependent on electrostatic interactions between analytes of 
interest and the stationary phase. For some applications, this restriction may require a buffer 
exchange step prior to analysis. Another limitation of weak ion exchangers is their pH dependence. 
When working outside of their optimal pH range, these resins rapidly lose capacity and resolution. 
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Nanoparticle separation by electrophoretic methods is based on the migration of charged 
species due to the application of an electric field. The most common techniques and highly applied 
to metallic and metal oxides nanoparticles separation are gel and capillary electrophoresis. 
Gel electrophoresis (GE) is a separation technique based on differential migration of species 
according to their size and charge, normally proteins or nucleic acids, in a gel medium placed in 
an electric field. Different types of nanoparticles could also be separated by gel electrophoresis. 
Thus, smaller particles experience less resistance from the gel and can move more rapidly [207].  
Regarding detection methods, gel electrophoresis separation tends to be coupled to visual 
detection, optical extinction spectroscopy or TEM. Coupling to ICP-MS needs the use of a laser 
ablation system, but it was demonstrated by Helfrich et al. that on-line coupling of LC and gel 
electrophoresis to inductively coupled plasma for a separation by size of gold nanoparticle 
standards was also possible [192]. 
In the case of capillary electrophoresis (CE), separation occurs due to the differential 
mobilities of the species that are injected into hair-thin capillaries filled with an electrolyte, whilst 
a high voltage is applied to the electrolyte reservoir-dipped capillary ends. In fact, a major 
breakthrough in the separation of nanoparticles by size has been achieved by application of this 
technique. The methods developed for nanoparticles offer all the advantages associated with CE, 
including automation [207].  
Detection methods are mainly based on UV-vis spectroscopy due to its simplicity, acceptable 
results and low cost. However, for the detection of metallic nanoparticles in biological or 
environmental samples at ultra-trace levels, ICP-MS must be employed. 
Micellar Electrokinetic Chromatography (MEKC) is a CE mode more suitable for the 
separation of metallic nanoparticles by size. It is based on the addition to the buffer solution of a 
micellar “pseudo-stationary” phase, which interacts with the analytes according to partitioning 
mechanisms, just like in a chromatographic method. The “pseudo-stationary” phase is composed 
of a surfactant added to the buffer solution in a concentration above its critical micellar 
concentration (CMC). The most commonly surfactant used is sodium dodecyl sulphate (SDS), an 
anionic surfactant that adheres to the surface of the particles and determines the particle size Vs. 
charge and consequently, achieves the migration [208, 209]. 
Main advantages of CE are the high resolution, short measurements time and the possibility 
of analysing both nanoparticles and metallic ions. However, it must be remarked that 
nanoparticles mobility depends on surface charge and this can be modified when a surfactant is 
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eluent, the application of the cross-flow results in a force, dragging the particles/macromolecules 
to the surface of the membrane [212, 213]. 
At first, FFF was mostly coupled to UV–visible detection and mainly used in biomolecule 
research [214]. The introduction of multi-angle light scattering detectors in the 1990s promoted 
the appearance of several applications in polymer research, enabling fractionation and molar-
mass determination [215]. However, neither UV–visible nor light-scattering detection was 
selective and sensitive enough to answer questions regarding the interaction of natural aquatic 
colloids and trace metals. Few years later, ICP-MS emerged as the ideal detector providing high 
sensitivity, elemental selectivity, a species and/or fraction-unspecific response, enabling 
quantification [211, 216], and isotope information enabling the use of isotopically enriched tracers 
and isotope dilution. 
Published studies show FFF-ICP-MS as a powerful, applicable tool for nanoparticle analysis. 
However, some challenges have been identified, especially regarding sample preparation and 
studies conducted in real matrices. Hence, further basic investigations concerning nanoparticle 
stability and its interaction with the fractionation system are necessary [217]. Additional basic 
studies on membrane-NPs interactions are also highly necessary [218]. Once more, a crucial point 
not yet addressed is the need for stable, certified nano reference materials, certified in size and 
fraction-related quantity for method calibration and validation. However, institutions (NIST, IRRM, 
and BAM) are working on this requirement and will probably overcome existing challenges in the 
near future. 
 
1.5. Isotope dilution analysis 
During this work, IDA has been conducted for the quantification of iron in serum and cell 
samples for the speciation of nanoparticles and ionic species. The basic principle of this analytical 
method is graphically described in Figure 10 by a diagram adapted from Alonso and González 
[219]. Basically, the addition of a known amount of an internal standard (black spheres) to a 
sample containing an unknown (n) number of an analyte (blue spheres) changes the concentration 
of the analyte. By determining the ratio of internal standard to unknown analyte in the resulting 
mixture, it is possible to back-calculate the amount of the analyte present in the sample. At the 
bottom of the figure the example of iron isotopes is shown. A spike solution whose isotope ratio 
and concentration are known, is added to a sample with an unknown concentration of the natural 
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independent from corresponding intensities. However, this variant has some limited applications, 
e.g. complex biomolecules as peptides or proteins are not available for this quantification 
methodology, as they require more laborious and difficult preparation of the isotopically enriched 
homologues. 
The second mode is called species-unspecific or post-column, and here the spike can be added 
in any available chemical form, even different from the analyte form. In general, it is introduced 
at the exit of the column (post-column), once the chromatographic separation has taken place. In 
this case, analyte losses during the sample preparation and separation are not compensated. 
Here, it is crucial that the mass flow of the spike is well characterized in terms of concentration 
and amount of solvent delivered from the pump. Moreover, the spike solution must be pumped 
continuously and mixed with the mobile phase coming from the chromatographic column. 
The concentration of the spike can be determined by the reversed IDA method: a known 
amount of the element with natural isotopic abundances is added to the spike solution. The 
concentration of the spike is then calculated according to equation 1: 𝐶𝑠𝑝𝑖𝑘𝑒 = 𝐶𝑠𝑎𝑚𝑝𝑙𝑒 ∗  𝑚𝑠𝑎𝑚𝑝𝑙𝑒𝑚𝑠𝑝𝑖𝑘𝑒 ∗  𝑀𝑠𝑝𝑖𝑘𝑒𝑀𝑛𝑎𝑡 ∗  𝐴𝑛𝑎𝑡𝑎𝐴𝑠𝑝𝑖𝑘𝑒𝑏 ∗  1− 𝑅𝑚∗ 𝑅𝑛𝑎𝑡𝑅𝑚− 𝑅𝑠𝑝𝑖𝑘𝑒                (Eq. 1) 
where: 
 𝐶𝑠𝑝𝑖𝑘𝑒 = 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑝𝑖𝑘𝑒 
 𝐶𝑠𝑎𝑚𝑝𝑙𝑒 = 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 
 𝑚𝑠𝑎𝑚𝑝𝑙𝑒 = 𝑆𝑎𝑚𝑝𝑙𝑒 𝑎𝑑𝑑𝑒𝑑 𝑡𝑜 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 
 𝑚𝑠𝑝𝑖𝑘𝑒 = 𝑆𝑝𝑖𝑘𝑒 𝑎𝑑𝑑𝑒𝑑 𝑡𝑜 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 
 𝑀𝑠𝑝𝑖𝑘𝑒 = 𝐴𝑡𝑜𝑚𝑖𝑐 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑝𝑖𝑘𝑒 
 𝑀𝑛𝑎𝑡 = 𝐴𝑡𝑜𝑚𝑖𝑐 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑛𝑎𝑡𝑢𝑟𝑎𝑙 𝑒𝑙𝑒𝑚𝑒𝑛𝑡 
 𝐴𝑛𝑎𝑡𝑎 = 𝐴𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑚𝑜𝑠𝑡 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑡 𝑖𝑠𝑜𝑡𝑜𝑝𝑒 𝑎 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 
 𝐴𝑠𝑝𝑖𝑘𝑒𝑏 = 𝐴𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑒𝑛𝑟𝑖𝑐ℎ𝑒𝑑 𝑖𝑠𝑜𝑡𝑜𝑝𝑒 𝑏 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑝𝑖𝑘𝑒 
 𝑅𝑚 = 𝐼𝑠𝑜𝑡𝑜𝑝𝑒 𝑟𝑎𝑡𝑖𝑜 (𝑎 𝑏⁄ ) 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 
 𝑅𝑛𝑎𝑡 = 𝑁𝑎𝑡𝑢𝑟𝑎𝑙 𝑖𝑠𝑜𝑡𝑜𝑝𝑒 𝑟𝑎𝑡𝑖𝑜 (𝑏 𝑎⁄ ) 
 𝑅𝑠𝑝𝑖𝑘𝑒 = 𝐼𝑠𝑜𝑡𝑜𝑝𝑒 𝑟𝑎𝑡𝑖𝑜 (𝑎 𝑏⁄ ) 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑝𝑖𝑘𝑒 
Once the spike is characterized, the concentration of an element in a given sample can be 
calculated by equation 2 after mixing it with a known amount of the previous characterized spike: 
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𝐶𝑠𝑎𝑚𝑝𝑙𝑒 = 𝐶𝑠𝑝𝑖𝑘𝑒 ∗  𝑚𝑠𝑝𝑖𝑘𝑒𝑚𝑠𝑎𝑚𝑝𝑙𝑒 ∗  𝑀𝑛𝑎𝑡𝑀𝑠𝑝𝑖𝑘𝑒 ∗  𝐴𝑠𝑝𝑖𝑘𝑒𝑏𝐴𝑛𝑎𝑡𝑎 ∗  𝑅𝑚− 𝑅𝑠𝑝𝑖𝑘𝑒1− 𝑅𝑚∗ 𝑅𝑛𝑎𝑡               (Eq. 2) 
For species-specific IDA, the spike is added to the sample during sample preparation. After 
chromatographic separation of the analyte and its co-eluting homologue from interfering species, 
the detected peak areas of both isotopes were integrated to calculate the isotope ratio of the 
mixture. Concentration of the analyte can be then calculated by applying equation 2. 
For species-unspecific IDA the experimental procedure has to be modified: the inorganic 
tracer was mixed with the mobile phase at the exit of the chromatographic column as previously 
described in section 1.2.2.4. To examine the absolute amount of the injected analyte, the resulting 
chromatogram must be converted into a so-called mass flow chromatogram and the following 
equation 3 is applied: 𝑀𝑓𝑠𝑎𝑚𝑝𝑙𝑒 = 𝐶𝑠𝑝𝑖𝑘𝑒 ∗  𝑑𝑠𝑝𝑖𝑘𝑒 ∗  𝑓𝑠𝑝𝑖𝑘𝑒 ∗ 𝑀𝑛𝑎𝑡𝑀𝑠𝑝𝑖𝑘𝑒 ∗  𝐴𝑠𝑝𝑖𝑘𝑒𝑏𝐴𝑛𝑎𝑡𝑎 ∗  𝑅𝑚− 𝑅𝑠𝑝𝑖𝑘𝑒1− 𝑅𝑚∗ 𝑅𝑛𝑎𝑡               (Eq. 3) 
where: 
 𝑀𝑓𝑠𝑎𝑚𝑝𝑙𝑒 = 𝑀𝑎𝑠𝑠 𝑓𝑙𝑜𝑤 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 
 𝑑𝑠𝑝𝑖𝑘𝑒 = 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑝𝑖𝑘𝑒 
 𝑓𝑠𝑝𝑖𝑘𝑒 = 𝐹𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 𝑠𝑝𝑖𝑘𝑒 𝑝𝑢𝑚𝑝 (𝑤𝑒𝑖𝑔ℎ𝑡 𝑝𝑒𝑟 𝑡𝑖𝑚𝑒) 
As can be seen in equation 3, the intensities chromatogram can be converted into mass flow 
(ng min-1) chromatogram with the spike information (isotope ratio, flow rate, concentration) and 
the chromatographic data obtained. By integration of the peaks in the mass flow chromatograms, 
the absolute amount of the analyte that is presented can be then calculated. 
Isotope pattern deconvolution for the analysis of clinical parameters involved in 
iron metabolism 
The Isotope pattern deconvolution (IPD) is a mathematical tool which allows the calculation 
of individual contributions of every isotope of the analyte in the mixture with a different isotope 
pattern. 
In this work, transferrin sialoforms separation by anion exchange chromatography needs the 
previous saturation with iron of the transferrin. Moreover, when the saturation is produced with 
natural iron, the transferrin determination by IDA allows the calculation of clinical parameters 
(TIBC and transferrin total concentration) in human serum samples. Similarly, transferrin 
saturation can be carried out by a tracer (57Fe). In this case, there will be a percentage of natural 
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iron (the one containing originally in the serum) and a percentage of enriched isotopic iron (the 
one which is added for the complete saturation). 
IPD application to the obtained data from IDA (monitoring 56Fe and 57Fe isotopes) in serum 
samples, allows the determination of the naturally present iron level (endogenous iron) and the 
incorporated iron level (exogenous iron) in each sialoform from the transferrin. 
The procedure consists on the addition of a known amount of the spike (57Fe) to the sample 
(serum) containing natural iron. There will be two iron isotopic profiles in the mixture (natural and 
spike abundances). The iron total amount in the sample can be splitted in two contributions: 𝑁𝑠𝑎𝑚𝑝𝑙𝑒𝐹𝑒 =  𝑁𝑛𝑎𝑡𝐹𝑒 + 𝑁𝑠𝑝𝑖𝑘𝑒𝐹𝑒                  (Eq. 4) 
where: 
 𝑁𝑠𝑎𝑚𝑝𝑙𝑒𝐹𝑒 = 𝑡𝑜𝑡𝑎𝑙 𝑖𝑟𝑜𝑛 (𝑚𝑜𝑙) 𝑓𝑜𝑢𝑛𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 
 𝑁𝑛𝑎𝑡𝐹𝑒 = 𝑛𝑎𝑡𝑢𝑟𝑎𝑙 𝑖𝑟𝑜𝑛 𝑝𝑟𝑒𝑠𝑒𝑛𝑡 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 (𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 𝑓𝑜𝑟𝑚) 
 𝑁𝑠𝑝𝑖𝑘𝑒𝐹𝑒 = 𝑖𝑟𝑜𝑛 𝑓𝑟𝑜𝑚 𝑡ℎ𝑒 𝑡𝑟𝑎𝑐𝑒𝑟 𝑡ℎ𝑎𝑡 𝑖𝑠 𝑝𝑟𝑒𝑠𝑒𝑛𝑡 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑓𝑡𝑒𝑟 𝑠𝑝𝑖𝑘𝑒 𝑎𝑑𝑑𝑖𝑡𝑖𝑜𝑛 
It is possible to obtain an individual mass balance for both iron isotopes (56 and 57) as it is 
shown in the following equations: 𝑁𝑠𝑎𝑚𝑝𝑙𝑒56 =  𝑁𝑛𝑎𝑡56 + 𝑁𝑠𝑝𝑖𝑘𝑒56                  (Eq. 5) 𝑁𝑠𝑎𝑚𝑝𝑙𝑒57 =  𝑁𝑛𝑎𝑡57 + 𝑁𝑠𝑝𝑖𝑘𝑒57                  (Eq. 6) 
Both equations can be expressed as a linear combination of total amount (mol of iron) and 
original isotopic abundance of the natural iron and the spike present in the sample: 𝑁𝑠𝑎𝑚𝑝𝑙𝑒𝐹𝑒 𝐴𝑠𝑎𝑚𝑝𝑙𝑒56 =  𝑁𝑛𝑎𝑡𝐹𝑒 𝐴𝑛𝑎𝑡56 + 𝑁𝑠𝑝𝑖𝑘𝑒𝐹𝑒 𝐴𝑠𝑝𝑖𝑘𝑒56                    (Eq. 7) 
where: 𝐴𝑠𝑎𝑚𝑝𝑙𝑒56 = 𝐼𝑠𝑜𝑡𝑜𝑝𝑖𝑐 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒 𝑜𝑓 𝐹𝑒56  𝑖𝑛 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑡56 = 𝑁𝑎𝑡𝑢𝑟𝑎𝑙 𝑖𝑠𝑜𝑡𝑜𝑝𝑖𝑐 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒 𝑜𝑓 𝐹𝑒56  
 
When equation 7 is divided by equation 4, the next expression is obtained: 𝐴𝑠𝑎𝑚𝑝𝑙𝑒56 =  𝑥𝑛𝑎𝑡𝐴𝑛𝑎𝑡56 + 𝑥𝑠𝑝𝑖𝑘𝑒𝐴𝑠𝑝𝑖𝑘𝑒56                    (Eq. 8) 
where: 
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𝑥𝑛𝑎𝑡 =  𝑁𝑛𝑎𝑡𝐹𝑒𝑁𝑛𝑎𝑡𝐹𝑒 +𝑁𝑠𝑝𝑖𝑘𝑒𝐹𝑒                             (Eq. 9) 𝑥𝑠𝑝𝑖𝑘𝑒 =  𝑁𝑠𝑝𝑖𝑘𝑒𝐹𝑒𝑁𝑛𝑎𝑡𝐹𝑒 +𝑁𝑠𝑝𝑖𝑘𝑒𝐹𝑒                             (Eq. 10) 
being: 𝑥𝑛𝑎𝑡 = 𝑖𝑟𝑜𝑛 𝑚𝑜𝑙𝑎𝑟 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑖𝑛 𝑡ℎ𝑒 𝑚𝑖𝑥𝑡𝑢𝑟𝑒 (𝑛𝑎𝑡𝑢𝑟𝑎𝑙 𝑖𝑟𝑜𝑛, 𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛) 
 𝑥𝑠𝑝𝑖𝑘𝑒 = 𝑖𝑟𝑜𝑛 𝑚𝑜𝑙𝑎𝑟 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑖𝑛 𝑡ℎ𝑒 𝑚𝑖𝑥𝑡𝑢𝑟𝑒 (𝑠𝑝𝑖𝑘𝑒, 𝑒𝑥𝑜𝑔𝑒𝑛𝑜𝑢𝑠 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛) 
Similar to equation 8, referred to 56Fe isotope, equations for the rest of iron isotopes can be 
obtained and expressed in matrix notation as follows: (𝐴𝑠𝑎𝑚𝑝𝑙𝑒56𝐴𝑠𝑎𝑚𝑝𝑙𝑒57 ) = (𝐴𝑛𝑎𝑡56  𝐴𝑠𝑝𝑖𝑘𝑒56𝐴𝑛𝑎𝑡57  𝐴𝑠𝑝𝑖𝑘𝑒57 ) ( 𝑥𝑛𝑎𝑡𝑥𝑠𝑝𝑖𝑘𝑒)                      (Eq. 11) 
The matrix from the left refers to experimental isotopic abundances obtained for 56Fe and 57Fe 
in each chromatographic peak and are derived from isotopes intensities and the following 
equations: 𝐴𝑠𝑎𝑚𝑝𝑙𝑒56 = 1 − ( 𝑅𝑚1+𝑅𝑚)                      (Eq. 12) 𝐴𝑠𝑎𝑚𝑝𝑙𝑒57 = ( 𝑅𝑚1+𝑅𝑚)                     (Eq. 13) 
where: 𝑅𝑚 = 𝐼𝑠𝑜𝑡𝑜𝑝𝑒 𝑟𝑎𝑡𝑖𝑜 57 56 𝑖𝑛 𝑒𝑎𝑐ℎ 𝑐ℎ𝑟𝑜𝑚𝑎𝑡𝑜𝑔𝑟𝑎𝑚 𝑝𝑜𝑖𝑛𝑡⁄  
The second matrix is composed by two columns containing the isotopic abundance of natural 
iron (left column) and iron in the spike (right column). In this specific case: 5657 (0.91754 0.044270.02119 0.95055)            (Eq. 14) 
The 56Fe and 57Fe intensities are related to isotopic abundances of natural iron and spike by 
the 𝑥𝑠𝑝𝑖𝑘𝑒 and 𝑥𝑛𝑎𝑡 coefficients. These values are calculated by least squares by using the LINEST 
function in Excel. Therefore, 𝑥𝑠𝑝𝑖𝑘𝑒 and 𝑥𝑛𝑎𝑡 express the contribution of exogenous and 
endogenous iron for each sialoform in the transferrin and from these data, different parameters 
of clinical interest could be extracted such as: 
• Transferrin saturation: 𝑥𝑛𝑎𝑡 or endogenous iron represents the transferrin saturation 
percentage in each sialoform and considering the contribution of each sialoform, 
global saturation percentage can be obtained. 
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• Serum iron: by multiplying the 𝑥𝑛𝑎𝑡 for the TIBC, serum iron in each sialoform can be 
obtained. The sum of all sialoforms results in the total natural iron present in serum. 
• Unsaturated Binding Capacity (UIBC): by multiplying 𝑥𝑠𝑝𝑖𝑘𝑒 for the TIBC, unbound iron 
in each sialoform can be obtained and, again, the sum of all sialoforms results in the 
total unbound iron. This parameter would be also extracted by this expression: 𝑈𝐼𝐵𝐶 = 𝑇𝐼𝐵𝐶 − 𝑆𝑒𝑟𝑢𝑚 𝑖𝑟𝑜𝑛          (Eq. 15) 
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2 OBJECTIVES 
The overall goal of the thesis was based on the development of analytical methods based on 
mass spectrometry to quantitatively study the uptake and biological interactions of metallic 
nanoparticles with cells and animal tissues. Considering that, this work was focused on iron 
nanoparticles in particular, because of the nature of the iron as an essential element in living 
organisms and its several applications in biomedical sciences. Moreover, the increasing interest 
on nanochemistry and the interaction of new nanomaterials within their special properties with 
biological cells make this goal even more challengeable, trying to clarify if there are harmful 
effects or establishing metabolic pathways of these nanostructures in human body.  
In this framework, the first objective was to fully characterize the commercial preparation 
for intravenous treatment of anaemia, Venofer®, in terms of particle size and shape (HR-TEM, 
DLS, UV-vis) and accomplish quantitative studies on the iron bioavailability from these NPs in 
serum and blood by using isotope dilution and ICP-MS. The interaction of iron with different 
proteins in serum samples incubated with the commercial preparation was studied using UV-vis 
and ICP-MS detection after previous chromatographic separation. 
The second objective was focused on the searching of a suitable synthesis of non-
aggregated iron oxide nanoparticles potentially used as oral supplements for the treatment of 
anaemia. In this way, a synthesis based on the precipitation of FeCl3 salt in basic medium and 
the use of sodium tartrate and adipic acid as coating agents was carried out, mimicking the 
mineral core located inside the ferritin. Resultant iron nanoparticles were characterized using 
different techniques (HR-TEM, DLS, EDX, UV-vis, SAXS, WAXS). Acid lability studies were 
conducted to assess nanoparticles stability in simulated gastric conditions. 
The third objective here proposed was the development of in vitro studies concerning the 
uptake, subcellular location, and toxicity after incubation of different cell lines (THP-1, 
macrophages, HT-29, and Caco-2) with these self-synthesized FeNPs. 
In order to investigate nanoparticles structure and behaviour once they enter the cells, a 
fourth objective based on the speciation and quantification of nanoparticles and ionic species 
of iron based on a reversed phase high performance liquid chromatography was optimized and 
applied to Caco-2 cell samples. Quantification approach was tackled by ICP-MS and the 
application of an online post column isotope dilution analysis with 57Fe as isotopically enriched 
standard. 
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The fifth objective was related to the in vivo studies. For this purpose, small intestine 
perfusion studies were carried out to determine the iron absorption degree in different regions 
throughout the small intestine, as well as the fate of these FeNPs after intestinal uptake by 
analysing other tissues involved in iron metabolism such as liver, kidney, spleen, or blood. 
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3 EXPERIMENTAL SECTION 
3.1. Reagents and solutions 
All working standard solutions were prepared using 18 MΩ cm-1 deionized water obtained 
from a Milli-Q system (Millipore, Bedford, MA, USA).  
Venofer® was kindly provided by the Hematology Group of the Hospital Central Universitario 
de Asturias (Oviedo, Spain) in the form of an aqueous complex of polynuclear iron (III)-hydroxide 
in sucrose containing 20 mg elemental iron per mL. Upon reception, the content of the vial (5 
mL) was separated into aliquots of 1 mL and stored at -4 ºC until further use. Successive dilutions 
of the parenteral solution were conducted in 0.9 % sodium chloride NaCl, as stated by the 
manufacturer. 
Serum and blood samples from controls were provided by the Hospital Central of Asturias, 
Laboratory of Biochemical Analysis (Oviedo, Spain). All blood samples were collected by venous 
puncture using BD Vacutainer® (Franklin Lakes, NJ, USA) containing gel for serum separation. 
Samples were anonymous and collected in accordance with protocols approved by the relevant 
institutional review boards and with the Declaration of Helsinki. Serum was separated by 
centrifugation (3000 g, 20 min). Samples were then stored in 1 mL aliquots in the fridge until 
corresponding analysis. In the case of blood samples, they are stored in tubes containing 
Ethylenediaminetetraacetic acid (EDTA) as anticoagulant agent. 
The protein standards used were cyanocobalamin (B12), α-lactalbumin from bovine milk, 
albumin from human serum, human apo-transferrin and ferritin from equine spleen and were 
all from Sigma-Aldrich (St. Louis, MO, USA). 
All ICP standards (iron 1000 mg L-1, germanium 1000 mg L-1 from Merck), tuning solutions 
and elemental tracer were diluted with 0.1 % nitric acid (Panreac). The nitric acid was previously 
purified using a quartz sub-boiling distillation in a fume hood. Isotopically enriched elemental 
iron with relative abundances 0.043 % 54Fe, 4.96 % 56Fe, 94.52 % 57Fe, 0.47 % 58Fe was obtained 
from Cambridge Isotope Laboratories, Inc. (MA, USA).  
The mobile phases for anion exchange separation of serum proteins contained:  
• 50 mmol L-1 TRIS from Sigma-Aldrich (St. Louis, MO, USA) adjusted to pH 7.4 using 
acetic acid from Merck (Darmstadt, Germany), 
• 50 mmol L-1 TRIS at pH 7.4 and 1.5 mol L-1 ammonium acetate. 
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For the separation of transferrin sialoforms the mobile phases contained:  
• 25 mmol L-1 TRIS from Sigma-Aldrich adjusted to pH 6.5 using acetic acid,  
• 25 mmol L-1 TRIS at pH 6.5 and 250 mmol L-1 ammonium acetate. 
Mobile phases were degasified with helium prior to use them. 
For cleaning and conditioning the chromatography columns, sodium chloride, sodium 
hydroxide, EDTA solutions from Sigma, as well as ethanol, acetic acid and acetonitrile from 
Merck, were employed. 
For iron nanoparticles preparation, iron(III)chloride hexahydrate, sodium tartrate, adipic 
acid, sodium chloride, sodium hydroxide, and ammonium acetate from Sigma were employed.  
For the cell culture experiments:  
• Minimum Essential Medium (MEM, PAA Laboratories, Yeovil, UK) supplemented 
with 10 % fetal bovine serum (FBS “Gold”, PAA Laboratories), 1 % 
penicillin/streptomycin and 1 % fungizone (Invitrogen, Paisley, UK) as well as 
Phosphate Buffer Saline (PBS, PAA Laboratories, Yeovil, UK) were used for Caco-2 
and HT-29 cell lines. 
• In the case of THP-1 Monocytes and macrophages (grown from THP-1 by PMA 
addition: 100 µM Phorobol-12-myristat-13-acetate) the culture medium was RPMI 
supplemented with BSA 10 %, Sodium pyruvate, penicillin/streptomycin and HEPES. 
High purity nitric acid (subboiling distilled acid) and hydrogen peroxide 30 % (Merck) were 
used for acid digestion of biological samples.  
Concerning the nanoparticle extraction procedure, a protease inhibitor cocktail (Sigma-
Aldrich) and a sucrose solution (Sigma) were used. 
The mobile phase for the speciation of iron nanoparticles contained: 
• 10 mmol L-1 Sodium Dodecyl Sulfate (Sigma) and 10 mmol L-1 ammonium acetate at 
pH 6.8. 
In acid lability assays, hydrochloric acid 37 % from Merck was used to set the medium pH. 
For the sample preparation for TEM images, tissues had to be previously fixated using 
glutaraldehyde and formaldehyde in 0.05 M sodium cacodylate buffer, and post-fixed with 
osmium tetroxide and potassium ferrocyanide in Milli-Q water. 
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Cell viability assays were conducted using WST-1 kit assay and MTT assay (Roche, Sigma), 
both for evaluating cell proliferation. Oxidative stress damage was assessed by using a ROS Assay 
kit (Bioquochem, Spain), based on 2’-7’dichlorofluorescin diacetate (DCFH-DA) reagent. Tert-
butyl hydroperoxide (TBHP) was employed as positive control. 
For animal intestinal perfusion experiments, a sodium thiopental solution 0.5 % (m/V, 
Tiobarbital®, BBraun Vetcare, Spain) was used as anaesthetic. Moreover, Tyrode solution was 
prepared containing 8.0 g L−1 NaCl, 0.2 g L−1 KCl, 0.2 g L−1 CaCl2 anhydrous, 0.1 g L−1 MgCl2 
anhydrous, 0.05 g L−1 NaH2PO4·H2O and 1 g L−1 glucose at pH 7. 
Argon, nitrogen, helium and hydrogen gases (99.999% of purity) were supplied by Air Liquide 
(Madrid, Spain). 
 
3.2. Instrumentation 
3.2.1. Inductively coupled plasma mass spectrometry 
Four different ICP-MS instruments have been used throughout this work. The Agilent 7700x, 
the Agilent 7500 CE and the iCAP TQ ICP-MS and Element XR from Thermo Scientific. The 
operational parameters which have been applied for analysis are summarized in this section. All 
instruments have been tuned prior analysis with a tune solution containing several elements 
with a concentration of 10 ng g-1 to calibrate the functional conditions of the mass spectrometer. 
Here, flow rates between 0.5 to 1 mL min-1 have been applied by a peristaltic pump. 
Subsequently, the torch position, gas flows, lenses and other important instrumental 
parameters were carefully optimized by analysing a tuning solution containing the elements to 
be determined to ensure optimal signal to noise ratios for the detection of the analyte.  
 
3.2.1.1. Agilent 7500 CE  
The Agilent 7500 CE (Agilent Technologies, Tokyo, Japan) is equipped with a quadrupole as 
mass filter. In addition, this mass spectrometric device contains an octapole reaction system 
(ICP-ORS-MS) which serves as collision/reaction cell using hydrogen or helium as collision gas to 
remove polyatomic interferences. When it is not used as detector in chromatography, sample is 
aspirated by a peristaltic pump and nebulized by a concentric nebulizer (Meinhard type). A 
sample solution mist forms and passes through a double- pass spray chamber where the larger 
sample droplets are removed by collision with the spray chamber wall. To prevent the spray 
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Tune solution containing Li, Co, Y, Tl and Ce 10 ng g-1 in 1 % nitric acid was used with and 
without reaction gas to get the highest sensitivity and check the instrument status. 
Important instrument parameters are summarized in Table 10. 
Table 10. ICP-MS parameters used in Agilent 7500 CE. 
Instrument Agilent 7500c 
RF Power 1500 W 
Sampling Depth 8 mm 
Carrier gas flow rate 1.15 L min-1 
Coolant plasma gas flow rate 15 L min-1 
Reaction/collision H2 gas flow 3.5 mL min-1 
Octapole bias -18 V 
QP bias -16 V 
Nebulizer Meinhard Type 
Spray chamber Double pass, Peltier cooled (2 oC) 
m/z monitored 54, 56, 57 
Dwell time 0.1 s 
 
3.2.1.2. Agilent 7700x 
As the above-described instrument, the Agilent 7700x (Agilent Technologies, Tokyo, Japan) 
also contains a quadrupole as mass filter as well as an octapole reaction system (ICP-ORS-MS) 
which serves as collision/reaction cell using helium as collision gas to remove polyatomic 
interferences. The most significant improvements in comparison to the previous model are:  
• A new generation of octapole reaction system that includes longer and narrower 
rods and higher cell pressure and frequency. This allows a more reliable 
performance in helium mode.  
• High Matrix Introduction kit that enables high dissolved solids samples to be run 
directly with minimal matrix deposition in the interface cones.  
• A Shield Torch System that provides effective plasma grounding. 
Selected parameters used in the instrument for the bioavailability studies of Venofer® are 
compiled in Table 11. 
3 EXPERIMENTAL SECTION 
76 
 
Table 11. Instrument parameters used in Agilent 7700x. 
Instrument Agilent 7700x 
RF Power 1500 W 
Carrier gas flow rate 0.87 L min-1 
Coolant plasma gas flow rate 15.5 L min-1 
Reaction/collision He gas flow 2.5 mL min-1 
Octapole bias -18 V 
QP bias -15 V 
Nebulizer Meinhard type 
Spray chamber Double pass, Peltier cooled Scott-type (2 oC) 
m/z monitored 54, 56, 57 
Dwell time 0.1 s 
 
3.2.1.3. iCAP TQ Thermo Scientific 
The iCAP -TQ-ICP-MS from Thermo Scientific (Bremen, Germany) was used for the total iron 
quantification studies in nanoparticle aqueous suspensions as well as cells and animal tissues 
samples. It is equipped with a compact, low pulsation, four-channel peristaltic pump with inner 
rollers to minimize signal disturbances. A Peltier cooled cyclonic spray chamber filters out larger 
aerosol droplets and improve plasma stability. A push-in, demountable single piece quartz torch 
is used, and nickel cones consisted on sampler and skimmer of 1.1 mm and 0.5 mm diameter 
orifice, respectively, are optimized for reduced matrix deposition and maintenance. Moreover, 
the High Sensitivity Interface provides optimal signal to noise ratio for ultratrace analysis and 
advanced applications. One of the special features of this instrument is the 90º cylindrical ion 
lens at a single fixed voltage that provide high ion transmission across the entire mass range. 
Mass analyser system is composed by three sequential quadrupoles: 
• Q1 Quadrupole: High frequency quadrupole mass analyser with pre and post filter 
for isolation of analyte ions and filter out unwanted ions. 
• Q2 Collision/Reaction Cell (CRC): Pressurized with reactive gas to selectively 
generate reaction products. Four gas specific mass flow controllers deliver H2, NH3, 
O2 and He according to the analyte requirements. In this case, different flows of H2 
were used and optimized prior analysis.  
• Q3 Quadrupole: It isolates ions required for measurement with a manual definable 
mass resolution. 
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3.2.1.4. Thermo Element XR 
The Thermo Element XR from Thermo Scientific (Bremen, Germany) is a mass spectrometric 
device based on double-focusing sector field which was used in medium resolution for 
monitoring iron. The ICP-MS Element XR was synchronized with the laser ablation unit 
(NWR213 from ESI, Fremont, USA) in external triggering mode and daily tuned for maximum 
ion intensity and good signal stability (RSD > 5 %), keeping the oxide ratio (ThO/Th) below 
1% during ablation of a glass slide. Helium was used as carrier gas and argon was added 
before reaching the ICP torch using a y-piece. 
Typical instrumental settings which have been applied are listed in Table 13. 
Table 13. Element XR operating parameters. 
Instrument Thermo Element XR 
RF power / W 1350 
Guard electrode Platinum, active 
Ar cooling gas flow rate / L min-1 16 
Ar auxiliary gas flow rate / L min-1 1.0 
Ar sample gas flow rate / L min-1 0.6 
Sample and skimmer cone  Ni 
Mass resolution Medium (R = 4000) 
Scan optimization Speed 
Isotopes monitored 56Fe, 57Fe 
Magnet settling time / s 0.001 
Runs x pass 480 – 880 x 1 (depending on the length of the 
line) 
Detection mode Both isotopes with SEM (triple) 
Sample time / s 0.002 
Samples per peak 20 
Segment duration per isotope / s 0.012 
Mass window per isotope / % 30 
Search window / % 60 
Integration window / % 30 
Scan type E-scan 
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3.2.2. High performance liquid chromatography 
3.2.2.1. HPLC systems 
For chromatographic experiments the following instrumentation was used: 
• HPLC system based on high pressure dual-piston pump LC-20AD from Shimadzu 
Corporation, Kyoto, Japan. Sample injection was conducted with a dual mode 
injection valve from Rheodyne, model 9125 (Cotati, California, USA), fitted with a 
20, 50 and 100 µL PEEK injection loop (Up-church Scientific, Oak Harbor, 
Washington, USA). 
• Chromatographic analysis applying UV-vis detection was accomplished with a 
conventional Agilent 1100 series quaternary HPLC pump (Agilent, Waldbronn, 
Germany) that is composed by a vacuum degasser, autosampler, a thermostatted 
column compartment (TCC) which is a Peltier-based design offering stable operation 
at ambient, sub-ambient and above-ambient temperatures, and a diode array 
detector giving outstanding sensitivity over the entire wavelength range (both UV 
and visible). Its features include deuterium and tungsten lamps that ensure the 
highest light output, from 190 to 950 nm with a whopping 1024 diodes and a 
programmable slit to optimize wavelength resolution. 
• Agilent 1200 series HPLC pump (Agilent, Waldbronn, Germany) similar to the 
previous Agilent series described, was used for collecting fractions at the exit of the 
chromatographic column. 
3.2.2.2. Chromatographic columns and related parameters 
The chromatographic columns used for the different separation purposes were summarized 
in Table 14: 
Table 14. HPLC columns applied.  
Column Bed vol. (mL) 
Bed size 
(mm) 
Particle 
size (µm) 
Flow rate 
(mL min-1) 
Superdex 200 10/300 GL (GE Healthcare) 24 10 x 300 13 0.6 
Mono Q 5/50 GL (GE Healthcare) 1 5 x 50 10 1 
Nucleosil 1000-7 C18 (Macherey-Nagel) 4.15 4.6 x 250 7 0.5 
 
For the chromatographic separation of Venofer® via size exclusion mechanism, a Superdex 
200 10/300 GL column from GE Healthcare was used. This column has an upper exclusion limit 
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of 600 kDa. 50 mM ammonium acetate (pH 7.4) was used as mobile phase, applying a flow rate 
of 0.6 mL·min-1 and an injection volume of 100 µL. 
For the transferrin saturation, a Mono Q 5/50 GL anion exchange column (strong cation) 
from GE Healthcare Life Sciences was employed, applying gradient elution detailed in Table 15. 
Mobile phase A was composed of 25 mM Tris acetic acid (pH 6), and 25 mM Tris acetic acid and 
250 mM ammonium acetate (pH 6) was mobile phase B composition. A flow rate of 1 mL min-1 
and an injection volume of 100 µL were used for these experiments. 
Table 15. Gradient employed for transferrin sialoforms separation. 
Time (min) A concentration (%) B concentration (%) 
0 100 0 
45 25 75 
46 0 100 
50 0 100 
51 100 0 
 
In the speciation of serum iron-binding proteins, the same anion exchange column (Mono Q 
5/50 GL) was utilised with different conditions. Gradient elution was also used and collected in 
Table 16. Mobile phase A was composed on 50 mM Tris acetic acid (pH 7.4) while mobile phase 
B composition was based on the mixture of mobile phase A and 0.75 M ammonium acetate (pH 
7.4). A flow rate of 1 mL min-1 and an injection volume of 50 µL were employed in this case. 
Table 16. Gradient used for serum proteins separation 
Time (min) A concentration (%) B concentration (%) 
0 100 0 
30 0 100 
31 100 0 
 
For the speciation of nanoparticles and soluble species of iron, a C18 reversed-phase column 
with a pore size of 1000 Å was used (Nucleosil 1000-7 C18, Macherey-Nagel). Mobile phase was 
composed of 10 mM ammonium acetate modified with 10 mM SDS (pH 6.8). Here, flow rate of 
0.5 mL min-1 and an injection volume of 20 µL were employed. 
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3.2.2.3. Hyphenation of HPLC to ICP-MS 
Hyphenated online systems for speciation studies are well established in elemental 
speciation and provide highly reproducible results in much less time than traditional off-line 
methodologies. Moreover, these hyphenated techniques allow a fast and direct application of 
on line isotope dilution, improving significantly the metallic speciation accuracy. 
HPLC hyphenation to ICP-MS is quite simple due to the compatibility between 
chromatographic flows (usually around 1 mL min-1) and most conventional nebulizers used for 
ICP-MS. From a technical point of view, it consists on coupling the exit of the column to the 
nebulizer by using PEEK tubing with reduced inner diameters (approximately 50 and 76 µm, 0.03 
and 0.04 in., respectively) and reduced length in order to avoid death volumes and 
chromatographic peak broadening. 
In this work, the following hyphenation procedures were accomplished: 
• Size exclusion HPLC-ICP-MS for determination of Venofer® molecular weight. 
• Anion exchange HPLC-ICP-MS for the separation of transferrin sialoforms and the 
on-line iron bounded detection in serum samples. 
• Anion exchange HPLC-ICP-MS for the separation and detection of other serum iron-
binding proteins. 
• Reversed phase HPLC-ICP-MS for the speciation of nanoparticles and ionic species 
of iron in aqueous solutions and cell samples. 
 
3.2.2.4. Experimental set-up for post-column IDA 
To carry out the iron quantification by on-line IDA, the eluent was mixed at the exit of the 
column at a continuous flow rate of 0.1 mL min-1 with the spike solution of 57Fe by using an 
auxiliary peristaltic pump. A T-piece (Upchurch Scientific, Oak Harbor, Washington, USA) was 
installed after the column to allow the mixing of both solutions and consequently nebulization 
at the same time in the plasma. In order to establish the exact spike flow rate, a calibration 
before and after analysis was carried out every measurement day. The 57Fe tracer was 
solubilized first in ultrapure water and then 0.1 % HNO3, reaching the most stability signal in the 
latter. In Figure 13, a scheme of the experimental set-up is shown. 
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3.2.4. Miscellaneous 
For the measurement of the absorbance spectra in different iron nanoparticle solutions, a 
Genesys 10 S UV-Vis from Thermo Fischer Scientific (Wi, USA) was used. A TECAN GENios 
microplate reader (Tecan, Switzerland) was used for measuring the absorbance in the cell 
viability assays. Fluorescence of the ROS assays was measured using a microplate reader 
Infinitive 200 (Tecan, Switzerland). Cell counting was carried out with a CASY® Cell Counter + 
Analyzer Model TT from Roche Innovatis AG. Lyophilization of animal tissues was achieved by 
using a LyoLab 3000 freeze-dryer from Heto (Alleød, Denmark). Digestion of animal samples was 
carried out using a microwave system Ethos 1 from Milestone (Sorisole, Italy). For centrifugation 
and ultrafiltration, a Heraeus Biofuge Stratos from Kendro (Osterode, Germany) was used. The 
centrifuge was equipped with a 35º fixed angle rotor. 
 
3.3. Data acquisition and treatment 
In this work, different types of software have been applied for data treatment. The most 
relevant ones are here summarized:  
• The Agilent 1100 series with UV-vis detection was controlled by HP Chemstation. 
• Calculations for IDA-based quantitative analysis was conducted by Excel and 
OriginPro 8. 
• Agilent 7500CE and 7700x ICP-MS were controlled by MassHunter Workstation 
software. 
• iCAP TQ-ICP-MS from Thermo Scientific was controlled by QtegraTM version 
2.8.2944.159. 
• Chromatographic data treatment was achieved by Excel in combination with 
OriginPro 8. 
• For the images processing from HR-TEM, ImageJ version 1.43u was used. 
• DLS measurements files were processed using Malvern Zetasizer Software 7.11. 
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3.4. Experimental procedures 
3.4.1. Characterization of iron-sucrose formulations: Venofer®  
Commercial preparation, Venofer®, was thoroughly characterized in terms of particle size 
and by different hyphenated techniques such as SEC-UV-vis and SEC-ICP-MS in order to 
determine the molecular weight of the complex and evaluate the possible presence of other 
iron containing species in the suspension. For this purpose, several experiments were carried 
out: 
• HR-TEM measurements were done in a JEOL-JEM 2100F (Tokyo, Japan) transmission 
electron microscope with TEM operation voltage at 200 kV to image iron NPs 
suspensions deposited on Cu grids. The instrument permits also to obtain the 
elemental composition of the sample. Images were then analysed and treated with 
software ImageJ to obtain particle diameter average and check nanoparticle shape 
and aggregation. 
• Dynamic Light Scattering technique was applied to have an idea of the Polydispersity 
Index, as well as the hydrodynamic volume of the sample in solution using a Malvern 
Zetasizer Nano ZS (Malvern Instruments Limited, Worcestershire, UK) with a 
detection angle of 173°. All measurements were taken at a temperature of 25 ºC. 
Three replicates on each sample were taken to assess the repeatability of the 
measurements. The Nano S uses a 4 mW He–Ne laser operating at a wavelength of 
633 nm. 
• A UV-vis spectrum was also obtained to evaluate the energy band gap of the 
semiconductor Fe-based nanomaterial. The optical absorbance measurement was 
carried out at room conditions on a Genesys 10S UV/Vis spectrophotometer 
(Thermo Scientific, USA). 
• Size Exclusion Chromatography coupled to UV-vis and ICP-MS detection were 
conducted as a way to detect its molecular weight (prior calibration of the 
chromatographic column with protein standards) as well as to identify the iron in 
the nanostructure. Chromatographic separation was performed with a Superdex-
200 (range of size exclusion: 10-600 kDa, GE Healthcare Bio-Sciences Uppsala, 
Sweden) using a mobile phase of ammonium acetate (50 mM, pH 7.4). The HPLC 
system used consisted of a dual piston HPLC pump (Shimazdu LC-20AD, Shimazdu 
corporation, Kyoto, Japan) and was equipped with a sampler injection valve, 
Rheodyne, Model 9125 (Cotati, CA, USA) fitted with a 100 μL loop. Chromatograms 
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were obtained using a diode array detector (model 1100, Agilent Technologies, 
Waldbron, Germany). ICP-MS experiments were conducted on an Agilent 7700x ICP-
MS (Agilent Technologies, Santa Clara, CA). 
 
3.4.2. Incubation of serum and blood samples with Venofer® 
For this study, pooled serum and whole blood samples from anonymous patients from the 
Hospital Universitario Central de Asturias (HUCA) have been used. Samples were collected in 
accordance with protocols approved by the relevant institutional review boards (HUCA) and 
with the Declaration of Helsinki. For experiments with serum, the samples were taken in 5 mL 
vacutainer tubes (Greiner Bio-one, Madrid, Spain) for trace elements and the serum was 
obtained by immediate centrifugation. Serum samples were pooled to obtain a large sample 
volume and divided into different aliquots of 2 mL (for incubation with Venofer®). In the case of 
whole blood, the samples were taken in heparin containing tubes to avoid coagulation and, 
similarly to serum, separated into aliquots for further incubation with Venofer®. 
The posology of Venofer® depends on a number of parameters including body weight, 
haemoglobin level, etc. [220]. To conduct the in vitro experiment, the doses were calculated 
according with the manufacturer recommendation of 7 mg iron per kg body weight. Assuming 
an average weight of 70 kg, this corresponds to about 500 mg iron. Since the experiments are 
conducted in 2 mL of serum and considering that the doses are estimated for 5 L of blood 
(average value per individual), an adequate dilution of the preparation in 0.9 % NaCl was done 
to achieve a final concentration of approximately 100 µg iron per mL serum. Then, the serum 
and whole blood samples were maintained at room temperature (21 ± 2 ºC) and continuously 
shaking for 1, 3.5, and 7 hours respectively, since the elimination half-life of Venofer® is about 
5−6 hours [221]. Then, the samples were centrifuged and filtered through 0.45 µm to remove 
the remaining nanoparticulate material and obtain the solubilized iron from the particles. 
Total iron determination in serum and blood samples  
Blood and serum samples were diluted in 0.1 % HNO3 and spiked with isotopically enriched 
57Fe (Cambridge Isotope Laboratories) of known concentration. By using the isotope dilution 
calculations (Eq. 2), the concentration of Fe in the samples and the bioavailable Fe by comparing 
the concentration before and after incubation were obtained. Samples were measured by 
Agilent 7700x ICP-MS and important parameters are collected in Table 11. 
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3.4.3. Evaluation of the quantitative association of released Fe to transferrin 
sialoforms  
3.4.3.1. Iron Transferrin saturation 
Chromatographic separation of different isomers of Tf (sialoforms) methods are based on 
their different charge according to their different isoelectric points and therefore, the separation 
depends on the sialic acids content and the potential iron content.  
Thus, a first step before separation of the sialoforms is the complete saturation of Tf with 
iron, so that every sialoform contains the same amount of the metal. Once the Tf is fully 
saturated, charge contribution comes exclusively from sialic acids and, therefore, different 
isoforms (sialoforms) can be separated considering the number of sialic acids [222]. 
For iron saturation of human serum transferrin, 0.5 mL of the serum sample was diluted 
(1+1) in 25 mM Tris-acetic acid buffer and then incubated with 25 µL of a 10 mM Fe solution (as 
FeCl3) and 25 µL of a 500 mM sodium bicarbonate solution, as synergistic anion, for 30 min at 
room temperature. The samples previously saturated with iron were subsequently filtered 
through 0.22 µm syringe filters before injecting in the HPLC system (100 µL). The Tf isoforms 
were separated by means of a linear gradient of ammonium acetate (0-250 mM in 45 min) 
buffered by 25 mM Tris-acetic acid (pH 6.5) solution.  
Previous studies in our research group [140, 223] established the optimum methodology to 
separate Tf sialoforms with the highest resolution. It is based on an anion exchange 
chromatography (Mono Q 5/50 GL) using a linear gradient of 250 mM ammonium acetate from 
0 to 75 % in 45 min at pH 6, as it was here described. 
3.4.3.2. Optimization of Transferrin sialoforms separation 
The main parameter to be optimized in the Tf sialoforms separation is the eluting pH due to 
proximity between the isoelectric points of every sialoform in the human serum protein. pI of 
the most abundant sialoform (S4) is 5.4, while the rest of the sialoforms have pI values of 5.9, 
5.8 and 5.7 (S0, S1 and S2, respectively). In a lesser abundance are the other sialoforms (S3, S5 and 
S6) with pIs of 5.6, 5.2 and 5.0, respectively. 
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3.4.4. Iron association to other binding proteins 
Relating to the chromatographic separation of the Fe binding serum proteins, a strategy 
already reported was followed [224]. An HPLC system containing a dual-piston liquid 
chromatographic pump (Shimadzu LC-20AD, Shimadzu Corporation, Kyoto, Japan) and a sample 
injection valve from Rheodyne, fitted with a 50 μL injection loop, was used. The used column for 
the separation was an anion exchange Mono Q 5/50 GL (50 x 5 mm id, Pharmacia, Amersham 
Bioscience, Sweden). The mobile phase flow was 1 mL min-1 and the absorbance of the proteins 
was monitored at 280 nm using a Diode Array Detector (DAD) detector (model 1100, Agilent 
Technologies, Waldbronn, Germany). For the ICP-MS detection the Agilent 7700x (Agilent 
Technologies, Santa Clara, CA) was used. 
 
3.4.5. Iron nanoparticles  
Several approaches for iron nanoparticles syntheses were tried, all based in the co-
precipitation of FeCl3 and FeCl2 or FeSO4 in presence of a coating agent (dextran or sucrose) in 
aqueous alkaline solution under inert atmosphere (Argon or Nitrogen atmosphere). First, 
dextran-coated iron nanoparticles were assayed using dextran previously reduced (with NaBH4) 
[225] or non-reduced dextran [226]. Other approaches were tried for dextran iron oxide 
nanoparticles synthesis not using inert atmosphere [227], again  with reduced and non-reduced 
dextran. The use of an enriched urea medium for precipitation was also tried in order to achieve 
more homogenous precipitation [228]. 
Trying to mimic the starting composition of the commercial preparation (Venofer®) and 
looking at the best results obtained until that moment in terms of monodispersity and non-
aggregation/agglomeration of nanoparticles, a sucrose-coated iron nanoparticles synthesis was 
carried out following previous reference using dextran [225] properly modified and adapted to 
the use of sucrose but keeping the stoichiometry from the reported protocol. 
For a suitable and reproducible synthesis of non-aggregated iron oxide nanoparticles, a 
synthesis based on the precipitation of FeCl3 salt in basic medium and the use of sodium tartrate 
and adipic acid as coating agents was carried out and the resultant iron nanoparticles were 
characterized using different techniques. 
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tissues more easily by mass spectrometry. The protocol followed for the FeNPs was slightly 
modified. As the stable iron isotope 57Fe (95.53 %) was purchased in elemental form (Cambridge 
Isotope Laboratories, Inc., MA, USA), aqueous solutions of the tracer were prepared by 
dissolving the metal in a mixture of HCl:H2O2 (8:1) at 60 ºC, in order to obtain similar 
Fe(III)chloride precursor to the one used in the original FeNPs synthesis. Then, same steps as 
described in previous section were followed. Resulting nanoparticles were further characterized 
using HR-TEM (JEOL JEM-2100F, Tokyo, Japan) and analysed to obtain particle diameter average 
and check nanoparticle shape and aggregation. Iron content was measured, and nanoparticle 
and soluble fractions were also quantified by ICP-MS (Agilent 7700x ICPMS, Agilent 
Technologies, Santa Clara, CA), using H2 as reaction gas to remove polyatomic interferences. 
3.4.5.1.2. Synthesis of Holmium-doped FeNPs 
To employ more suitable nanoparticles to be detected in complex matrixes by ICP-MS, an 
alternative to isotopically enriched 57FeNPs was developed. In this case, FeNPs were synthesized 
following the same protocol as previously detailed but including 1 % of Holmium in the 
procedure. In brief, calculations were accordingly made so 1 % of the total amount of 
Fe(III)chloride employed in the original procedure was replaced by 1 % Holmium 
(Holmium(III)chloride, abcr, Karlsruhe, Germany). Precipitation and purification procedure 
remained without modifications. Characterization by DLS (Malvern Zetasizer Nano ZS, Malvern 
Instruments Limited, Worcestershire, UK) and UV-vis absorbance (Genesys 10S UV-vis, Thermo 
Scientific, USA) was specifically performed. 
3.4.5.2. Acid lability assays 
As a potential use of these FeNPs on the oral treatment of anaemia, their possible behaviour 
facing the gastrointestinal barrier is a matter of interest. In this environment, pH range goes 
from 1.0-2.5 in the stomach to 6.6-7.5 in the proximal end to the ileum of the small intestine 
[229]. Thus, the stability of the synthesized FeNPs was checked by performing acid lability assays 
based on the work of Pereira et al. [55]. The freshly prepared FeNPs were suspended in 0.15 M 
NaCl to an iron concentration of 2 mM and incubated for 95 minutes at room temperature. The 
pH was set at 3.0 with 1 M NaOH and 1 M HCl. Samples were collected at different times (0, 5, 
10, 15, 35, 55 and 95 minutes). To assess the fractionation of the iron into percentages of 
microparticulate, nanoparticulate, and soluble iron during the process, centrifugation and 
ultrafiltration steps were applied. NPs suspensions were first centrifuged (10000 g x 5 min) and 
the sediment (if present) was considered as the microparticulate fraction. In order to isolate the 
soluble iron and to distinguish it from the nanoparticulate form, the supernatant from the 
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previous centrifugation was ultrafiltered (10000 g x 10 min, Mr cut off: 3000 Da, Amicon Ultra 
Centrifugal Filters, EMD Millipore, Darmstadt, Germany). The total iron was determined by ICP-
MS and microparticulate, nanoparticulate and soluble fractions were expressed as percentage 
in relation to total iron content as described elsewhere [55]. 
 
3.4.6. In vitro studies 
With the aim of clarifying FeNPs behaviour in cellular media, several experiments were 
carried out to determine the level of iron uptake, distribution and toxicity in different cell lines 
such as THP-1 monocytes, macrophages, Caco-2 and HT-29.  
3.4.6.1. Cell culture 
THP-1 cells, a pro-monocytic cell line, were cultured in RPMI 1640 (Life Technologies, Grand 
Island, NY) supplemented with 10 % fetal bovine serum (Gemini Bio-Products, West Sacramento, 
CA), 10 mM Hepes, 0.1 mM MEM non-essential amino acids, 1 mM sodium pyruvate, and 100 
nM penicillin/streptomycin (Life Technologies) and incubated at 37 ºC in an atmosphere of 5 % 
CO2 and 95 % air at a relative humidity of approximately 95 %. Medium was changed every 2-3 
days and, approximately, once a week, cells were centrifuged for splitting and re-suspended in 
fresh medium at a lower concentration to keep growing. 
THP-1 cells were differentiated with 100 µM PMA (phorbol 12-myristate 13-acetate; Sigma-
Aldrich, St. Louis, MO) and incubated during 48 h to allow complete differentiation into 
macrophages. PMA treatment induces a terminal differentiation: cells no longer divide, they 
adhere, metabolise more slowly and take on an appearance of a real macrophage. 
HT-29 and Caco-2 cells were grown at 37 oC in an atmosphere of 5 % CO2 and 95 % air at a 
relative humidity of approximately 95 %. Cells were maintained in T-75 flasks using Minimum 
Essential Medium (MEM, PAA Laboratories, Yeovil, UK) supplemented with 10 % foetal bovine 
serum (FBS “Gold”, PAA Laboratories), 1 % penicillin/streptomycin and 1% fungizone (Invitrogen, 
Paisley, UK). The growth medium was changed every 2-3 days. Upon reaching confluence, cells 
were treated with trypsin–EDTA solution (Sigma, St Louis, MO, USA) and split 1/10 to allow for 
continuous growth. 
3.4.6.2. Cellular uptake studies 
HT-29 and Caco-2 cells were grown on 6-well plates and incubated with four different 
concentrations of FeNPs (0, 0.5, 1 and 2 mM) and FeSO4 (0, 0.25, 0.5 and 1 mM) during 48 h. For 
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each experiment, every condition was investigated in triplicate wells. After washing with 
Phosphate Buffered Saline (PBS), cell pellets were collected for the quantification of total iron 
by ICP-MS.  
3.4.6.3. Total iron quantification in cell samples 
For this goal, cell pellets were lysed using an acid digestion protocol consisted on the 
addition of 0.5 mL sub-boiling HNO3 and 0.5 mL H2O2 30 % and incubation at 70 oC for 4 hours. 
Total iron quantification was measured by collision cell ICP-MS (H2 mode, iCAP™ TQ ICP-MS, 
Thermo Fisher Scientific). Calibration curves were prepared following the germanium addition 
technique as an internal standard, using stock solutions of 1000 mg L-1 (Merck). The mean of five 
separate replicates was used for determination of iron concentration. Obtained values were 
expressed as pg Fe cell-1. 
3.4.6.4. Nanoparticle extraction protocol 
In order to separate particle-bound from unbound cell proteins prior to HPLC speciation, an 
extraction protocol was carried out following Iglesias et al. publication [160]. In brief, cell 
samples were mixed with a protease inhibitor cocktail (Sigma-Aldrich) and centrifuged 10000 g 
for 5 min at 4 oC with the aim of isolating nanoparticles content in the supernatant from cell 
debris precipitated. Then, purification is achieved by high concentrated sucrose solution (0.7 M, 
Sigma-Aldrich), Phosphate Buffered Saline and centrifugation steps for 30 min at 18000 g 
keeping always the temperature constant to 4 oC. Extracts were stored in the fridge until 
injection on the chromatographic system. 
3.4.6.5. Sample preparation for LA-ICP-MS measurements 
For LA-ICP-MS experiments, Caco-2 cells were grown on sterile coverslips (Thermo Fisher 
Scientific, Waltham, USA) in an 8-well plate. 4 wells were used as control and the rest were 
incubated with 500 µL of iron nanoparticle suspension (0.7 mM FeNPs) in standard cell culture 
medium. After an exposure time of 48 h, Caco-2 cells were washed thoroughly with phosphate 
buffered saline (PBS), immediately fixed with 4 % para-formaldehyde in PBS, and dehydrated in 
a graded series of ethanol for LA-ICP-MS analysis. 
3.4.6.6. Viability assays 
To evaluate the potential cytotoxicity induced by the FeNPs, a WST-Assay (Roche 
Diagnostics, Mannheim, Germany) was carried out in THP-1 monocytes and macrophages. This 
is a colorimetric assay based on the use of tetrazolium salts, that are cleaved to a soluble 
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formazan by a complex cellular mechanism that occurs primarily at the cell surface. This 
bioreduction is largely dependent on the glycolytic production of NAD(P)H in viable cells (Figure 
15.A). Therefore, the amount of formazan dye formed directly correlates to the number of 
metabolically active cells in the culture. 
Cells grown in a 96-well flat bottom plate, are incubated with the WST-1 reagent for 2 h in 
a humidified atmosphere (37 oC, 5 % CO2, 87 % humidity). After this incubation period, the 
formazan dye formed is quantified with a scanning multiwell spectrophotometer. The measured 
absorbance at appropriate wavelength directly correlates to the number of viable cells (the 
wavelength for measuring the absorbance of formazan product is between 420-480 nm with a 
maximum absorption at about 450 nm). For best results, the following protocol was carried out: 
• THP-1 Monocytes and macrophages, grown from THP-1 by PMA addition and 24 h 
incubation, were seeded at a density of 1 104 cells/well (measured by CASY® MODEL TT 
cell counter + analyser, Roche INNOVATIS AG, Germany) in 96-well plates (100 µL/well). 
(culture medium: RPMI + BSA 10 % (50 mL), + Sodium pyruvate (5 mL), + 
penycillamine/streptomicine (5 mL), + HEPES (5 mL). 
• Cells were then treated with different concentrations of FeNPs (0-4.5 mM). 
• After 24 h incubation, the cell proliferation reagent WST-1 for viability/cytotoxicity 
studies was used (10 μL/well, 1:10 final dilution, including a medium control; 2 h 
incubation). 
• Solutions from each well are collected in Eppendorfs for centrifugation (13000 rpm x 15 
min) and supernatant is transferred to a new 96-well plate to be measured in a TECAN 
GENios microplate reader (TECAN, Switzerland) at 450 nm. 
Similarly, a MTT-assay was conducted in Caco-2 and HT-29. The MTT assay involves the 
conversion of the water soluble MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) to an insoluble formazan. The formazan is then solubilized, and the concentration 
determined by absorbance at 570 nm (Figure 15.B). Cells grown in a 96-well flat bottom plate 
are incubated with different concentrations of FeNPs (0 to 4 mM, in triplicate wells) for 48 h. 
The MTT reagent is added and incubated for 2 h in a humidified atmosphere (37 ºC, 5 % CO2,    
95 % humidity). After this incubation period, the formazan dye formed is quantified with a 
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solution) at a rate of 0.19 mL min−1 at 37 °C using a peristaltic pump for 100 minutes. 
Composition of the perfusion solution was as follows: 8.0 g L−1 NaCl, 0.2 g L−1 KCl, 0.2 g L−1 CaCl2 
anhydrous, 0.1 g L−1 MgCl2 anhydrous, 0.05 g L−1 NaH2PO4·H2O and 1 g L−1 glucose (pH 7). The 
experiment was performed in a thermoregulated chamber. After perfusion, solutions at the exit 
of the small intestine were collected, intestine was extracted, and its length and width were 
registered. Then, fractions of duodenum, jejunum and ileum were collected, as well as fractions 
of liver and kidney. Additionally, aliquots of blood were drawn from the aorta by a heparinized 
syringe. All samples were frozen at −80 °C until further analysis. 
All experiments were undertaken according to Directional Guides Related to Animal Housing 
and Care (European Community Council, 2010), and the Animal Experimentation Ethics 
Committee of the University of Granada approved all procedures. 
3.4.7.2. Total iron quantification in animal tissues 
Tissue samples were freeze-dried and digested using a microwave oven (Ethos 1, Milestone 
S.r.l., Italy). In brief, approximately 0.1 g of each lyophilized sample was placed into a 
polytetrafluoroethylene digestion vessel. Then, 5 mL of sub-boiling nitric acid (30 %) and 3 mL 
of Suprapur hydrogen peroxide (30 %) were added and digestion program was applied [231]. All 
the plastic containers used in the analysis were previously cleaned with high purity nitric acid 
and ultra-pure water. Digestion and cleaning conditions selected are collected in Table 18. At 
the end of the digestion, the resulting solutions were made up to 50 mL with ultrapure water 
for further ICP-MS analysis. 
Table 18. Microwave oven digestion programs for animal tissues and cleaning. 
 Step Power (W) Time (min) Temperature (ºC) 
Sample 
digestion 
1 1200 15 140 
2 1200 15 190 
3 1200 30 190 
Cleaning 
1 900 10 150 
2 900 10 150 
 
Iron total quantification was measured by collision cell ICP-MS (H2 mode, iCAP™ TQ ICP-MS, 
Thermo Fisher Scientific). Calibration curves were prepared following the germanium addition 
technique as an internal standard, using stock solutions of 1000 mg L-1 (Merck). The mean of five 
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separate replicates was used for determination of iron concentration. Obtained values were 
expressed as mg Fe kg-1 of dried sample. 
3.4.7.3. TEM images 
Cell cultures and other tissues samples (blood, spleen) were fixed with fresh primary fixative 
(1.5 % glutaraldehyde, 1.0 % formaldehyde in 0.05 M sodium cacodylate buffer, pH 7.4) and 
post-fixed with secondary fixative (1 % osmium tetroxide, 1 % potassium ferrocyanide in Milli Q 
water) followed by dehydration with ascending series of alcohol before embedding samples in 
epoxy resin. Ultra-thin sections were cut and doubly stained with uranyl acetate and lead citrate. 
A transmission electron microscope LIBRA 120 PLUS microscope at 120 kV (Carl Zeiss SMT., 
Oberkochen, Germany) was used to determine the distribution and uptake of FeNPs into cells.  
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4 RESULTS AND DISCUSSION 
When working with nanoparticles, especially in living organisms, it is important to check 
specific properties that affect enormously the nanoparticle structure. 
Agglomeration/aggregation, polydispersity index, solubilization grade and, consequently, 
degradation level into ionic species are features that need to be well-established before 
designing an experiment. The analytical techniques to face up these challenges must combine 
separation and quantification competences, using suitable detectors to overcome the limitation 
of extremely narrow size range between those species. In fact, the interactions of 
nanomedicines with their biological environment are complex issues that have to deal with the 
“a priori” controllable properties of the particles (size and shape, surface chemistry, pH stability) 
and the unhandled properties of the surrounding media once the nanoparticle penetrates the 
cell, such as the cellular uptake, the degree of protein adsorption, the bio-distribution pattern 
or the influence that this media play on the nanoparticle structure [117].   
In the framework of this study, transmission electron microscopy as well as different 
spectroscopy techniques (spectrophotometry, light scattering, X-ray diffraction) especially, mass 
spectrometry, were used to provide valuable information about this kind of nanostructures and 
evaluate their interaction in different biological media.  
Moreover, two different nanosystems based on iron preparations for the treatment of 
anaemia were evaluated. On the one hand, Venofer® is a commercial preparation available in 
the market for the intravenous treatment of severe anaemia based on iron-sucrose 
nanoparticles. There are several commercial preparations based on iron nanoparticles with 
different carbohydrate shells, which overcome anaemia’s disease efficiently. But, although their 
use is approved by official organisms (as the FDA in USA, or the EMA in the EU), the mechanism 
of iron release that takes place in the human body needs further investigations. This work may 
serve as starting point to further investigate other iron preparations available in the 
pharmaceutical industry. 
On the other hand, the most extended treatment for anaemia has always been the oral iron 
supplementation due to its inexpensive costs and the ease of administration. However, there 
are not products in the market including this type of nanostructures to enhance the 
effectiveness of the treatment, and thus, numerous side effects are associated nowadays to this 
oral treatment. Therefore, the need for the development of better iron preparations for the oral 
treatment of anaemia is clear and the use of nanodrugs play an important role not only in the 
increase of bioavailability, but also in the reduction of undesirable effects. In this sense, FeNPs 
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Out of these experiments, it can be confirmed that a high concentration of iron is directly 
“dissolved” from the preparation in the presence of biological media (as they contain efficient 
complexing agents such as transferrin). Such results confirmed the semi-robust (kinetically) and 
moderately strong (thermodynamically) nature of the Venofer® formulation probably related to 
a weak interaction of the iron-oxide NPs with the sucrose molecules forming the coating surface. 
In addition, the level of iron release turned out to be time dependent. After 7 h, the solubilization 
level reaches 70 % of the initial iron concentration used for incubation in both, serum and whole 
blood. Therefore, little iron remains in the injected form after intravenous administration to the 
patients but as soluble iron (smaller iron nanoclusters or ions) that should be further evaluated 
for potential deposits in tissues etc.  
 
4.1.3. Released iron incorporation into transferrin binding sites 
4.1.3.1. Separation of the transferrin sialoforms in serum by anion 
exchange chromatography 
Transferrin (Tf) contains two sites available for metals binding and in normal human serum 
are partially filled (~30 %) with iron atoms. The complete saturation of these metal binding sites 
is necessary to separate Tf sialoforms (forms with different oligosaccharide composition 
naturally present in serum) by anion exchange chromatography [234]. Thus, the serum blank as 
well as the Venofer® treated serum samples were further incubated with 57Fe but, in this case, 
in the presence of NaHCO3 (required as synergistic ion) for complete saturation of Tf.  
Figure 23 shows the actual separation of the most abundant Tf sialoforms containing 2, 3, 4, 
and 5 sialic acids in a serum sample incubated with Venofer®. Figure 23.A shows the separation 
after 1, 3.5 and 7 h of incubation and the evolution of 56Fe signal. The most abundant form of 
this glycoprotein is normally the S4 accounting for about 75 % of the total Tf (as can be identified 
in Figure 23 as the highest peak detected).  
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4.1.3.2. Quantitative analysis of the iron incorporated in the different 
sialoforms of transferrin by Isotope Pattern Deconvolution 
By using this treatment previous described and applying the so-called isotope pattern 
deconvolution (IPD), the contribution of endogenous and exogenous iron to the different Tf 
isoform can be obtained, as described elsewhere [239]. Thus, the level of natural iron will give 
an idea of the endogenous concentration of the metal or in other words, the level of transferrin 
saturation while the level of the 57Fe added for saturation will provide information on the 
unsaturated iron binding capacity (UIBC) of Tf [239]. The results are plotted in Figure 24 for the 
four sialoforms obtained (S2, S3, S4 and S5) and for the different assayed incubation times as an 
example. As can be seen, the same pattern was obtained for all the sialoforms.  
Figure 23. Chromatograms corresponding to the separation of the sialoforms in serum by anion 
exchange chromatography (disialoTf-S2, trisialoTf-S3, tetrasialoTf-S4, pentasialoTf-S5) after saturation 
with 57Fe. A. After 1, 3.5 and 7h of incubation with Venofer® (monitorizing 56Fe signal). B. After 3.5h of 
incubation with Venofer® (monitorizing 56Fe and 57Fe signals). 
4 RESULTS AND DISCUSSION 
107 
 
 
Figure 24. Quantitative analysis of the iron incorporated in the disialoTf-S2, trisialoTf-S3, tetrasialoTf-
S4 and pentasialoTf-S5 after incubation with Venofer® for 1, 3.5 and 7h (blue columns: iron required for 
complete saturation; red columns: iron incorporated into the corresponding sialoform). 
As expected, the longer the incubation time, the higher the incorporation of iron from 
Venofer® to transferrin sialoforms (red columns of Figure 24). However, according to our results, 
the complete iron saturation is not achieved even after 7 h of incubation, even if the 
incorporation of iron in Tf-binding sites reached almost 95 %. Similarly, the data of 57Fe reveal 
the unsaturated ion binding capacity (UIBC) of the Tf that decreases dramatically upon exposure 
to Venofer® (blue columns of Figure 24). This is not surprising since serum samples with regular 
Tf levels (about 3 mg mL-1) can bind up to 5 mg L-1 of iron (Tf binding sites can accommodate two 
atoms of iron per molecule) and solubilized levels exceed this value. Therefore, other serum 
proteins or small molecular weight binders might be carrying the non-Tf bound solubilized iron 
from Venofer®. 
 
4.1.4. Iron association to other serum proteins 
Since the observed iron solubilization levels would definitely overload the iron-binding 
capabilities of Tf, other serum proteins could act as potential additional binders and transporters 
of iron in the blood of the exposed patients. In order to address this possibility, speciation 
experiments of other possible serum proteins were conducted in the incubated samples using 
UV-Vis and ICP-MS elemental detection without the addition of any external iron. Figure 25.A 
shows the HPLC-UV (280 nm) profile corresponding to the most abundant serum proteins 
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Regarding the ICP-MS trace (Figure 25.B), a main peak can be detected (at about 6.5 min) 
that corresponds to the iron associated to Tf (with slight delay in respect to the UV trace due to 
the interface between the LC and the ICP). Small iron traces seem to be present in the albumin 
peak additionally (see peak at about 13 min in Figure 25.B). In summary, the serum speciation 
results showed that albumin carries a low fraction of the solubilized iron. It is known that 
albumin can bind iron ions in a non-specific way in contrast to Tf [240]. Interestingly, an increase 
in the oxidative state of albumin (mainly referred to an increase in sulfenic (−SOH), sulfinic 
(−SO2H) and sulfonic (−SO3H) forms from oxidation of the only reduced cysteine present in 
albumin) has been documented upon intravenous iron administration in the form of 
nanoparticles in hemodialysis patients but also in experiments in vitro like those conducted here 
[241]. Moreover, small molecular weight iron complexes seem to be formed that elute (partially) 
when increasing the ionic strength of the mobile phase. Some of them might be also due to iron 
hydroxides that could, most likely, precipitate in the column due to the physiological pH of the 
mobile phase or much smaller nanoparticles remaining from the original product. 
 
In summary, the parenteral iron formulation, Venofer®, liberates iron-ions in contact with 
the serum components, even in the absence of the RES system. This was confirmed by the 
saturation of the serum Tf binding sites after incubation of human serum with the 
pharmaceutical preparation whose analytical characterization did not show the presence of 
ultrafiltrable iron species. Other proteins present in serum, such as albumin, do not seem to 
carry much iron from the disrupted particles. Thus, upon injection in the patients, a fraction of 
NP is possibly disrupted into smaller size particles and ions that will circulate in the bloodstream.  
The method here developed gives new insights for the monitoring of ions released from 
nanoparticles in body fluids and it can be considered as a competitive tool, especially in terms 
of accuracy and precision for the quantitative speciation of these iron species. Moreover, it can 
be considered as an appropriate alternative to study the iron pathway in other similar 
intravenous preparations for the treatment of anaemia. 
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4.2. In vitro studies on iron nanoparticles for the oral treatment 
of anaemia 
4.2.1. Synthesis and purification of iron nanoparticles potentially used for the 
oral treatment of anaemia 
Different approaches for the synthesis of iron oxide nanoparticles were carried out as it was 
previously mentioned in the Experimental Section.  
Basically, there are two different methods for synthesizing iron oxide nanoparticles: 
1) Co-precipitation of Fe(III) and Fe(II) species in presence of a coating agent in aqueous 
basic solution. The main advantage of this strategy is the large amount of nanomaterial 
that can be produced by a one-pot synthesis. However, it generally results in 
polydisperse samples and therefore, additional purification steps are required to 
separate smaller particles from the larger ones. 
2) Sequential method based on the formation of the iron core, first, followed by the 
coating with a polysaccharide. Generally, this synthetic route leads to more 
homogeneous nanoparticles as the whole process takes place slowly and well 
controlled. However, it is more time consuming and there are more parameters that 
can affect the reproducibility. 
Synthesized iron nanomaterials usually face a great limitation considering their strong 
tendency to agglomerate due to Van der Waal forces. Moreover, magnetite particles are easily 
air oxidized [242]. Thus, different variations were tried referring to inert atmosphere conditions 
and the use of different additives which can prevent or partially reduce agglomeration.  
First attempts were based on the use of dextran as coating agent. Dextran is a 
polysaccharide which have a linear backbone of α-linked D-glucopyranosyl repeating units. It 
has many advantages such as its biocompatibility, biodegradability and transfection efficiency 
which makes it suitable for its application in biological systems. It is inexpensive, non-toxic and 
easily available, too [228]. Previous reduction of dextran with NaBH4 was considered as an 
alternative to achieve a better control of the nanoparticle size. In those cases, a previous step 
of dextran reduction was performed 12 h at least, in advance. In that reaction, a polyol is formed 
which is thought to improve the stability of dextran-NP bond [243]. On the other hand, the use 
of nitrogen or argon during the synthesis process, not only prevents the oxidation of the 
magnetite, but also reduces the particle size. 
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The pH is also an important factor when precipitation takes place. Urea was used as an 
additive to the formation medium as it is known that it is decomposed in ammonia when heated 
over 80 ºC. The effect of ammonia added to the hydroxide ions coming from NaOH solution can 
help to increase pH gradually and homogenously, resulting in a more stable solution. 
Ionic strength is also well established as an important parameter to control morphology and 
size when synthesizing metallic nanoparticles. NaCl and KCl enrichment medium was also tried 
as a possible variation which can improve resulting nanoparticles.  
Final attempt was based on Powell et al. procedure [71] already detailed in Experimental 
Section. It basically consists in three steps: 
1) Mixing of metal ions and ligands (tartrate and adipic acid in this case) at an initial pH 
value where all reagents are solubilized. 
2) pH change by adding a basic solution (NaOH) so, a solid precipitate containing the 
nanoparticles is formed. 
3) Separation and purification of the solid produced in the previous step. 
This strategy can be performed in air conditions as there is no co-precipitation of Fe2+ and 
Fe3+. Only FeCl3 is used as precursor reagent, so oxidation is not needed to prevent. Moreover, 
reaction occurs in one-pot, simplifying and accelerating considerably the nanoparticle 
production. Ferrihydrite core nanoparticles resulted from this protocol and structural 
information was checked by HR-TEM, DLS, UV-vis and X-ray diffraction techniques. 
All approaches applied, as well as main limitations and considerations that justify the choice 
of the most suitable synthetic route were collected in Table 19.  
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Table 19. Summary of the different synthesis approaches of iron oxide nanoparticles and their main 
considerations and limitations. 
Approach Atmosphere Specification Main drawbacks References 
Dextran coated 
iron oxide NPs Nitrogen 
-Reduced Dextran 
(by NaBH4) 
-Reflux conditions 
(T= 89 ºC, 2 h) 
-Low 
reproducibility 
-Isolation from O2 
crucial 
-Important loss of 
product during 
filtration steps for 
purification 
[225] 
Dextran coated 
iron oxide NPs Nitrogen 
-Non-reduced 
Dextran 
-Ultrasonication 
Room 
temperature 
[226] 
Dextran coated 
iron oxide NPs Oxygen (Air) 
-Reduced Dextran 
(by NaBH4) 
-Heating and 
stirring (T= 80 ºC) 
-Process in 2 
steps: 1) Iron NPs 
precipitation; 2) 
Dextran coating 
step 
-Low 
reproducibility 
[227] -Non-reduced Dextran 
-Heating and 
stirring (T= 80 ºC) 
NaCl medium 
enrichment 
Dextran coated 
iron oxide NPs Nitrogen 
-Urea medium 
enrichment 
-Heating and 
stirring (T= 91 ºC) 
- Centrifugation 
and dialysis 
-Time consuming 
purification step  
[228] 
-Urea medium 
enrichment 
-Heating and 
stirring (T= 91 ºC) 
-No dialysis 
-Important loss of 
product during 
washing steps 
due to 
solubilization 
Sucrose coated 
iron oxide NPs Argon 
-Heating and 
stirring (T= 89 ºC, 
3 h) 
-Ultrasonication 
-Ultrafiltration 
and dialysis 
-Time consuming 
purification step [225]
(adapted) 
Tartrate-
modified coated-
iron oxide NPs 
Oxygen (Air) 
-Stirring, room 
temperature 
-KCl enrichment 
media 
-Centrifugation 
and ultrafiltration 
Synthesis of 
choice [71] 
 






4 RESULTS AND DISCUSSION 
119 
 
 
DLS measurements were also compared and hydrodynamic volume was slightly higher (5 
nm more than original structure) and so the polydispersity index, although it remains below 0.5 
value, which determines an acceptable quality for the measurement. Table 21 displays the 
comparison. 
Table 21. Average of hydrodynamic diameter and polydispersity index obtained by DLS for FeNPs and 
Fe-Ho NPs. 
DLS FeNPs Fe-Ho NPs 
Z-average 
(d. nm) 11.77 16.81 
PdI 0.276 0.485 
 
In order to determine the structure of the nanoparticle in terms of average particle size, 
shape, distribution and surface-to-volume ratio, SAXS measurements were performed (Figure 
35.A.). WAXS technique was also applied to elucidate crystalline structure of the 
nanosuspension. It only differs from SAXS in the shorter distance from sample to the detector 
and thus diffraction maxima at larger angles are observed (Figure 35.B.C). However, looking at 
the results obtained, homogeneity and monodisperse particles detected by HR-TEM were not 
confirmed by SAXS. Data from SAXS reveal a possible agglomeration and polydispersity. 
Moreover, spherical shape is not clear as the parameter P is not 4, expected value for spherical 
particles (except in the case of Venofer® samples, see Table 22). 
Figure 34. UV-vis absorption spectra of FeNPs diluted 1:100 (red trace) and Holmium doped FeNPs 
diluted 1:100 (green trace). 
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4.2.5. Toxicity assessment 
4.2.5.1. Cell viability assays 
Viability assays were accomplished using high concentration levels of FeNPs (up to 4000 µM) 
and long incubation times (48 h). Results of the MTT assay are showed in Figure 42. This 
colorimetric assay is based on the production of formazan via an enzymatic reduction, so the 
more formazan is produced, the more number of metabolically active cells are in culture. In this 
range of concentrations, considered in therapeutic levels, no cytotoxicity is detected neither in 
Caco-2 or HT-29. It should be remarked that no effects were observed on cell viability at low 
FeNPs concentration. But as FeNPs concentration increases, cell viability percentages also 
increase, especially in Caco-2 cells, which can be associated to their highest capability to absorb 
iron and may suggest a positive effect of the nanoparticles on the enzymatic activity. At higher 
FeNP concentrations, cell viability falls down until reaching control values again. This reduction 
could be attributed to an increase of ROS production due to the great amount of iron absorbed 
at these levels. In spite of these cell viability rates around 100 %, cell damage cannot be 
completely discarded since the cell has repair mechanisms that are impossible to detect with 
the MTT assay.  
Moreover, cytotoxicity studies based on WST-1 reagent were carried out in THP-1 
monocytes and macrophages. The results, corresponding to three independent experiments, 
demonstrated that exposure to the synthesized FeNPs during 24 h resulted in a non-significant 
toxicity, especially up to 1600 μM in both cell lines, THP-1 and its differentiated line, 
macrophages. An increment in the cytotoxicity when incubation time is increased up to 48 h was 
Figure 42. Cell viability in HT-29 (dark blue bars) and Caco-2 (light blue bars) after 48 h of FeNPs exposure 
from 0-4000 µM of Fe concentration. 
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As it can be seen in Figure 44, the cellular DCFDA assay revealed the evidence of reactive 
oxygen species generation with time after incubating with FeNPs and FeSO4, which is in good 
agreement with the expected for iron compounds [130]. Fluorescence intensity increases with 
time in both cases and duplicates the background values from the compounds by themselves or 
cells without any modification. Thus, there is a proof of cell damage although it was not 
previously shown in terms of cell mortality. 
It should be noticed that cellular oxidative stress might have a more pronounced impact 
when using FeSO4 in comparison with the use of the same concentration of FeNPs, judging by 
the greater fluorescence intensity reached in the first case. This could be due to a lower 
bioavailability of the iron present in FeNPs as it is confined in the nanostructure and protected 
by its shell, minimizing its oxidant capability. These values are the result of applying a correction 
that considers the lower degree of absorption of the FeSO4 compared to the FeNPs uptake. 
Concentration level of 0.25 mM was chosen attending to the plasma levels reached in patients 
after iron administration at pharmacological doses [250]. So, results here presented could 
validate the use of these nano-preparations for the effective treatment of iron deficiency 
disease.  
 
  
Figure 44. ROS assay comparing the exposure to FeNPs (grey bars) Vs FeSO4 (orange bars) in Caco-2. 
Tert-butyl hydroperoxide (TBHP) was used as positive control (blue bars) and controls of FeNPs (red 
bars), FeSO4 (grey bars) and cells (yellow bars) were used to establish background levels of fluorescence 
intensity. 
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4.2.6. Speciation and quantitative analysis of nanoparticles and ionic species 
of iron by HPLC-ICP-MS in combination with Isotope Dilution Analysis 
 
4.2.6.1. Optimization of HPLC conditions 
For the speciation goal, the methodology already designed for the separation of engineered 
silver containing nanoparticles and Ag(I) species in a single chromatographic run was modified 
to be applied for the speciation of iron nanoparticles and their ionic species, Fe(III). For these 
studies, a reversed-phase column with a pore size of 1000 Å and an ammonium acetate buffer 
containing SDS as modifier were used. Parameters used in this study are summarized in Table 
23. 
Table 23. Instrumental parameters of the HPLC used for the speciation of Fe-NPs. 
HPLC  
Column Nucleosil 7 μm particle size, C18, 1000 Å pore size, 250 x 4.6 mm 
Flow rate 0.5 mL min-1 
Injection Volume 20 μL 
Mobile phase 10 mM SDS, 10 mM ammonium acetate, pH = 6.8 
 
Mobile phase studies  
First studies were carried out by diluting the self-synthesized iron nanoparticles in a solution 
of 10 mmol L-1 SDS, 10 mmol L-1 ammonium acetate, pH = 6.8 to final concentrations between 1 
and 50 μg L-1 of iron. Moreover, Venofer® solutions were also prepared in the same mobile phase 
to final concentrations between 1-30 μg L-1. Figure 45 displays the variation of intensities in these 
chromatograms according to different iron concentrations injected for both complexes, 
Venofer® (Figure 45.A) and FeNPs (Figure 45.B).  
Chromatograms also revealed an only peak at a retention time of 4.4 min in the case of 
Venofer® (used as a standard of 4.55 ± 0.55 nm), and 4.8 min for the self-synthesized FeNPs, in 
agreement with what we expected according to their smaller size (3.65 ± 0.39 nm) and the size 
exclusion mechanism followed in this kind of separation (Figure 46).  
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With the aim of eluting the iron ionic species, studies on the HPLC separation conditions 
were carried out. For this purpose, 1 mM EDTA and 1 mM sodium citrate were included for 
dilution of the samples. Both reagents are considered as iron high chelating agents (stability 
constants: Fe(III)-EDTA=25.7; Fe(III)-citric acid=11.85) so the soluble iron present in the samples 
is supposed to elute from the column chelated with these ligands. However, chromatograms 
show the appearance of two peaks, especially a high intensity signal at 5.7 min (Figure 47) that 
reveals the increasing solubilization of these nano-structures in these media with time and the 
high strength of these ligands in comparison to original binding of nanoparticles, especially in 
the case of EDTA, as expected regarding the stability constant (Figure 47.A). 
 
4.2.6.2. Quantitative studies 
4.2.6.2.1. Recovery studies for Venofer®, FeNPs and soluble species 
of iron 
To determine the recovery rates of the Venofer®, FeNPs and soluble iron, total iron 
quantification was measured as previously described in section 3.4.6.3. On the other hand, on-
line quantification using the IDA approach was carried out. The application of post-column IDA, 
with an isotopically enriched 57Fe isotope standard, resulted in three peaks at retention times of 
4.4 min, 4.8 min and 5.7 min for Venofer®, FeNPs and Fe(III), respectively. Concentration of iron 
was calculated according to Rottman et al. using the equation for time-resolved IDA [251]. Table 
24. shows obtained recoveries for those species.  
Figure 47. Chromatograms of Venofer® and FeNPs using 1 mM EDTA (A) and 1 mM sodium citrate (B) as solvent 
agents. 
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Table 24. Total Fe concentration measured for Venofer®, FeNPs and Fe(III) and corresponding 
recoveries. 
Sample 
Determined Fe 
concentration by 
ICP-MS (µg L-1) 
Determined Fe 
concentration by 
IDA (µg L-1) 
Recoveries (%) 
Venofer® 12.2 11.4 ± 1.8 93.2 
FeNPs 19.4 17.4 ± 1.0 89.9 
Fe(III) 15.3 5.7 ± 0.1 37.5 
 
Satisfactory recovery rates of 89.9 % and 93.2 % were obtained for FeNPs and Venofer®, 
whereas a value below 40 % was determined for soluble species. This can be attributed to a 
higher retention of these small ions in the column due to their strong interactions with the 
negatively charged sulphate groups from the SDS contained in the mobile phase and a 
consequent entrapment in the column. Repeatability in terms of retention time and peak area 
was assessed and collected in Table 25.  
Table 25. Repeatability in terms of retention times and peak areas for Venofer®, FeNPs and the ionic 
species of Fe and the LODs for the analyzed samples using the 1000 Å column (N = 3). 
Sample Retention time peak (min) 
Peak Area 
(ng min-1) LOD (µg L
-1) 
Venofer® 4.44 ± 0.01 0.25 ± 0.05 1.65 
FeNPs 4.80 ± 0.01 0.35 ± 0.02 0.53 
Fe(III) 5.61 ± 0.01 0.11 ± 0.01 1.11 
 
The suggested chromatographic strategy shows repeatable results by looking at the 
standard deviations values: 0.01 for retention times (N = 3) and below 0.05 for peak area (N=3). 
Lowest detection limit was achieved for the self-synthesized FeNPs (0.53 µg L-1) whereas the 
highest was obtained for Venofer® nanoparticles with a value of 1.65 µg L-1. There are no 
comparable results as there is no analogous strategy for the speciation and quantification of iron 
nanoparticles, especially in the low nm-range as these ones. 
4.2.6.2.2. Analysis of iron species in Caco-2 cell samples 
The protocol for the FeNPs extraction from cellular samples was followed as detailed in 
section 3.4.6.4. Purification steps based on sedimentation through sucrose cushion seem to be 
more effective in terms of detaching loosely bound proteins and isolating the nanoparticle, 
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without affecting its intrinsic structure. In parallel, acid digestion and iron total quantification of 
Caco-2 cell pellets containing the FeNPs were carried out by ICP-MS.  
Once the cell extracts are injected in the column, separation in three peaks occurs as it is 
shown in Figure 48. A peak at 4.8 minutes that is only missing in the control sample and increases 
the intensity with increasing iron concentrations denotes the elution of NP-bound iron species, 
and so it was previously determined in aqueous solution studies (Figures 45.B and 46). 
 
 Another peak at 5.7 minutes tends to increase when iron content gets also higher in the 
samples. It can be correlated to ionic iron species based on the retention time obtained for Fe(III) 
in prior mobile phase studies (see Figure 47). This increment can be justified by the solubilization 
of the nanoparticles that takes place gradually when entering the cells. By using the 
nanoparticles whose sizes are well-known by complementary techniques, such as HR-TEM, it is 
possible to obtain a size calibration considering different retention times. Thus, a mean size of 
1.62 ± 0.03 nm could be estimated for these soluble iron species.  
Chromatograms also show another peak at a retention time of 3.7 min which needed further 
analysis for its identification. For this purpose, fractions between 3.2 and 4.2 min were collected 
at the exit of the column and examined by HR-TEM. At such a retention time, estimated particle 
size was 6.1 ± 0.8 nm and, in fact, images corresponding to these fractions verified this value. 
Figure 48. Chromatograms of solutions extracted from Caco-2 cell samples containing 0, 0.1, 0.25 and 
0.5 mM FeNPs. 

4 RESULTS AND DISCUSSION 
135 
 
Table 26. Determined FeNP, ionic Fe and total Fe concentration for four injected sample concentrations 
of the FeNPs in Caco-2 extract samples. 
Sample 
Fe total 
concentration 
by ICPMS 
(µg L-1) 
Determined 
FeNP 
concentration 
(µg L-1) 
Determined 
Fe3+ 
concentration 
(µg L-1) 
Fe total 
concentration 
(µg L-1) 
Recoveries (%) 
Control 7.9 - 2.7 ± 0.1 5.6 ± 0.2 70.6 
0.1 mM FeNPs 318.1 73.7 ± 3.8 89.2 ± 5.1 250.8 ± 42.8 78.8 
0.25 mM FeNPs 687.3 88.6 ± 3.3 149.4 ± 13.1 503.2 ± 25.2 73.2 
0.5 mM FeNPs 995.3 161.4 ± 21.4 148.3 ± 12.8 590.7 ± 28.9 59.3 
 
4.3. In vivo studies on iron nanoparticles for the oral treatment of 
anaemia: distribution and bioaccumulation assessment in rats 
Iron absorption takes place at the apical membrane of duodenal enterocytes. Usually, in 
vitro studies are made to address drug absorption. However, true absorption of ingested trace 
metals is defined as the uptake and transfer of dietary mineral across the mucosal cells [252]. In 
this sense, small intestine perfusion experiments seem to be particularly adequate to study 
metallodrugs absorption in animal models [230, 253]. 
4.3.1. Acid lability assays to check the stability of FeNPs in gastric conditions 
Usually, one of the most important aspects to determine the bioavailability of an iron 
supplement is the solubility that it presents when passing through the gastrointestinal barrier. 
Thus, it is important to check the stability of the self-synthesized iron nanoparticles in this sort 
of media, which is quite far from the pH values of the original medium. For this purpose, acid 
lability assays were performed following protocol already detailed in Experimental Section 
(3.4.5.2.). 
With this experiment, FeNPs were checked in a simulated digestion medium with time and 
results are shown in Figure 50. In brief, three different degrees of solubilization are detected. 
During the first 5 minutes, the main solubilization occurs (soluble fraction increases from 12 to 
33 %), duplicating the soluble fraction from the initial point. During the next 5 minutes, another 
important solubilization takes place but not as significant as the first one (soluble fraction 
increases from 33 to 46 %). Finally, a balance between both species (nanoparticulate and soluble 
fractions) is reached, and the situation remains until the end of the experiment (95 minutes), 
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confirming the stability of these nanostructures in the gastric tract. This fact is in agreement 
with the bibliography consulted [55]. 
 
 
4.3.2. Iron absorption and distribution through the small intestine 
Iron absorption studies by intestinal perfusion of FeNPs suspensions were accomplished for 
the first time in anaesthetized animals. For this purpose, the animals were treated as described 
in the Experimental section (3.4.7.1.) and the total iron was measured by ICP-MS after adequate 
dilution and using H2 as cell gas in the infused solution before and after perfusion. The obtained 
results (before and after normalization by the dimensions of the intestine of the different 
animals) are shown in Table 27.  
Table 27. Results obtained for the perfusion experiments. 
Compound Number Perfused Fe (mg L-1) Absorbed Fe (mg L-1) % Absorption 
Absorption by 
intestinal surface  
(V at mg L-1 cm-2) 
Control 4 0.004 ± 0.003 -0.2 ± 0.1 - -0.006 ± 0.001 
FeNPs 4 35.6 ± 0.6 28.2 ± 2.1 79.3 ± 6.1 0.3 ± 0.1 
 
As can be observed, the absorption of the FeNPs achieves a value of 79.3 % compared to the 
control group, that proves the effectiveness of potential absorption that these nanoparticles 
Figure 50. Acid lability assay of FeNPs at pH 3 showing the evolution of the nano-compound composition 
with time (nanoparticulate fraction is showed as dark orange bars; soluble fraction is represented as 
light orange bars.) 
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would have if they were orally administered. The absorption rate of iron from FeNPs is 
significantly higher than the one commonly obtained in the literature (from 1-50 % depending 
on specific conditions [254, 255]). In particular, in previous bioavailability studies using FeSO4, 
absorption values between 26-57 % were obtained [256, 257]. 
It is known that iron absorption normally occurs in the duodenum and upper part of the 
jejunum. However, it is important to remark that the availability of ingested iron for absorption 
can vary and the amount absorbed depends on the chemical nature and quantity of iron in the 
diet, the presence of other factors in ingested food, the effects of gastrointestinal secretions 
and the absorptive capacity of the intestinal mucosa [254, 255]. Moreover, in a similar study for 
iron absorption assessment by duodenum perfusion using ferric citrate, uptake levels of 30 % 
were obtained [258], being clearly lower than the values here presented. 
This great absorption value can be attributed to the higher capacity of FeNPs absorption due 
to the several uptake mechanisms that can take place in in vivo models. The ionic fraction 
released from nanoparticles may be absorbed by DMT-1 protein, whereas the non-digested 
FeNPs could be uptaken by endocytosis and released to the interstitial space, increasing the 
yield of the absorptive process. It has also been described that alternatively, macromolecules 
may cross the “tight junction” barrier between cells and diffuse into the intercellular space, so 
they can be absorbed by paracellular pathways. In both cases, FeNPs would access to the portal 
veins via mesenteric lymph [259]. The participation of both mechanisms would allow to increase 
iron intestinal absorption capacity. Furthermore, this hypothesis would be supported by the 
presence of FeNPs in blood and spleen of the perfused rats that will be presented in following 
section (Figure 54 A, B) and this would justify the existence of the absorption mechanisms 
previously discussed. 
By conducting this perfusion experiment, the distribution and accumulation of iron 
throughout the three regions (duodenum, jejunum and ileum) of the small intestine were also 
evaluated. Tissues were lyophilized, and microwave-assisted digestion was carried out as it was 
described in the previous section. Then, corresponding dilutions were made in order to measure 
total iron concentration by ICP-MS, using H2 as collision gas to remove polyatomic interferences 
affecting the 56Fe monitorization.  
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Figure 51 shows the total iron concentration in duodenum, jejunum and ileum after 
perfusing a saline solution in the case of the control group, and FeNP solutions in the target 
group. 
As can be seen in the graph, an equal accumulation of iron in the three regions is obtained 
for control samples (concentrations are between 32 ± 16 mg kg-1 in the duodenum and 29 ± 12 
mg kg-1 in the ileum), while a clear pattern of decreasing iron concentration is observed 
throughout the three regions of the small intestine where the FeNPs were perfused. The 
determining role of duodenum in the absorption of iron is here evident and in agreement with 
what it was expected according to literature [258]. Moreover, the iron content incorporated to 
the small intestine by injecting FeNPs solutions is significantly present in the three parts and 
means an important increment of 300 %, 163 % and 67 % over control duodenum, jejunum and 
ileum samples, respectively. These results are in good agreement with previous comments 
(section 3.2) about DMT-1 transporter in different regions through the small intestine and their 
absorption capability [260]. 
4.3.3. Small intestine perfusion experiment using 57FeNPs  
Parallel experiments were carried out in small intestine of 4 rats using isotopically labelled 
57FeNPs. Table 28 shows the total iron absorption before and after normalization by the 
dimensions of the intestine of the different animals and the comparison between values 
obtained in both kind of FeNPs employed as well as the difference with the control samples. 
 
Figure 51. Total Fe concentration levels in duodenum, jejunum and ileum after FeNPs perfusion (red 
bars, N = 4) and comparison with control samples (grey bars, N = 4). 
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Table 28. Results obtained after perfusion experiments (including 57FeNPs). 
Compound Number Perfused Fe (mg L-1) Absorbed Fe (mg L-1) % Absorption 
Absorption by 
intestinal surface  
(V at mg L-1 cm-2) 
Control 4 0.004 ± 0.003 -0.2 ± 0.1 - -0.006 ± 0.001 
FeNPs 4 35.6 ± 0.6 28.2 ± 2.1 79.3 ± 6.1 0.3 ± 0.1 
57FeNPs 3 16.9 ± 0.4 13.3 ± 1.0 78.3 ± 5.4 0.2 ± 0.1 
 
As it was previously shown in case of FeNPs perfusion, Figure 52 shows the total iron 
concentration in duodenum, jejunum and ileum after perfusing a saline solution in the case of 
the control group, and 57FeNP solutions in the target group. 
Iron absorption pattern is in agreement with the one detected in previous experiment with 
FeNPs, with a prevailing role of duodenum in comparison to the other small intestine parts. 
However, main differences are founded in the high levels of total concentration detected in all 
intestine regions (duodenum, jejunum and ileum) being almost 2 times higher when using 
57FeNPs for the perfusion experiment.  
 
Figure 52. Total Fe concentration levels in duodenum, jejunum and ileum after 57FeNPs perfusion (yellow 
bars, N = 4) and comparison with control samples (grey bars, N = 4). 
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4.3.4. Iron distribution in other tissues 
As a first step to address the fate of FeNPs once they are absorbed in the small intestine, 
reaching the bloodstream, samples from other tissues that could be involved in the iron 
metabolism were collected and treated as the intestine fragments. Figure 53 displays the total 
iron quantification in kidney, liver and blood samples after intestinal perfusion experiment with 
and without FeNPs and quantitative results of total iron measurements after perfusion 
experiments were summarized and collected in Table 29.  
 
Table 29. Iron content in small intestine and other tissues after FeNPs perfusion and iron increment 
compared to control samples. 
 
 Total iron content in 
control samples     
(mg kg-1) 
Total iron content in 
FeNPs-perfused 
samples  
(mg kg-1) 
Increment of iron 
(%) 
Duodenum 31.7 ± 15.8 128.9 ± 17.7 300 
Jejunum 30.2 ± 10.9 79.7 ± 14.2 163 
Ileum 29.5 ± 12.0 49.4 ± 9.4 67 
Kidney 47.9 ± 5.4 57.3 ± 7.1 20 
Liver 110.8 ± 17.2 109.7 ± 26.6 -1 
Blood 289.3 ± 17.1 340.1 ± 11.4 18 
Figure 53. Fe content in other tissues after intestinal perfusion of FeNPs (dark bars) and saline solutions 
without iron (light bars). 
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Al together these studies and results could confirm a high stability of the nanoparticle 
structure, a rapid metabolization of the FeNPs in the body and also a fast incorporation into 
bloodstream, in the light of the results of the total iron measurements as well as TEM images. 
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5 CONCLUSIONS AND OUTLOOK 
The main conclusions that can be extracted from the present dissertation can be 
summarized in the following paragraphs. 
Concerning the full characterization and bioavailability studies of a commercial preparation 
for the parenteral treatment of severe anaemia (Venofer®), it can be emphasized that: 
• The physicochemical characterization of iron-sucrose nanoparticle formulation, 
Venofer®, revealed a monodisperse iron-NPs preparation of 4.55 ± 0.55 nm and an 
average hydrodynamic diameter of 15.11 nm. 
 
• Solubilization studies in serum and blood samples were carried out by Isotope Dilution 
Analysis (IDA) with the addition of a stable tracer (57Fe) and application of the IDA 
equation. It was revealed that a high concentration of iron is directly dissolved from the 
preparation in the presence of biological media after 7 hours of incubation, reaching    
70 % of the initial iron concentration. Such results confirmed the semi-robust 
(kinetically) and moderately strong (thermodynamically) character of Venofer® 
formulation, probably due to the relatively labile nature of iron oxide-sucrose binding. 
 
• The released iron incorporation into transferrin binding sites was addressed by 
separation of Tf sialoforms using anion exchange chromatography coupled to ICP-MS 
detection. Complete saturation was accomplished by adding 57Fe and application of 
isotope pattern deconvolution showed the contribution of endogenous and exogenous 
iron to each Tf isoform obtained. It was detected that complete iron saturation is not 
achieved even after 7 h of incubation, when the incorporation of iron to Tf-binding sites 
reached almost 95 %. 
 
• Iron association to other serum proteins was evaluated by anion exchange 
chromatography coupled to UV and ICP-MS detection. Small iron traces were detected 
in the ICP-MS trace corresponding to albumin retention time. However, no other 
proteins seem to carry much iron from the disrupted particles. Thus, it can be concluded 
that part of the nanostructure might be disrupted into smaller size particles and ions 
that will circulate in the blood stream. 
 
5. CONCLUSIONS AND OUTLOOK 
146 
 
• The method here developed gives new insights for the monitoring of ions released from 
nanoparticles in body fluids and it can be considered as a competitive tool, especially in 
terms of accuracy and precision for the quantitative speciation of these iron species. 
Moreover, it can be considered as a suitable alternative to investigate the iron 
metabolism in other similar intravenous preparations for the treatment of anaemia. 
From the synthesis of FeNPs suitable for the oral treatment of anaemia, it can be extracted 
that: 
• A synthesis of non-aggregated FeNPs potentially used as iron supplements was carried 
out with satisfactory results in terms of monodispersity, reproducibility, and simplicity. 
 
• Physico-chemical characterization by HR-TEM and DLS revealed a particle diameter of 
3.65 ± 0.39 nm and a hydrodynamic volume of 11.77 nm, respectively. SAXS and WAXS 
measurements could show the non-total crystalline structure of the nanoparticles, 
although the 2-line ferrihydrite structure expected was not discarded by the results 
obtained. Moreover, nanoparticle structure stability in acidic medium was assessed by 
adding HCl, simulating gastric conditions and nanostructure remained stable during the 
whole experiment. 
Regarding the in vitro studies developed in different cell lines, it should be highlighted that: 
• Cellular uptake was evaluated by incubation of HT-29 and Caco-2 cell lines with different 
concentrations of FeNPs during 48 h and consequently, digestion and quantification by 
total iron analysis using ICP-MS. It was significantly higher in Caco-2 cells than in HT-29, 
although in both, the absorption of FeNP was clearly detected.  
 
• Cell samples were fixated and prepared for TEM imaging in order to get information 
about subcellular location. TEM images suggested an endocytic pathway of FeNPs to 
enter the cells and a subsequent confinement in vesicles for further release and 
distribution to other tissues in the body. 
 
• Toxicity was also evaluated. Cell viability assays displayed a non-harmful effect of these 
nanoparticles in the range of therapeutic levels (up to 4 mM Fe concentration) after 48 
h of exposure in different cell lines (THP-1, macrophages, HT-29, and Caco-2). ROS 
experiments detected an increment of fluorescence intensity in cells incubated with 
FeNPs, but the oxidative stress effect caused by the FeNPs is lower than the FeSO4 at the 
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same concentration level. Thus, it is a significant improvement in the oral treatments 
supplied up to now.  
The main conclusions concerning the speciation and quantification of iron nanoparticles and 
soluble iron species by reversed phase chromatography coupled to ICP-MS can be summarized 
as follows: 
• Chromatography separation of different size nanoparticles and corresponding ions was 
optimized and satisfactorily applied to different iron compounds: Venofer®, self-
synthesized FeNPs, and Fe(III) salts. The methodology here developed improved the 
range of size in the separation that was assumed for this type of reversed-phase column, 
allowing the separation of two iron nanostructures (below 5 nm diameter size) differing 
in only 1 nm between them. 
 
• Caco-2 cells were incubated with three different concentrations of FeNPs and extraction 
of nanoparticles from the cell matrix was carried out before injecting on the 
chromatographic column. Separation of three different iron species in the range of 1.6 
to 6.1 nm was detected in less than 7 minutes in one single run. Nanoparticle fraction 
was clearly detected by comparison with the blank samples (without FeNPs incubation). 
 
• Simultaneous quantification of all iron species was achieved by using post-column 
isotope dilution analysis and recoveries between 90-93 % and between 60-80 % were 
obtained for nanoparticles aqueous solutions and cell extracts, respectively. Moreover, 
repeatability values and limits of detection in the low µg L-1 range make this 
methodology suitable for the speciation of iron species in biological samples and mean 
a significant enhancement considering there are no comparable studies neither for iron 
nanoparticles nor for such small size nanoparticles. 
Regarding in vivo studies, following conclusions must be remarked: 
• Small intestine perfusion was carried out for the first time with this kind of FeNPs and 
absorption degree of approximately 80 % was observed after 100 minutes of 
experiment, proving the effectiveness of the FeNPs and the capability of these perfusion 
experiments to mimic the real absorption that would take place after oral uptake. 
Moreover, the important role of duodenum in the iron absorption was shown with 
significant differences over jejunum and ileum.  
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• In order to assess the pathway of the FeNPs after being absorbed in the small intestine, 
other tissues such as liver, kidney, blood and spleen were also digested and analysed by 
ICP-MS. FeNPs showed a possible clearance via kidney as there was no variation found 
on liver tissues before and after FeNPs perfusion. 
 
• The release of nanoparticles to bloodstream without any degradation was also proven 
to be fast as they were already found in blood samples examined by TEM.  
 
Although the different aims of this dissertation have been described and achieved in the 
light of the conclusions, the nature of scientific research leads to new challenges that can be 
investigated in the future. Here, some remaining questions are raised: 
o As it was mentioned, there are several parenteral preparations in the market for the 
treatment of anaemia based on iron-carbohydrate nanoparticles suspensions. However, 
release and behaviour of these iron compounds in the blood stream and their 
interaction with proteins are still issues to be cleared. Thus, analytical strategies here 
proposed and successfully applied to Venofer® could be also applied to other similar 
preparations and comparison in terms of solubilization, bond lability or association to 
iron binding proteins would be established. 
 
o Speciation of FeNPs and ionic species of iron was here achieved by using reversed phase 
chromatography coupled to ICP-MS. This methodology was applied to aqueous 
suspensions and Caco-2 cells samples with satisfactory quantitative recoveries. 
Therefore, similar strategy might be carried out in more complex biological samples, 
such as organ tissues or in vivo experiments, so the stability and solubilization of the 
nanoparticle were assessed and toxicological effects or metabolic disorders could be 
better understood. 
 
o Syntheses of different “labelled” FeNPs were here developed, using lanthanides as 
Holmium, and isotopic enriched standards as 57Fe. This leads to multiple possibilities in 
detection and quantification by mass spectrometric techniques which were not tackled 
here. For example, LA-ICP-MS approach could be achieved with higher sensitivity and 
avoiding polyatomic interferences that usually affect 56Fe detection. 
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6 GLOSSARY 
ACD  Anaemia of chronic disease 
AF4 Asymmetric flow field flow fractionation 
AFM Atomic force microscopy 
ATP Adenosine triphosphate 
BSA Bovine serum albumin 
Calcein AM Calcein acetoxymethyl  
CE Capillary electrophoresis 
CMC Critical micellar concentration 
CRC Collision/Reaction cell 
CRP C-reactive protein 
DAD Diode array detector 
DCF 2’-7’dichlorofluorescein 
DCFH-DA 2’-7’dichlorofluorescin diacetate 
DLS Dynamic light scattering 
DMT1 Divalent Metal Transporter 1 
DNA Deoxyribonucleic acid 
EDTA Ethylenediaminetetraacetic acid 
EDX Energy dispersive X-ray analysis 
EM Electron microscopy 
ESA Erythropoiesis-stimulating agents 
FBS Fetal bovine serum 
FFF Field flow fractionation 
GE Gel electrophoresis 
GSH Glutathione redox system 
Hb Haemoglobin 
HCP1 Haem carrier protein 1 
HDC Hydrodynamic chromatography 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HFE Human hemochromatosis protein 
HPLC High performance liquid chromatography 
HR-TEM High resolution transmission electron microscopy 
IC Ion exchange chromatography 
ICP-ORS-MS ICP-MS with octapole reaction system 
IDA Iron deficiency anaemia 
    Isotope dilution analysis 
IPD Isotope pattern deconvolution 
LA-ICP-MS Laser ablation coupled to ICP-MS 
LDH Lactate dehydrogenase 
MALLS Multiangle laser light scattering 
MALS Multiangle light scattering 
MDA Malondialdehyde 
MEKC Micellar electrokinetic chromatography 
MEM Minimum essential medium 
MIC Minimum inhibitory concentration 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
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NADPH Nicotinamide adenine dinucleotide phosphate 
PBS Phosphate buffer saline 
PLGA Poly(lactic-co-glycolic acid) 
PLGA-PEG Polyethylene glycol–poly lactic acid-co-glycolic acid 
PMA Phorbol 12-myristate 13-acetate 
RES Reticuloendothelial system 
ROS Reactive oxygen species 
RP-HPLC Reversed phase high performance liquid chromatography 
RPMI Roswell Park Memorial Institute cellular medium 
SAXS Small-angle X-ray scattering 
SDS Sodium dodecyl sulphate 
SEC Size exclusion chromatography 
SEM Scanning electron microscopy 
spICP-MS Single particle detection 
sTfR Serum transferrin receptor 
TBHP Tert-butyl hydroperoxide 
TEM Transmission electron microscopy 
Tf Transferrin 
TIBC Total iron-binding capacity 
TRIS Tris(hydroxymethyl)aminomethan 
UIBC Unsaturated iron-binding capacity 
WAXS Wide-angle X-ray scattering 
WST 2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H 
tetrazolium, monosodium salt 
XRD X-ray difraction 
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